| Other |
laboratory biomarker analysis |
220 |
2015 |
| Other |
pharmacological study |
133 |
2014 |
| Drug |
carboplatin |
115 |
2014 |
| Other |
questionnaire administration |
108 |
2015 |
| Drug |
paclitaxel |
99 |
2014 |
| Other |
quality-of-life assessment |
86 |
2015 |
| Drug |
cisplatin |
84 |
2010 |
| Drug |
cyclophosphamide |
83 |
2016 |
| Drug |
pembrolizumab |
80 |
2015 |
| placebo |
placebo |
76 |
2017 |
| Drug |
nivolumab |
74 |
2016 |
| Drug |
gemcitabine |
66 |
2014 |
| Drug |
bevacizumab |
57 |
2018 |
| Drug |
docetaxel |
57 |
2016 |
| Drug |
capecitabine |
49 |
2014 |
| Drug |
etoposide |
44 |
2018 |
| Drug |
oxaliplatin |
44 |
2018 |
| Radiation |
radiotherapy |
44 |
2015 |
| Drug |
fludarabine |
40 |
2010 |
| Drug |
ipilimumab |
40 |
2014 |
| Drug |
temozolomide |
40 |
2014 |
| Drug |
irinotecan |
38 |
2014 |
| Drug |
irinotecan hydrochloride |
38 |
2013 |
| Biological |
filgrastim |
34 |
2018 |
| Drug |
melphalan |
31 |
2015 |
| Procedure |
peripheral blood stem cell transplantation |
30 |
2015 |
| Drug |
everolimus |
28 |
2017 |
| Drug |
durvalumab |
27 |
2016 |
| Other |
questionnaire |
27 |
2015 |
| Drug |
busulfan |
25 |
2014 |
| Drug |
fludarabine phosphate |
25 |
2015 |
| Drug |
olaparib |
25 |
2017 |
| Drug |
temsirolimus |
25 |
2010 |
| Drug |
cetuximab |
24 |
2011 |
| Drug |
sorafenib |
24 |
2010 |
| Drug |
fluorouracil |
23 |
2014 |
| Drug |
sirolimus |
23 |
2010 |
| Drug |
tacrolimus |
22 |
2015 |
| Drug |
atezolizumab |
21 |
2015 |
| Drug |
bortezomib |
20 |
2015 |
| Drug |
mycophenolate mofetil |
20 |
2015 |
| Drug |
pemetrexed |
20 |
2017 |
| Procedure |
allogeneic hematopoietic stem cell transplantation |
19 |
2015 |
| Drug |
dexamethasone |
19 |
2015 |
| Drug |
erlotinib |
19 |
2011 |
| Drug |
chemotherapy |
18 |
2018 |
| Drug |
ifosfamide |
18 |
2012 |
| Drug |
nab-paclitaxel |
18 |
2014 |
| Drug |
rituximab |
18 |
2013 |
| Drug |
topotecan |
18 |
2013 |
| Drug |
azacitidine |
17 |
2017 |
| Drug |
methotrexate |
17 |
2014 |
| Drug |
cytarabine |
16 |
2018 |
| Drug |
leucovorin |
16 |
2020 |
| Drug |
trastuzumab |
16 |
2014 |
| Other |
educational intervention |
15 |
2008 |
| Procedure |
positron emission tomography |
15 |
2016 |
| Radiation |
stereotactic radiosurgery |
15 |
2018 |
| Drug |
dasatinib |
14 |
2009 |
| Drug |
gemcitabine hydrochloride |
14 |
2019 |
| Drug |
palbociclib |
14 |
2017 |
| Drug |
thiotepa |
14 |
2019 |
| Drug |
trametinib |
14 |
2017 |
| Drug |
vorinostat |
14 |
2009 |
| Drug |
darbepoetin alfa |
13 |
2007 |
| Drug |
decitabine |
13 |
2020 |
| Drug |
abemaciclib |
12 |
2016 |
| Drug |
cabozantinib |
12 |
2015 |
| Procedure |
computed tomography |
12 |
2014 |
| Drug |
cyclosporine |
12 |
2010 |
| Drug |
doxorubicin |
12 |
2018 |
| Drug |
leucovorin calcium |
12 |
2015 |
| Device |
nanoknife |
12 |
2015 |
| Drug |
pazopanib |
12 |
2010 |
| Procedure |
therapeutic conventional surgery |
12 |
2009 |
| Radiation |
total-body irradiation |
12 |
2010 |
| Drug |
tremelimumab |
12 |
2016 |
| Procedure |
autologous bone marrow transplantation |
11 |
2008 |
| Drug |
avelumab |
11 |
2018 |
| Procedure |
biopsy |
11 |
2014 |
| Drug |
crizotinib |
11 |
2020 |
| Drug |
fulvestrant |
11 |
2017 |
| Procedure |
irreversible electroporation (ire) |
11 |
2015 |
| Drug |
ixabepilone |
11 |
2009 |
| Drug |
prednisone |
11 |
2013 |
| Biological |
sargramostim |
11 |
2019 |
| Drug |
sunitinib |
11 |
2014 |
| Drug |
vemurafenib |
11 |
2013 |
| Drug |
vincristine sulfate |
11 |
2009 |
| Drug |
5-fluorouracil |
10 |
2014 |
| Drug |
5-fu |
10 |
2018 |
| Biological |
aldesleukin |
10 |
2016 |
| Drug |
alvocidib |
10 |
2006 |
| Other |
best available therapy |
10 |
2018 |
| Procedure |
conventional surgery |
10 |
2018 |
| Device |
ct-scan |
10 |
2018 |
| Drug |
g-csf |
10 |
2014 |
| Drug |
gefitinib |
10 |
2017 |
| Drug |
lenvatinib |
10 |
2019 |
| Other |
standard care |
10 |
2016 |
| Radiation |
stereotactic body radiation therapy |
10 |
2018 |
| Biological |
anti-thymocyte globulin |
9 |
2014 |
| Behavioral |
exercise intervention |
9 |
2018 |
| Drug |
itraconazole |
9 |
2014 |
| Drug |
lenalidomide |
9 |
2010 |
| Drug |
letrozole |
9 |
2012 |
| Procedure |
magnetic resonance imaging |
9 |
2015 |
| Drug |
midazolam |
9 |
2018 |
| Drug |
sorafenib tosylate |
9 |
2014 |
| Drug |
venetoclax |
9 |
2018 |
| Drug |
vincristine |
9 |
2008 |
| Drug |
alisertib |
8 |
2010 |
| Biological |
bleomycin sulfate |
8 |
2010 |
| Drug |
cobimetinib |
8 |
2017 |
| Drug |
imiquimod |
8 |
2014 |
| Other |
immunohistochemistry staining method |
8 |
2008 |
| Drug |
lapatinib |
8 |
2010 |
| Drug |
metformin |
8 |
2019 |
| Drug |
neratinib |
8 |
2017 |
| Drug |
patupilone |
8 |
2007 |
| Other |
pharmacokinetic study |
8 |
2014 |
| Drug |
prexasertib |
8 |
2019 |
| Drug |
talazoparib |
8 |
2014 |
| Drug |
topotecan hydrochloride |
8 |
2009 |
| Drug |
veliparib |
8 |
2010 |
| Drug |
afatinib |
7 |
2017 |
| Biological |
cixutumumab |
7 |
2009 |
| Procedure |
cognitive assessment |
7 |
2017 |
| Drug |
dabrafenib |
7 |
2020 |
| Drug |
doxorubicin hydrochloride |
7 |
2009 |
| Other |
internet-based intervention |
7 |
2019 |
| Procedure |
management of therapy complications |
7 |
2014 |
| Drug |
medi4736 |
7 |
2013 |
| Drug |
mek162 |
7 |
2014 |
| Drug |
ombrabulin (ave8062) |
7 |
2011 |
| Drug |
panitumumab |
7 |
2018 |
| Drug |
pdr001 |
7 |
2017 |
| Drug |
pegfilgrastim |
7 |
2010 |
| Drug |
ramucirumab |
7 |
2016 |
| Drug |
regorafenib |
7 |
2014 |
| Drug |
ribociclib |
7 |
2018 |
| Drug |
sapanisertib |
7 |
2015 |
| Drug |
selumetinib |
7 |
2010 |
| Behavioral |
telephone-based intervention |
7 |
2014 |
| Drug |
valproic acid |
7 |
2019 |
| Drug |
abbv-181 |
6 |
2019 |
| Biological |
alemtuzumab |
6 |
2012 |
| Procedure |
blood sample |
6 |
2018 |
| Procedure |
bone marrow ablation with stem cell support |
6 |
2003 |
| Drug |
cabozantinib s-malate |
6 |
2015 |
| Drug |
carmustine |
6 |
2009 |
| Drug |
cladribine |
6 |
2018 |
| Drug |
clofarabine |
6 |
2009 |
| Procedure |
dynamic contrast-enhanced magnetic resonance imaging |
6 |
2012 |
| Drug |
epacadostat |
6 |
2018 |
| Drug |
eribulin mesylate |
6 |
2010 |
| Drug |
erlotinib hydrochloride |
6 |
2009 |
| Drug |
etoposide phosphate |
6 |
2008 |
| Radiation |
external beam radiation therapy |
6 |
2014 |
| Drug |
hydroxychloroquine |
6 |
2010 |
| Drug |
imatinib mesylate |
6 |
2012 |
| Other |
immunologic technique |
6 |
2009 |
| Other |
informational intervention |
6 |
2018 |
| Drug |
interleukin-2 |
6 |
2017 |
| Drug |
liposomal doxorubicin |
6 |
2010 |
| Drug |
rifampin |
6 |
2020 |
| Drug |
romidepsin |
6 |
2013 |
| Drug |
ruxolitinib |
6 |
2020 |
| Drug |
saline |
6 |
2014 |
| Drug |
sunitinib malate |
6 |
2015 |
| Procedure |
surgery |
6 |
2013 |
| Radiation |
total body irradiation |
6 |
2010 |
| Radiation |
whole-brain radiotherapy |
6 |
2015 |
| Drug |
7-hydroxystaurosporine |
5 |
2000 |
| Drug |
abt-263 |
5 |
2009 |
| Drug |
adavosertib |
5 |
2014 |
| Procedure |
allogeneic bone marrow transplantation |
5 |
2015 |
| Procedure |
allogeneic stem cell transplantation |
5 |
2013 |
| Drug |
amg 706 |
5 |
2010 |
| Drug |
anlotinib |
5 |
2019 |
| Drug |
azd5363 |
5 |
2017 |
| Drug |
azd6244 |
5 |
2009 |
| Drug |
bkm120 |
5 |
2012 |
| Procedure |
care |
5 |
2011 |
| Drug |
celecoxib |
5 |
2014 |
| Drug |
ceritinib |
5 |
2014 |
| Drug |
entinostat |
5 |
2016 |
| Drug |
epirubicin |
5 |
2016 |
| Drug |
exemestane |
5 |
2014 |
| Drug |
folfiri |
5 |
2011 |
| Drug |
inc280 |
5 |
2015 |
| Drug |
kg |
5 |
2019 |
| Drug |
lurbinectedin (pm01183) |
5 |
2015 |
| Other |
mass spectrometry |
5 |
2008 |
| Drug |
mesna |
5 |
2012 |
| Drug |
methylprednisolone |
5 |
2016 |
| Drug |
mk-2206 |
5 |
2009 |
| Device |
mri |
5 |
2016 |
| Drug |
obinutuzumab |
5 |
2014 |
| Drug |
ono-4538 |
5 |
2014 |
| Drug |
pazopanib hydrochloride |
5 |
2009 |
| Drug |
pemetrexed disodium |
5 |
2015 |
| Genetic |
protein expression analysis |
5 |
2009 |
| Procedure |
psychosocial assessment |
5 |
2011 |
| Procedure |
psychosocial assessment/care |
5 |
2011 |
| Drug |
rad001 |
5 |
2009 |
| Drug |
ridaforolimus |
5 |
2011 |
| Procedure |
stem cell transplantation |
5 |
2009 |
| Drug |
tamoxifen |
5 |
2018 |
| Drug |
tanespimycin |
5 |
2008 |
| Drug |
thalidomide |
5 |
2012 |
| Drug |
tislelizumab |
5 |
2016 |
| Drug |
trabectedin |
5 |
2013 |
| Behavioral |
video |
5 |
2018 |
| Drug |
abi-007 |
4 |
2011 |
| Drug |
abraxane |
4 |
2016 |
| Drug |
acalabrutinib |
4 |
2015 |
| Drug |
apr-246 |
4 |
2017 |
| Drug |
arry-334543, egfr |
4 |
2009 |
| Drug |
arry-334543, egfr/erbb2 inhibitor; oral |
4 |
2009 |
| Drug |
arsenic trioxide |
4 |
2017 |
| Drug |
axitinib |
4 |
2013 |
| Drug |
azd1775 |
4 |
2015 |
| Drug |
bbi608 |
4 |
2015 |
| Drug |
bibf 1120 |
4 |
2009 |
| Drug |
byl719 |
4 |
2013 |
| Drug |
carfilzomib |
4 |
2014 |
| Drug |
cediranib |
4 |
2008 |
| Drug |
cediranib maleate |
4 |
2011 |
| Device |
clinimacs |
4 |
2012 |
| Other |
control |
4 |
2012 |
| Other |
cytology specimen collection procedure |
4 |
2015 |
| Drug |
denosumab |
4 |
2009 |
| Drug |
epoetin alfa |
4 |
2006 |
| Drug |
erbb2 inhibitor; oral |
4 |
2009 |
| Drug |
erdafitinib |
4 |
2019 |
| Other |
flow cytometry |
4 |
2007 |
| Drug |
folinic acid |
4 |
2009 |
| Genetic |
gene expression analysis |
4 |
2009 |
| Drug |
gimatecan |
4 |
2007 |
| Biological |
granulocyte colony-stimulating factor |
4 |
2018 |
| Drug |
gsk1120212 |
4 |
2010 |
| Procedure |
hyperthermic intraperitoneal chemotherapy (hipec) |
4 |
2016 |
| Radiation |
intensity-modulated radiation therapy |
4 |
2015 |
| Other |
interview |
4 |
2017 |
| Drug |
ixazomib |
4 |
2009 |
| Drug |
lbh589 |
4 |
2009 |
| Procedure |
leukapheresis |
4 |
2009 |
| Drug |
lirilumab |
4 |
2017 |
| Drug |
mkc-1 |
4 |
2008 |
| Device |
monitoring device |
4 |
2018 |
| Drug |
niraparib |
4 |
2017 |
| Drug |
o6-benzylguanine |
4 |
1999 |
| Drug |
olanzapine |
4 |
2017 |
| Drug |
olaparib tablet dosing |
4 |
2013 |
| Drug |
palonosetron hydrochloride |
4 |
2018 |
| Other |
patient observation |
4 |
2018 |
| Drug |
pemigatinib |
4 |
2017 |
| Drug |
perifosine |
4 |
2010 |
| Drug |
pertuzumab |
4 |
2014 |
| Device |
pet |
4 |
2018 |
| Other |
pharmacogenomic study |
4 |
2016 |
| Other |
physical activity |
4 |
2018 |
| Genetic |
polymerase chain reaction |
4 |
2010 |
| Drug |
pralatrexate |
4 |
2010 |
| Drug |
propofol |
4 |
2012 |
| Radiation |
radiation |
4 |
2012 |
| Drug |
rapamycin |
4 |
2008 |
| Drug |
rucaparib |
4 |
2018 |
| Drug |
s-1 |
4 |
2019 |
| Drug |
sar245408 |
4 |
2012 |
| Drug |
sintilimab |
4 |
2018 |
| Drug |
snx-5422 |
4 |
2012 |
| Procedure |
stem cell transplant |
4 |
2009 |
| Procedure |
supportive care |
4 |
2017 |
| Drug |
tas-102 |
4 |
2014 |
| Drug |
tazemetostat |
4 |
2017 |
| Drug |
tki258 |
4 |
2010 |
| Radiation |
total body irradiation (tbi) |
4 |
2011 |
| Drug |
trametinib dimethyl sulfoxide |
4 |
2020 |
| Drug |
vandetanib |
4 |
2012 |
| Drug |
vismodegib |
4 |
2010 |
| Genetic |
western blotting |
4 |
2009 |
| Drug |
zoledronic acid |
4 |
2009 |
| Drug |
5-fluorouracil (5-fu) |
3 |
2006 |
| Drug |
abt-806 |
3 |
2011 |
| Procedure |
acupuncture |
3 |
2018 |
| Drug |
afatinib dimaleate |
3 |
2020 |
| Drug |
ag-013736 |
3 |
2009 |
| Drug |
aldoxorubicin |
3 |
2014 |
| Drug |
amg 232 |
3 |
2014 |
| Drug |
amg 479 |
3 |
2009 |
| Drug |
anastrozole |
3 |
2010 |
| Drug |
antibodies |
3 |
2005 |
| Drug |
apatinib |
3 |
2017 |
| Drug |
arq 197 |
3 |
2011 |
| Procedure |
assessment of therapy complications |
3 |
2012 |
| Procedure |
autologous hematopoietic stem cell transplantation |
3 |
2008 |
| Drug |
belinostat |
3 |
2012 |
| Drug |
berzosertib |
3 |
2015 |
| Drug |
bez235 |
3 |
2011 |
| Drug |
bgb-3111 |
3 |
2015 |
| Drug |
binimetinib |
3 |
2020 |
| Procedure |
biospecimen collection |
3 |
2017 |
| Drug |
bleomycin |
3 |
2017 |
| Drug |
brigatinib |
3 |
2018 |
| Drug |
cabazitaxel (xrp6258) |
3 |
2010 |
| Dietary Supplement |
calcitriol |
3 |
2004 |
| Drug |
capivasertib |
3 |
2020 |
| Drug |
cc-486 |
3 |
2014 |
| Other |
chemoradiotherapy |
3 |
2018 |
| Procedure |
colposcopy |
3 |
2014 |
| Other |
communication intervention |
3 |
2016 |
| Drug |
copanlisib hydrochloride |
3 |
2019 |
| Procedure |
cord blood transplantation |
3 |
2013 |
| Other |
counseling |
3 |
2020 |
| Procedure |
cryoablation |
3 |
2018 |
| Radiation |
cyberknife stereotactic radiosurgery |
3 |
2014 |
| Biological |
dc vaccine |
3 |
2014 |
| Drug |
dexmedetomidine |
3 |
2014 |
| Other |
diagnostic laboratory biomarker analysis |
3 |
2010 |
| Drug |
doxil |
3 |
2013 |
| Drug |
ds-8201a |
3 |
2017 |
| Procedure |
dynamic susceptibility contrast-enhanced magnetic resonance imaging |
3 |
2015 |
| Drug |
e7386 |
3 |
2017 |
| Drug |
e7974 |
3 |
2005 |
| Drug |
enfortumab vedotin |
3 |
2017 |
| Drug |
entrectinib |
3 |
2016 |
| Drug |
enzalutamide |
3 |
2017 |
| Drug |
eribulin |
3 |
2015 |
| Drug |
fluconazole |
3 |
2014 |
| Radiation |
fludeoxyglucose f 18 |
3 |
2016 |
| Drug |
folfox |
3 |
2016 |
| Drug |
ga-68 psma-hbed-cc pet |
3 |
2017 |
| Drug |
haloperidol |
3 |
2017 |
| Other |
high performance liquid chromatography |
3 |
2010 |
| Drug |
hlx10 |
3 |
2019 |
| Radiation |
hypofractionated radiation therapy |
3 |
2020 |
| Drug |
ibi308 |
3 |
2016 |
| Drug |
ibrutinib |
3 |
2015 |
| Drug |
imatinib |
3 |
2015 |
| Other |
immunoenzyme technique |
3 |
2008 |
| Drug |
indocyanine green (icg) |
3 |
2014 |
| Drug |
indomethacin |
3 |
2012 |
| Radiation |
intensity modulated radiotherapy (imrt) |
3 |
2014 |
| Drug |
itacitinib |
3 |
2016 |
| Drug |
ketoconazole |
3 |
2011 |
| Drug |
lapatinib ditosylate |
3 |
2012 |
| Drug |
larotrectinib |
3 |
2017 |
| Drug |
larotrectinib sulfate |
3 |
2017 |
| Drug |
lcl161 |
3 |
2010 |
| Drug |
lee011 |
3 |
2016 |
| Drug |
lucitanib |
3 |
2016 |
| Drug |
ly3300054 |
3 |
2016 |
| Drug |
melatonin |
3 |
2012 |
| Drug |
merestinib |
3 |
2016 |
| Drug |
mgcd265 |
3 |
2013 |
| Drug |
mitomycin c |
3 |
2014 |
| Drug |
mitoxantrone |
3 |
2019 |
| Drug |
mitoxantrone hydrochloride |
3 |
2018 |
| Drug |
mln0128 |
3 |
2010 |
| Drug |
mln4924 |
3 |
2014 |
| Biological |
mogamulizumab |
3 |
2016 |
| Drug |
motexafin gadolinium |
3 |
2005 |
| Dietary Supplement |
multivitamin |
3 |
2016 |
| Drug |
nabiximols |
3 |
2011 |
| Biological |
navitoclax |
3 |
2014 |
| Drug |
ngr-htnf |
3 |
2009 |
| Drug |
nilotinib |
3 |
2010 |
| Biological |
nk cell infusion |
3 |
2013 |
| Procedure |
nonmyeloablative allogeneic hematopoietic stem cell transplantation |
3 |
2007 |
| Dietary Supplement |
ocoxin-viusidâ® |
3 |
2018 |
| Drug |
octreotide |
3 |
2015 |
| Drug |
octreotide acetate |
3 |
2019 |
| Drug |
oleclumab |
3 |
2020 |
| Drug |
omeprazole |
3 |
2016 |
| Drug |
onalespib |
3 |
2014 |
| Drug |
palifermin |
3 |
2011 |
| Drug |
pegylated liposomal doxorubicin |
3 |
2011 |
| Device |
pet/ct |
3 |
2018 |
| Drug |
pevonedistat |
3 |
2019 |
| Drug |
pf-04449913 |
3 |
2014 |
| Procedure |
pharmacokinetic sampling |
3 |
2013 |
| Drug |
pi3k-beta inhibitor gsk2636771 |
3 |
2020 |
| placebo |
placebo (ga-0034) |
3 |
2011 |
| Drug |
pomalidomide |
3 |
2010 |
| Drug |
prednisolone |
3 |
2019 |
| Genetic |
proteomic profiling |
3 |
2008 |
| Radiation |
proton beam radiation therapy |
3 |
2014 |
| Radiation |
radiosurgery |
3 |
2012 |
| Procedure |
rectal cancer surgery |
3 |
2019 |
| Drug |
ruxolitinib phosphate |
3 |
2013 |
| Drug |
sar125844 |
3 |
2012 |
| Procedure |
sham intervention |
3 |
2002 |
| Biological |
shr-1210 |
3 |
2017 |
| Drug |
shr-1701 |
3 |
2018 |
| Procedure |
standard follow-up care |
3 |
2016 |
| Radiation |
stereotactic body radiotherapy (sbrt) |
3 |
2011 |
| Procedure |
surgical resection |
3 |
2009 |
| Drug |
tak-228 |
3 |
2017 |
| Radiation |
tbi |
3 |
2019 |
| Drug |
tipifarnib |
3 |
2017 |
| Drug |
tocilizumab |
3 |
2014 |
| Drug |
toripalimab |
3 |
2019 |
| Biological |
trebananib |
3 |
2012 |
| Drug |
ulixertinib |
3 |
2018 |
| Drug |
utomilumab |
3 |
2017 |
| Drug |
vatalanib |
3 |
2003 |
| Drug |
veliparib (abt-888) |
3 |
2010 |
| Drug |
vinflunine |
3 |
2013 |
| Biological |
ziv-aflibercept |
3 |
2014 |
| Procedure |
3 tesla magnetic resonance imaging |
2 |
2008 |
| Drug |
5fluorouracil |
2 |
2018 |
| Drug |
68ga-dotatoc pet |
2 |
2012 |
| Drug |
90y-dota-tyr3-octreotide |
2 |
2015 |
| Drug |
ab122 |
2 |
2018 |
| Drug |
abbv-368 |
2 |
2019 |
| Drug |
abbv-927 |
2 |
2019 |
| Drug |
abiraterone acetate |
2 |
2016 |
| Drug |
abt-751 |
2 |
2002 |
| Drug |
abt-888 |
2 |
2008 |
| Drug |
adh -1 (exherinâ„¢) |
2 |
2005 |
| Procedure |
adjuvant therapy |
2 |
1999 |
| Drug |
aeg35156 |
2 |
2006 |
| Drug |
aflibercept |
2 |
2009 |
| Drug |
aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrapâ®) |
2 |
2007 |
| Drug |
ag-221 |
2 |
2014 |
| Biological |
alks 4230 |
2 |
2016 |
| Drug |
allopurinol |
2 |
2007 |
| Drug |
alvocidib hydrochloride |
2 |
2009 |
| Drug |
amg 386 |
2 |
2012 |
| Drug |
amifostine |
2 |
2013 |
| Drug |
amifostine trihydrate |
2 |
2000 |
| Drug |
amrubicin |
2 |
2009 |
| Drug |
anti-thymocyte globulin (rabbit) |
2 |
2013 |
| Drug |
apg-1387 for injection |
2 |
2020 |
| Drug |
apixaban |
2 |
2017 |
| Drug |
aprepitant |
2 |
2012 |
| Drug |
artesunate suppositories |
2 |
2017 |
| Drug |
asp1948 |
2 |
2018 |
| Drug |
asp3026 |
2 |
2011 |
| Drug |
asp8374 |
2 |
2017 |
| Combination Product |
aspirin |
2 |
2017 |
| Procedure |
assessment for surgical evaluation |
2 |
2014 |
| Drug |
at13387 |
2 |
2010 |
| Drug |
atg |
2 |
2019 |
| Biological |
atlcar.cd30 cells |
2 |
2016 |
| Drug |
auy922 |
2 |
2010 |
| Drug |
avapritinib |
2 |
2015 |
| Drug |
avastin |
2 |
2007 |
| Drug |
azd2014 |
2 |
2009 |
| Drug |
azd2171 |
2 |
2007 |
| Drug |
azd2281 |
2 |
2009 |
| Drug |
azd4635 |
2 |
2016 |
| Drug |
azd8055 |
2 |
2009 |
| Drug |
azd8931 |
2 |
2009 |
| Drug |
bay94-9343 |
2 |
2011 |
| Drug |
bbi503 |
2 |
2015 |
| Other |
behavioral, psychological |
2 |
2019 |
| Other |
behavioral, psychological/informational intervention |
2 |
2019 |
| Drug |
bendamustine |
2 |
2010 |
| Drug |
bevacizumab (avastin) |
2 |
2006 |
| Drug |
bgb-283 |
2 |
2015 |
| Drug |
bgb-290 |
2 |
2015 |
| Drug |
bgb-a317 |
2 |
2016 |
| Drug |
bgj398 |
2 |
2013 |
| Drug |
bi 754091 |
2 |
2017 |
| Drug |
biib021 |
2 |
2008 |
| Drug |
bms-214662 |
2 |
2000 |
| Drug |
bms-754807 |
2 |
2007 |
| Procedure |
bowel obstruction management |
2 |
2000 |
| Procedure |
brachytherapy |
2 |
2016 |
| Drug |
brivanib |
2 |
2006 |
| Drug |
carvedilol |
2 |
2018 |
| Biological |
cd20 |
2 |
2020 |
| Drug |
cediranib (recentin tm, azd2171) |
2 |
2008 |
| Drug |
cefixime |
2 |
2008 |
| Drug |
cemiplimab |
2 |
2016 |
| Drug |
cilengitide |
2 |
2003 |
| Drug |
clarithromycin |
2 |
2014 |
| Drug |
cmp-001 |
2 |
2018 |
| Procedure |
colposcopic biopsy |
2 |
2008 |
| Drug |
combined epidural-general anesthesia |
2 |
2016 |
| Genetic |
comparative genomic hybridization |
2 |
2006 |
| Behavioral |
conventional |
2 |
2016 |
| Drug |
copanlisib |
2 |
2019 |
| Other |
correlative studies |
2 |
2013 |
| Drug |
corticosteroid |
2 |
2009 |
| Other |
counseling intervention |
2 |
2011 |
| Drug |
cp-751,871 |
2 |
2009 |
| Biological |
cp-870,893 |
2 |
2014 |
| Drug |
cpi-613 |
2 |
2009 |
| Device |
cryosurgery |
2 |
2019 |
| Procedure |
cryotherapy |
2 |
2011 |
| Drug |
cs1001 |
2 |
2018 |
| Drug |
cs1002 |
2 |
2018 |
| Drug |
cs3006 |
2 |
2018 |
| Procedure |
cytoreductive surgery |
2 |
2013 |
| Drug |
cytoxan |
2 |
2010 |
| Procedure |
d2 radical gastrectomy |
2 |
2015 |
| Drug |
dabrafenib mesylate |
2 |
2020 |
| Biological |
dactinomycin |
2 |
2009 |
| Drug |
darinaparsin |
2 |
2010 |
| Biological |
dc-cik |
2 |
2020 |
| Drug |
defactinib |
2 |
2015 |
| Drug |
defactinib hydrochloride |
2 |
2020 |
| Procedure |
diagnostic laparoscopy |
2 |
2014 |
| Other |
dietary fasted |
2 |
2013 |
| Other |
dietary high fat |
2 |
2013 |
| Procedure |
diffusion-weighted magnetic resonance imaging |
2 |
2005 |
| Drug |
digoxin |
2 |
2015 |
| Drug |
dm-choc-pen |
2 |
2013 |
| Genetic |
dna analysis |
2 |
2010 |
| Drug |
docetaxel (xrp6976) |
2 |
2010 |
| Biological |
donor lymphocyte infusion |
2 |
2010 |
| Biological |
donor lymphocyte infusion (dli) |
2 |
2011 |
| Drug |
dovitinib (tki258) |
2 |
2013 |
| Drug |
doxycycline |
2 |
2012 |
| Drug |
e7050 |
2 |
2009 |
| Drug |
e7389-lf |
2 |
2019 |
| Other |
electron microscopy |
2 |
2008 |
| Behavioral |
empathic visitor |
2 |
2012 |
| Drug |
enasidenib |
2 |
2018 |
| Drug |
endocrine therapy |
2 |
2019 |
| Behavioral |
enhanced usual care |
2 |
2014 |
| Drug |
enmd-2076 |
2 |
2009 |
| Drug |
ensartinib |
2 |
2017 |
| Drug |
entospletinib |
2 |
2015 |
| Drug |
epo906 |
2 |
2007 |
| Drug |
epothilone b |
2 |
2002 |
| Device |
esd |
2 |
2017 |
| Device |
eus-guided rfa |
2 |
2016 |
| Behavioral |
exercise training |
2 |
2015 |
| Procedure |
extraperitoneal laparoscopic aortic lymphadenectomy |
2 |
2013 |
| Drug |
fenretinide |
2 |
2006 |
| Drug |
ferumoxytol |
2 |
2008 |
| Drug |
fgfr inhibitor azd4547 |
2 |
2020 |
| Drug |
floxuridine |
2 |
2000 |
| Drug |
folfox6 |
2 |
2011 |
| Biological |
g207 |
2 |
2019 |
| Drug |
gadolinium |
2 |
2008 |
| Biological |
ganitumab |
2 |
2011 |
| Drug |
gastrectomy |
2 |
2014 |
| Drug |
gdc-0919 |
2 |
2014 |
| Drug |
gem 231 |
2 |
2000 |
| Drug |
gemcitabine hcl oral formulation |
2 |
2013 |
| Drug |
gemcitabine/cisplatin |
2 |
2018 |
| Drug |
gemtuzumab ozogamicin |
2 |
2018 |
| Drug |
gm-csf |
2 |
2018 |
| Drug |
gsk1363089 |
2 |
2008 |
| Drug |
gvhd prophylaxis |
2 |
2016 |
| Drug |
gx-i7 |
2 |
2018 |
| Genetic |
hematopoietic stem cell transplantation |
2 |
2011 |
| Device |
hipec |
2 |
2017 |
| Drug |
hl-085 |
2 |
2018 |
| Drug |
hm30181ak tablet |
2 |
2009 |
| Drug |
hm30181ak tablet / irinotecan tablets |
2 |
2009 |
| Drug |
hmpl-523 |
2 |
2016 |
| Drug |
hs-10241 |
2 |
2016 |
| Drug |
hydrocortisone |
2 |
2005 |
| Procedure |
hyperthermia treatment |
2 |
2019 |
| Biological |
ibi188 |
2 |
2018 |
| Drug |
idasanutlin |
2 |
2017 |
| Radiation |
image-guided adaptive radiation therapy |
2 |
2015 |
| Biological |
imc-1121b |
2 |
2009 |
| Biological |
imc-a12 |
2 |
2008 |
| Drug |
incagn01876 |
2 |
2017 |
| Drug |
incb050465 |
2 |
2016 |
| Drug |
incb059872 |
2 |
2016 |
| Drug |
incmga00012 |
2 |
2018 |
| Drug |
indisulam |
2 |
1999 |
| Drug |
indocyanine green |
2 |
2016 |
| Drug |
induction chemotherapy |
2 |
2013 |
| Radiation |
intensity modulated radiation therapy |
2 |
2012 |
| Procedure |
intercostal uniportal vats |
2 |
2018 |
| Drug |
interferon alfa-2b |
2 |
2014 |
| Behavioral |
intervention |
2 |
2018 |
| Drug |
intra-arterial cetuximab |
2 |
2016 |
| Drug |
intra-arterial mannitol |
2 |
2016 |
| Drug |
irinotecan tablets |
2 |
2009 |
| Drug |
isatuximab sar650984 |
2 |
2010 |
| Drug |
ispinesib |
2 |
2006 |
| Drug |
ivosidenib |
2 |
2019 |
| Biological |
kn035 |
2 |
2016 |
| Drug |
kpt-330 |
2 |
2012 |
| Drug |
ku-0059436 (azd2281)(parp inhibitor) |
2 |
2007 |
| Biological |
lag525 |
2 |
2017 |
| Device |
led-based light infusion device |
2 |
2004 |
| Procedure |
light-scattering spectroscopy |
2 |
2008 |
| Device |
light emitting diodes (led) |
2 |
2004 |
| Drug |
linifanib |
2 |
2011 |
| Drug |
liposome-encapsulated daunorubicin-cytarabine |
2 |
2019 |
| Drug |
lomustine |
2 |
2018 |
| Procedure |
loop electrosurgical excision procedure |
2 |
2014 |
| Procedure |
loop electrosurgical excision procedure (leep) |
2 |
2011 |
| Drug |
lorazepam |
2 |
2013 |
| Drug |
ly2523355 |
2 |
2010 |
| Drug |
ly3022855 |
2 |
2014 |
| Drug |
ly3023414 |
2 |
2014 |
| Drug |
ly3039478 |
2 |
2016 |
| Drug |
ly3321367 |
2 |
2016 |
| Drug |
m2 |
2 |
2012 |
| Biological |
m7824 |
2 |
2020 |
| Device |
magnetic resonance high intensity focused ultrasound |
2 |
2015 |
| Procedure |
magnetic resonance imaging (mri) |
2 |
2018 |
| Procedure |
magnetic resonance spectroscopic imaging |
2 |
2014 |
| Behavioral |
meaning-making intervention (mmi) |
2 |
2012 |
| Drug |
medi-551 |
2 |
2009 |
| Biological |
medi0562 |
2 |
2014 |
| Biological |
medi4736 (durvalumab) |
2 |
2017 |
| Procedure |
meditation therapy |
2 |
2016 |
| Drug |
megestrol acetate |
2 |
2017 |
| Drug |
memantine |
2 |
2019 |
| Procedure |
metastasectomy |
2 |
2016 |
| Drug |
methoxyamine |
2 |
2009 |
| Drug |
methylphenidate |
2 |
2018 |
| Combination Product |
mfolfox6 |
2 |
2018 |
| Other |
mick assay |
2 |
2006 |
| Genetic |
microarray analysis |
2 |
2008 |
| Procedure |
microdialysis |
2 |
2014 |
| Procedure |
microwave ablation |
2 |
2016 |
| Device |
miltenyi biotec clinimacs |
2 |
2005 |
| Dietary Supplement |
mistletoe extract |
2 |
2000 |
| Drug |
mk-3475 |
2 |
2014 |
| Drug |
mk2461 |
2 |
2007 |
| Drug |
mm-121 |
2 |
2011 |
| Drug |
morphine |
2 |
2018 |
| Device |
mr-guided laser interstitial thermal therapy system |
2 |
2006 |
| Combination Product |
mr-hifu |
2 |
2020 |
| Drug |
mrtx849 |
2 |
2018 |
| Drug |
msb0011359c |
2 |
2015 |
| Drug |
msb2311 injection |
2 |
2018 |
| Drug |
msc1936369b |
2 |
2011 |
| Drug |
msc2156119j |
2 |
2009 |
| Biological |
multi-peptide cmv-modified vaccinia ankara vaccine |
2 |
2018 |
| Behavioral |
music therapy |
2 |
2018 |
| Genetic |
mutation analysis |
2 |
2007 |
| Drug |
nanoparticle albumin-bound rapamycin |
2 |
2016 |
| Drug |
nbm-bmx softgel capsules |
2 |
2019 |
| Biological |
necitumumab |
2 |
2012 |
| Drug |
nelfinavir mesylate |
2 |
2011 |
| Drug |
neo-adjuvant erbitux-based chemotherapy |
2 |
2011 |
| Procedure |
neoadjuvant therapy |
2 |
2002 |
| Drug |
neostigmine |
2 |
2017 |
| Drug |
netupitant |
2 |
2017 |
| Drug |
nicordâ® |
2 |
2010 |
| Drug |
nimotuzumab |
2 |
2019 |
| Drug |
nivolumab injection [opdivo] |
2 |
2018 |
| Biological |
nk cells |
2 |
2020 |
| Biological |
nk immunotherapy |
2 |
2016 |
| Genetic |
nucleic acid sequencing |
2 |
2010 |
| Biological |
ny-eso-1 reactive tcr retroviral vector transduced autologous pbl |
2 |
2016 |
| Dietary Supplement |
ocoxin-viusid |
2 |
2018 |
| Procedure |
ommaya reservoir |
2 |
2015 |
| Drug |
omp-52m51 |
2 |
2013 |
| Drug |
on 01910.na |
2 |
2010 |
| Drug |
ondansetron |
2 |
2012 |
| Drug |
opb-51602 |
2 |
2010 |
| Drug |
oprozomib |
2 |
2010 |
| Drug |
oral onc201 |
2 |
2014 |
| Drug |
oral repotrectinib (tpx-0005) |
2 |
2019 |
| Drug |
oraxol |
2 |
2016 |
| Drug |
osimertinib |
2 |
2014 |
| Drug |
oxycodone |
2 |
2018 |
| Drug |
p1446a-05 |
2 |
2009 |
| Drug |
paclitaxel albumin-stabilized nanoparticle formulation |
2 |
2004 |
| Radiation |
palliative radiation therapy |
2 |
2016 |
| Procedure |
pancreaticoduodenectomy |
2 |
2013 |
| Drug |
patupilone/epo906 |
2 |
2007 |
| Drug |
pd-0332991 |
2 |
2011 |
| Biological |
peg-filgrastim |
2 |
2019 |
| Biological |
peg-interferon alfa-2b |
2 |
2001 |
| Drug |
pegph20 |
2 |
2010 |
| Drug |
pep02 |
2 |
2016 |
| Drug |
pexidartinib |
2 |
2015 |
| Drug |
pf-04518600 |
2 |
2015 |
| Drug |
pf-05082566 |
2 |
2014 |
| Other |
pharmacodynamic study |
2 |
2017 |
| Other |
pharmacogenomic studies |
2 |
2010 |
| Procedure |
photodynamic therapy |
2 |
2004 |
| Procedure |
phototherapy |
2 |
2004 |
| Procedure |
physical therapy |
2 |
2016 |
| Drug |
pioglitazone |
2 |
2010 |
| Drug |
plx3397 |
2 |
2009 |
| Biological |
poly-iclc |
2 |
2009 |
| Genetic |
polymorphism analysis |
2 |
2010 |
| Drug |
pr-104 |
2 |
2006 |
| Drug |
pr104 |
2 |
2011 |
| Drug |
proflavine |
2 |
2016 |
| Biological |
prostvac-f |
2 |
2016 |
| Biological |
prostvac-v |
2 |
2016 |
| Radiation |
proton therapy |
2 |
2014 |
| Drug |
psc 833 |
2 |
1999 |
| Device |
radiofrequency ablation |
2 |
2014 |
| Drug |
rdea119 |
2 |
2008 |
| Drug |
rebastinib |
2 |
2018 |
| Drug |
regorafenib (bay73-4506) |
2 |
2009 |
| Drug |
regorafenib (stivarga, bay73-4506) |
2 |
2015 |
| Drug |
relatlimab |
2 |
2018 |
| Behavioral |
resistance training |
2 |
2016 |
| Drug |
retifanlimab |
2 |
2019 |
| Genetic |
reverse transcriptase-polymerase chain reaction |
2 |
2006 |
| Drug |
rhuepo |
2 |
2005 |
| Drug |
rhumab 2c4 |
2 |
2015 |
| Drug |
ribavirin |
2 |
2014 |
| Drug |
rifampicin |
2 |
2016 |
| Drug |
rigosertib sodium |
2 |
2012 |
| Drug |
rimiducid |
2 |
2018 |
| Drug |
rmc-4630 |
2 |
2018 |
| Drug |
ro6958688 |
2 |
2014 |
| Drug |
ropivacaine |
2 |
2015 |
| Drug |
rosuvastatin |
2 |
2015 |
| Drug |
s-3304 |
2 |
2002 |
| Drug |
sabarubicin |
2 |
1999 |
| Drug |
samotolisib |
2 |
2017 |
| Drug |
sar245409 |
2 |
2012 |
| Drug |
sar405838 |
2 |
2013 |
| Biological |
sar408701 |
2 |
2017 |
| Drug |
satraplatin |
2 |
2010 |
| Drug |
sb-715992 |
2 |
2005 |
| Drug |
sb1518 |
2 |
2010 |
| Combination Product |
second-line chemotherapy |
2 |
2018 |
| Dietary Supplement |
selenium |
2 |
2003 |
| Drug |
selicrelumab |
2 |
2014 |
| Drug |
selinexor |
2 |
2014 |
| Drug |
selumetinib sulfate |
2 |
2017 |
| Procedure |
sham rtms (same parameters but with coil elevated |
2 |
2014 |
| Drug |
shr-1501 |
2 |
2019 |
| Drug |
simvastatin |
2 |
2010 |
| Procedure |
single photon emission computed tomography |
2 |
2013 |
| Biological |
sipuleucel-t |
2 |
2011 |
| Drug |
sjg-136 |
2 |
2005 |
| Behavioral |
smoking cessation intervention |
2 |
2018 |
| Drug |
sns-032 injection |
2 |
2007 |
| Drug |
sodium thiosulfate |
2 |
2019 |
| Drug |
sonidegib |
2 |
2018 |
| Drug |
sta-5312 |
2 |
2006 |
| Radiation |
stereotactic body radiotherapy |
2 |
2019 |
| Radiation |
stereotactic radiotherapy |
2 |
2017 |
| Procedure |
subxiphoid uniportal vats |
2 |
2018 |
| Drug |
sugammadex |
2 |
2017 |
| Drug |
surufatinib |
2 |
2019 |
| Behavioral |
symptom questionnaire |
2 |
2017 |
| Drug |
t-1101 (tosylate) |
2 |
2017 |
| Biological |
t601 |
2 |
2019 |
| Combination Product |
tace |
2 |
2018 |
| Drug |
tak-117 |
2 |
2013 |
| Drug |
talabostat mesylate |
2 |
2019 |
| Drug |
talaporfin sodium (ls11) |
2 |
2004 |
| Drug |
taselisib |
2 |
2020 |
| Drug |
taxotere |
2 |
2005 |
| Behavioral |
telephone coaching |
2 |
2017 |
| Biological |
therapeutic allogeneic lymphocytes |
2 |
2005 |
| Device |
thermal ablation |
2 |
2013 |
| Drug |
tilsotolimod |
2 |
2019 |
| Drug |
tirabrutinib |
2 |
2015 |
| Drug |
tirapazamine |
2 |
1999 |
| Drug |
tmz |
2 |
2010 |
| Drug |
total lymphoid irradiation |
2 |
2010 |
| Radiation |
total marrow irradiation |
2 |
2015 |
| Procedure |
transperitoneal laparoscopic aortic lymphadenectomy |
2 |
2013 |
| Biological |
trastuzumab emtansine |
2 |
2020 |
| Drug |
trc105 |
2 |
2011 |
| Drug |
treosulfan |
2 |
2010 |
| Biological |
urelumab |
2 |
2013 |
| Drug |
vadimezan |
2 |
2011 |
| Drug |
valganciclovir |
2 |
2017 |
| Drug |
vinblastine |
2 |
1999 |
| Drug |
vinorelbine |
2 |
2011 |
| Drug |
vinorelbine ditartrate |
2 |
2010 |
| Drug |
voriconazole |
2 |
2009 |
| Procedure |
wbrt |
2 |
2005 |
| Procedure |
week). |
2 |
2014 |
| Radiation |
whole brain radiation therapy |
2 |
2015 |
| Biological |
wild-type reovirus |
2 |
2010 |
| Combination Product |
with chemotherapy |
2 |
2019 |
| Behavioral |
yoga |
2 |
2018 |
| Drug |
zanubrutinib |
2 |
2019 |
| Drug |
zk222584 |
2 |
2008 |
| Biological |
NA |
1 |
2017 |
| Behavioral |
‘open window’ project |
1 |
2006 |
| Drug |
- certagen (multivitamins with minerals) |
1 |
2005 |
| Drug |
- lyc-o-mato (dietary supplement, 30 mg lycopene |
1 |
2005 |
| Drug |
- lyc-o-mato (dietary supplement, 30 mg lycopene/day) |
1 |
2005 |
| Drug |
(18f)mfbg |
1 |
2020 |
| Radiation |
(np-59) |
1 |
2007 |
| Drug |
(pdt) photodynamic therapy |
1 |
2012 |
| Other |
[11c] kinase inhibitor pet [15o]water pet |
1 |
2014 |
| Other |
[11c] kinase inhibitor pet [15o]water pet/tumor biopsies. |
1 |
2014 |
| Drug |
[13c]-radiolabeled idasanutlin |
1 |
2016 |
| Drug |
[14c]-fluzoparib |
1 |
2019 |
| Drug |
[14c]-pevonedistat |
1 |
2017 |
| Drug |
[14c]-radiolabeled idasanutlin |
1 |
2016 |
| Drug |
[14c]azd2014 |
1 |
2015 |
| Drug |
[14c]azd9291 |
1 |
2015 |
| Drug |
[18f] 4-l-fluoroglutamine (2s,4r) |
1 |
2012 |
| Drug |
[18f]flt-pet |
1 |
2019 |
| Drug |
[18f]flt-pet/ct |
1 |
2019 |
| Drug |
[â¹â´c]prexasertib |
1 |
2016 |
| Biological |
< 65 years old |
1 |
2016 |
| Drug |
0.125% bupivicaine with 2 mcg |
1 |
2014 |
| Drug |
0.125% bupivicaine with 2 mcg/ml fentanyl. |
1 |
2014 |
| Drug |
1-methyl-d-tryptophan |
1 |
2010 |
| Drug |
1 ml intravenous solution [keytruda] |
1 |
2018 |
| Drug |
1.7 ml subcutaneous solution [xgeva] |
1 |
2018 |
| Procedure |
1.eus-fna with |
1 |
2011 |
| Procedure |
1.eus-fna with/without suction |
1 |
2011 |
| Device |
10 mm nitinol zilver stent |
1 |
2005 |
| Device |
10 mm stainless steel wallstent |
1 |
2005 |
| Drug |
1000 mg iron isomaltoside 1000 |
1 |
2010 |
| Biological |
1121b |
1 |
2008 |
| Procedure |
11c-met pet |
1 |
2019 |
| Procedure |
11c-met pet/mri |
1 |
2019 |
| Drug |
120 mg ly2784544 |
1 |
2012 |
| Drug |
120 mg mmc in 60ml gel |
1 |
2014 |
| Drug |
120 mg mmc in 90ml gel |
1 |
2014 |
| Drug |
124-iodine-cg250 (124i-cg250) |
1 |
2005 |
| Drug |
13-cis-retinoic acid |
1 |
2018 |
| Drug |
131i-mibg |
1 |
2017 |
| Drug |
140 mg mmc in 60ml gel |
1 |
2014 |
| Drug |
140 mg mmc in 90ml gel |
1 |
2014 |
| Drug |
14c-labeled gilteritinib |
1 |
2015 |
| Drug |
160 mg mmc in 60ml gel |
1 |
2014 |
| Drug |
160 mg mmc in 90ml gel |
1 |
2014 |
| Drug |
177lu-dota0-tyr3-octreotate |
1 |
2012 |
| Drug |
177lu-octreotate |
1 |
2016 |
| Procedure |
18 bivalent vaccine |
1 |
2015 |
| Biological |
18 l1 virus-like particle |
1 |
2005 |
| Biological |
18 vaccine (cervarixâ„¢) |
1 |
2006 |
| Radiation |
18f-(2s,4r)4-fluoroglutamine |
1 |
2018 |
| Drug |
18f-alf-nota-octreotide |
1 |
2018 |
| Drug |
18f-dcfpyl |
1 |
2017 |
| Drug |
18f-dcfpyl injection |
1 |
2015 |
| Drug |
18f-fdg |
1 |
2017 |
| Radiation |
18f-fdg pet-mri-imaging |
1 |
2015 |
| Other |
18f-fhbg |
1 |
2017 |
| Drug |
18f-fluciclovine |
1 |
2019 |
| Drug |
18f-fluorothymidine pet scan |
1 |
2008 |
| Drug |
18f-î±vî²6-bp |
1 |
2017 |
| Drug |
18f-naf |
1 |
2017 |
| Device |
2-dimensional distal pancreatectomy |
1 |
2016 |
| Drug |
2-methoxyestradiol |
1 |
2002 |
| Biological |
2-mpp (pbcar3-phosphopeptide |
1 |
2013 |
| Biological |
2-mpp (pbcar3-phosphopeptide / pirs2-phosphopeptide) |
1 |
2013 |
| Procedure |
2 doses of hpv 16 |
1 |
2015 |
| Procedure |
2 doses of hpv 16/18 bivalent vaccine |
1 |
2015 |
| Procedure |
2.pushing the stylet |
1 |
2011 |
| Procedure |
2.pushing the stylet/injecting air |
1 |
2011 |
| Procedure |
20 hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days |
1 |
2014 |
| Procedure |
20 hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week). |
1 |
2014 |
| Device |
22-gauge needle |
1 |
2016 |
| Drug |
22 gbq 177lu-dotatate |
1 |
2016 |
| Device |
25-gauge needle |
1 |
2016 |
| Drug |
2503 |
1 |
2011 |
| Drug |
28 gbq 177lu-dotatate |
1 |
2016 |
| Device |
3’-deoxy-3’-[18f]fluorothymidine |
1 |
2009 |
| Device |
3-dimensional distal pancreatectomy |
1 |
2016 |
| Drug |
3 day thiarabine |
1 |
2010 |
| Procedure |
3 doses of hpv 16 |
1 |
2015 |
| Procedure |
3 doses of hpv 16/18 bivalent vaccine |
1 |
2015 |
| Biological |
30î¼g hpv |
1 |
2011 |
| Device |
3d-printed patient-specific titanium plates |
1 |
2017 |
| Procedure |
3d conformal radiation therapy |
1 |
2005 |
| Procedure |
3d conformal radiation therapy/radiosurgery |
1 |
2005 |
| Diagnostic Test |
3t mri scanner |
1 |
2018 |
| Drug |
4-demethyl-4-cholestryloxycarbonylpenclomedine |
1 |
2014 |
| Drug |
4 (a chimeric monoclonal antibody) |
1 |
2012 |
| Device |
40 mg mmc in 40 ml tc-3. |
1 |
2016 |
| Drug |
40 mg po bid |
1 |
2019 |
| Procedure |
4d ct scans |
1 |
2007 |
| Drug |
4sc-202 |
1 |
2011 |
| Biological |
4scar-276 |
1 |
2020 |
| Genetic |
4scar-gd2 |
1 |
2016 |
| Biological |
4scar123 |
1 |
2017 |
| Biological |
4scar19 |
1 |
2017 |
| Biological |
4scar19/4scar123 |
1 |
2017 |
| Biological |
4scar19/4scar20 |
1 |
2017 |
| Biological |
4scar19/4scar22 |
1 |
2017 |
| Biological |
4scar19/4scar30 |
1 |
2017 |
| Biological |
4scar19/4scar38 |
1 |
2017 |
| Biological |
4scar19/4scar70 |
1 |
2017 |
| Biological |
4scar20 |
1 |
2017 |
| Biological |
4scar22 |
1 |
2017 |
| Biological |
4scar30 |
1 |
2017 |
| Biological |
4scar38 |
1 |
2017 |
| Biological |
4scar70 |
1 |
2017 |
| Drug |
5-azacitidine |
1 |
2018 |
| Drug |
5-azacytidine, erlotinib |
1 |
2009 |
| Combination Product |
5-fc |
1 |
2019 |
| Drug |
5-flourouracil |
1 |
2018 |
| Drug |
5-fluoro-2’-deoxycytidine (fdcyd) |
1 |
2009 |
| Drug |
5-fluoro-2’-deoxycytidine (fdcyd) / tetrahydrouridine (thu) |
1 |
2009 |
| Drug |
5-fluorouracil (5fu) |
1 |
2016 |
| Drug |
5-fluorouracil/capecitabine |
1 |
2014 |
| Drug |
5-fluorouracil/interferon |
1 |
2012 |
| Drug |
5-fluorouracile (5-fu) |
1 |
2015 |
| Drug |
5-fu bolus |
1 |
2013 |
| Drug |
5-fu infusion |
1 |
2013 |
| Drug |
5 - fluorouracil |
1 |
2010 |
| Drug |
5 - fu |
1 |
2010 |
| Drug |
5 azacytidine |
1 |
2017 |
| Drug |
5 day thiarabine |
1 |
2010 |
| Drug |
5 fu |
1 |
2005 |
| Drug |
5% albumin infusion 3 hours |
1 |
2016 |
| Drug |
5% albumin infusion 30 min |
1 |
2016 |
| Drug |
50% nitrogen premix |
1 |
2008 |
| Drug |
50% nitrous oxide premix (kalinox 170 bar) |
1 |
2008 |
| Drug |
50% oxygen |
1 |
2008 |
| Drug |
50% oxygen/50% nitrogen premix |
1 |
2008 |
| Drug |
50% oxygen/50% nitrous oxide premix (kalinox 170 bar) |
1 |
2008 |
| Drug |
500 mg iron isomaltoside 1000 |
1 |
2010 |
| Drug |
5fu) |
1 |
2017 |
| Device |
6 mm nitinol zilver stent |
1 |
2005 |
| Biological |
60î¼g hpv |
1 |
2011 |
| Drug |
68-gallium dotatate |
1 |
2019 |
| Drug |
68ga-dotatoc pet/c |
1 |
2012 |
| Drug |
68ga-dotatoc pet/ct |
1 |
2015 |
| Drug |
68ga-psma |
1 |
2018 |
| Drug |
6r-mthf 200 mg |
1 |
2012 |
| Drug |
6r-mthf 200 mg/m2 |
1 |
2012 |
| Drug |
6r-mthf 60 mg |
1 |
2012 |
| Drug |
6r-mthf 60 mg/m2 |
1 |
2012 |
| Drug |
7-hydroxystaurosporine (ucn-01) |
1 |
1999 |
| Drug |
7-t-butyldimethylsilyl-10-hydroxycamptothecin |
1 |
2010 |
| Device |
71 high cut-off brain microdialysis catheter |
1 |
2019 |
| Device |
80 mg mmc in 40 ml tc-3. |
1 |
2016 |
| Diagnostic Test |
89zr-kn035 |
1 |
2018 |
| Drug |
89zr-mmot0530a |
1 |
2013 |
| Drug |
89zr-tak-164 |
1 |
2018 |
| Drug |
89zrë—dfoë—regn3504 |
1 |
2018 |
| Drug |
9-ing-41 |
1 |
2018 |
| Biological |
90î¼g hpv |
1 |
2011 |
| Drug |
90y-dota-3-tyr-octreotide |
1 |
2017 |
| Other |
99mtc-sestamibi imaging |
1 |
2003 |
| Biological |
9vhpv vaccine |
1 |
2018 |
| Drug |
a-007 |
1 |
2008 |
| Behavioral |
a life review program |
1 |
2009 |
| Biological |
a second generation 4 1bbî¶ cd19-her2tg |
1 |
2018 |
| Biological |
a*0201 restricted peptides |
1 |
2013 |
| Biological |
≤75 years old |
1 |
2016 |
| Drug |
â¸â¹zr-df-iab22m2c infusion |
1 |
2017 |
| Drug |
a007 |
1 |
2006 |
| Drug |
a1: amg 386 10 mg |
1 |
2008 |
| Drug |
a1: amg 386 10 mg/kg / liposomal doxorubicin |
1 |
2008 |
| Drug |
a166 |
1 |
2018 |
| Other |
â²â¹â²pb-tcmc-trastuzumab |
1 |
2011 |
| Drug |
a3: amg 386 15mg |
1 |
2008 |
| Drug |
a3: amg 386 15mg/kg / liposomal doxorubicin |
1 |
2008 |
| Drug |
ab154 |
1 |
2018 |
| Drug |
ab680 |
1 |
2020 |
| Drug |
ab928 |
1 |
2020 |
| Diagnostic Test |
abbreviated pb mri |
1 |
2018 |
| Drug |
abbv-151 |
1 |
2019 |
| Drug |
abbv-155 |
1 |
2018 |
| Drug |
abbv-321 |
1 |
2017 |
| Drug |
abbv-399 |
1 |
2017 |
| Drug |
abbv-428 |
1 |
2016 |
| Drug |
abbv-621 |
1 |
2017 |
| Procedure |
abdominal subcutaneous adipose tissue biopsy |
1 |
2015 |
| Procedure |
abdominal surgery |
1 |
2007 |
| Drug |
abexinostat |
1 |
2018 |
| Drug |
abi-009 |
1 |
2008 |
| Drug |
abi-1968 |
1 |
2017 |
| Drug |
abiraterone |
1 |
2012 |
| Procedure |
ablation probe |
1 |
2013 |
| Procedure |
ablative |
1 |
2002 |
| Procedure |
ablative/excisional therapy |
1 |
2002 |
| Drug |
ablc |
1 |
2008 |
| Drug |
abm-1310 |
1 |
2019 |
| Drug |
abn401- escalation phase |
1 |
2019 |
| Drug |
abn401- expansion phase |
1 |
2019 |
| Drug |
abraxaneâ® |
1 |
2014 |
| Drug |
abt-165 |
1 |
2013 |
| Drug |
abt-348 |
1 |
2010 |
| Drug |
abt-348/carboplatin |
1 |
2010 |
| Drug |
abt-348/docetaxel |
1 |
2010 |
| Drug |
abt-700 |
1 |
2011 |
| Drug |
abt-767 |
1 |
2011 |
| Drug |
abt-806i |
1 |
2011 |
| Drug |
abt-869 |
1 |
2008 |
| Biological |
aca 125 |
1 |
2005 |
| Radiation |
accelerated partial breast irradiation |
1 |
2018 |
| Device |
accelerometer |
1 |
2016 |
| Device |
accelerometry |
1 |
2015 |
| Behavioral |
acceptance |
1 |
2015 |
| Behavioral |
acceptance/commitment therapy |
1 |
2015 |
| Drug |
ace1702 |
1 |
2020 |
| Drug |
acetaminophen |
1 |
2005 |
| Drug |
acp-319 |
1 |
2014 |
| Biological |
act-d |
1 |
2013 |
| Biological |
activated ptcy-mils |
1 |
2015 |
| Other |
active comparator: routine colposcopy |
1 |
2010 |
| Behavioral |
active measures of lifestyle modification |
1 |
2016 |
| Behavioral |
active smokers - control arm |
1 |
2015 |
| Behavioral |
active smokers - smoking cessation arm |
1 |
2015 |
| Device |
activity monitor |
1 |
2019 |
| Drug |
acy-1215 |
1 |
2014 |
| Drug |
acy-241 |
1 |
2015 |
| Drug |
ad-p53 |
1 |
2018 |
| Other |
adapted walking platform |
1 |
2018 |
| Procedure |
adback nk |
1 |
2007 |
| Procedure |
adback nk/t cell |
1 |
2007 |
| Procedure |
additional blood drawn |
1 |
2008 |
| Drug |
additive classical homeopathy |
1 |
2012 |
| Other |
additive homeopathic treatment |
1 |
2009 |
| Drug |
adh300004 |
1 |
2005 |
| Device |
adjustment of mechanical ventilator inspiratory to expiratory time ratio (1:1 to 1:2) |
1 |
2016 |
| Device |
adjustment of mechanical ventilator inspiratory to expiratory time ratio (1:2 to 1:1) |
1 |
2016 |
| Procedure |
adjuvant hipec (open |
1 |
2014 |
| Procedure |
adjuvant hipec (open/laparoscopic) |
1 |
2014 |
| Radiation |
adjuvant pelvic proton radiation |
1 |
2017 |
| Drug |
administration of hypertonic solution 7.5% vs mannitol 20% |
1 |
2005 |
| Drug |
adriamycin |
1 |
2005 |
| Behavioral |
advanced cancer symptom management |
1 |
2017 |
| Radiation |
advanced external radiotherapy by xrays |
1 |
2016 |
| Radiation |
advanced external radiotherapy by xrays/protons |
1 |
2016 |
| Procedure |
advanced magnetic resonance imaging scan |
1 |
2018 |
| Behavioral |
adventure-based training |
1 |
2013 |
| Behavioral |
advice to use condoms |
1 |
2016 |
| Biological |
adxs-neo |
1 |
2017 |
| Drug |
adxs31-164 |
1 |
2015 |
| Drug |
aee788 |
1 |
2005 |
| Behavioral |
aerobic exercise |
1 |
2016 |
| Biological |
aerosolized aldesleukin |
1 |
2012 |
| Drug |
aflibercept (ave0005) |
1 |
2010 |
| Drug |
aflibercept (ziv-aflibercept) |
1 |
2012 |
| Drug |
aflibercept ave0005 |
1 |
2013 |
| Drug |
ag-120 |
1 |
2014 |
| Drug |
ag881 |
1 |
2015 |
| Drug |
agen1181 |
1 |
2019 |
| Drug |
agen1223 |
1 |
2019 |
| Drug |
agen2034 |
1 |
2019 |
| Drug |
agen2373 |
1 |
2019 |
| Drug |
agi-134 |
1 |
2018 |
| Drug |
ags-22m6e |
1 |
2011 |
| Drug |
ags67e |
1 |
2014 |
| Other |
ah-ha tool in the epic ehr |
1 |
2019 |
| Procedure |
airway stent implantation |
1 |
2019 |
| Drug |
ak105 |
1 |
2019 |
| Drug |
al2846 |
1 |
2016 |
| Drug |
albumin-bound paclitaxel |
1 |
2020 |
| Drug |
alectinib |
1 |
2016 |
| Drug |
alimta |
1 |
2002 |
| Drug |
alks 4230 / pembrolizumab |
1 |
2016 |
| Drug |
all-trans retinoic acid (atra) |
1 |
2016 |
| Drug |
all trans retinoic acid |
1 |
2018 |
| Biological |
allo-501 follow-up |
1 |
2016 |
| Procedure |
allogeneic blood |
1 |
2010 |
| Procedure |
allogeneic blood/marrow transplant |
1 |
2010 |
| Biological |
allogeneic cd123car-cd28-cd3zeta-egfrt-expressing t-lymphocytes |
1 |
2014 |
| Procedure |
allogeneic cell transplantation |
1 |
2003 |
| Biological |
allogeneic cytomegalovirus-specific cytotoxic t lymphocytes |
1 |
2014 |
| Biological |
allogeneic epstein-barr virus-specific cytotoxic t lymphocytes |
1 |
1999 |
| Procedure |
allogeneic stem cell transplant |
1 |
2005 |
| Biological |
allostim |
1 |
2007 |
| Biological |
allostim-7 |
1 |
2009 |
| Biological |
allostim-9 |
1 |
2009 |
| Biological |
allostim8 |
1 |
2009 |
| Biological |
allostim8/allostim-9 |
1 |
2009 |
| Genetic |
allovectin-7â® |
1 |
2002 |
| Drug |
aln-vsp02 |
1 |
2009 |
| Drug |
alpelisib |
1 |
2014 |
| Drug |
alpha-lipoic acid |
1 |
2005 |
| Drug |
alpn-202 |
1 |
2019 |
| Drug |
alrn-6924 |
1 |
2018 |
| Biological |
alt-801 |
1 |
2007 |
| Biological |
alt-803 |
1 |
2013 |
| Biological |
alt-836 in combination with gemcitabine |
1 |
2011 |
| Device |
am4113-n5ut dino-lite |
1 |
2015 |
| Drug |
amc303 |
1 |
2016 |
| Drug |
american ginseng |
1 |
2008 |
| Genetic |
amg 162- 180 mg q 4 weeks |
1 |
2005 |
| Genetic |
amg 162 180 mg (sc) q 12 weeks |
1 |
2005 |
| Drug |
amg 208 |
1 |
2008 |
| Drug |
amg 319 |
1 |
2011 |
| Drug |
amg 337 |
1 |
2010 |
| Drug |
amg 404 |
1 |
2019 |
| Drug |
amg 510 |
1 |
2018 |
| Drug |
amg 531 |
1 |
2005 |
| Drug |
amg 650 |
1 |
2020 |
| Drug |
amg 820 |
1 |
2011 |
| Dietary Supplement |
amino acid based medical food |
1 |
2018 |
| Dietary Supplement |
amino acid based medical food/drink |
1 |
2018 |
| Drug |
aminobiphosphonate |
1 |
2010 |
| Drug |
aminolaevulinic acid |
1 |
2015 |
| Drug |
aminolaevulinic acid photodynamic therapy |
1 |
2014 |
| Drug |
aminosyn ii |
1 |
2015 |
| Drug |
amitriptyline |
1 |
2007 |
| Drug |
amorphous calcium carbonate |
1 |
2017 |
| Drug |
amorphous calcium carbonate (acc) - amor |
1 |
2018 |
| Drug |
amphinex |
1 |
2013 |
| Drug |
amphinex (tpcs2a) |
1 |
2009 |
| Drug |
amuvatinib (mp-470) |
1 |
2009 |
| Biological |
amv564 |
1 |
2019 |
| Drug |
anagrelide cr |
1 |
2014 |
| Biological |
anakinra |
1 |
2012 |
| Drug |
anamorelin hydrochloride |
1 |
2017 |
| Procedure |
anatomic pulmonary resection |
1 |
2016 |
| Drug |
ancillary treatment |
1 |
2014 |
| Biological |
androgen ablation (aa) |
1 |
2009 |
| Drug |
anetumab ravtansine (bay94-9343) |
1 |
2016 |
| Drug |
angiocalâ® (prs-050-peg40) |
1 |
2010 |
| Procedure |
angled away from the head) every day for 10 consecutive days (5 days |
1 |
2014 |
| Procedure |
angled away from the head)every day for ten consecutive days (5 days |
1 |
2014 |
| Drug |
anhydrovinblastine |
1 |
1999 |
| Drug |
anlotinib hydrochloride |
1 |
2019 |
| Drug |
antacid |
1 |
2009 |
| Drug |
anti-angiogenesis |
1 |
2004 |
| Biological |
anti-cd19-car t cells |
1 |
2016 |
| Biological |
anti-cd30-car-transduced t cells |
1 |
2016 |
| Genetic |
anti-cd30 car t cells |
1 |
2019 |
| Biological |
anti-cd33-car-transduced t cells |
1 |
2016 |
| Other |
anti-cd8 pet imaging agent |
1 |
2019 |
| Drug |
anti-egfr immunoliposomes loaded with doxorubicin |
1 |
2012 |
| Biological |
anti-endosialin |
1 |
2012 |
| Biological |
anti-endosialin/tem1 monoclonal antibody morab-004 |
1 |
2012 |
| Biological |
anti-epcam x anti-cd3 (removab) |
1 |
2005 |
| Drug |
anti-gitr agonistic monoclonal antibody bms-986156 |
1 |
2019 |
| Biological |
anti-ley-car-transduced t cells |
1 |
2016 |
| Biological |
anti-macrophage migration inhibitory factor (anti-mif) antibody |
1 |
2013 |
| Biological |
anti-mesothelin car-t cells |
1 |
2018 |
| Drug |
anti-nausea therapy |
1 |
2013 |
| Biological |
anti-ox40 antibody bms 986178 |
1 |
2019 |
| Biological |
anti-ox40 antibody pf-04518600 |
1 |
2017 |
| Drug |
anti-pd-1 antibody |
1 |
2016 |
| Drug |
anti-pd-1 monoclonal antibody |
1 |
2018 |
| Drug |
anti-pd-l1 |
1 |
2019 |
| Drug |
anti-seizure prophylaxis |
1 |
2012 |
| Drug |
anti-thymocyte globulin iv |
1 |
2008 |
| Biological |
anti-thyroglobulin mtcr-transduced autologous peripheral blood lymphocytes |
1 |
2016 |
| Drug |
antiandrogen therapy |
1 |
2011 |
| Drug |
antibiotics |
1 |
2013 |
| Drug |
antibodies as follows: |
1 |
2005 |
| Procedure |
antiestrogen therapy |
1 |
2002 |
| Drug |
antithymocyte globulin |
1 |
2009 |
| Drug |
anx-514 |
1 |
2008 |
| Drug |
ap-002 |
1 |
2019 |
| Drug |
ap 12009 |
1 |
2009 |
| Drug |
ap1903 |
1 |
2017 |
| Drug |
apatinib mesylate |
1 |
2020 |
| Drug |
apatinib mesylate tablets |
1 |
2017 |
| Radiation |
apbi |
1 |
2018 |
| Drug |
apg-2575 |
1 |
2018 |
| Drug |
apl-101 oral capsules |
1 |
2017 |
| Drug |
ar-67 (formerly db-67) |
1 |
2006 |
| Drug |
ara-c |
1 |
2007 |
| Drug |
aranespâ® |
1 |
2005 |
| Drug |
arginase1 peptide: arglong2(169-206) peptide sequence isakdivyiglrdvdpgehyilktlgikyfsmtevdrl |
1 |
2019 |
| Drug |
arginine recovery supplement |
1 |
2017 |
| Procedure |
argon plasma coagulation |
1 |
2007 |
| Drug |
argx-110 |
1 |
2013 |
| Drug |
arm 1- dose escalation |
1 |
2009 |
| Drug |
arm 1- dose expansion |
1 |
2009 |
| Radiation |
arm 1 600 cgy x 5 fractions |
1 |
2015 |
| Radiation |
arm 2 800 cgy x 3 fractions |
1 |
2015 |
| Drug |
armodafinil |
1 |
2009 |
| Drug |
aromatase inhibition |
1 |
2002 |
| Drug |
aroplatin |
1 |
2006 |
| Drug |
arq 092 |
1 |
2011 |
| Drug |
arq 501 |
1 |
2007 |
| Drug |
arq 531 |
1 |
2017 |
| Drug |
arq 621 |
1 |
2009 |
| Drug |
arq 736 |
1 |
2010 |
| Drug |
arq 751 |
1 |
2016 |
| Drug |
arq 751/fulvestrant |
1 |
2016 |
| Drug |
arq 751/paclitaxel |
1 |
2016 |
| Drug |
arq 761 |
1 |
2011 |
| Drug |
arq 761 weekly administration |
1 |
2011 |
| Drug |
arry-142886, mek inhibitor; oral |
1 |
2004 |
| Drug |
arry-382 |
1 |
2016 |
| Procedure |
art therapy |
1 |
2017 |
| Procedure |
arterial embolization |
1 |
2018 |
| Procedure |
arterial perfusion |
1 |
1999 |
| Drug |
artesunate ointment 40% |
1 |
2019 |
| Drug |
arx788 |
1 |
2017 |
| Biological |
as04 vaccine |
1 |
2005 |
| Drug |
as1411 |
1 |
2009 |
| Drug |
as703569 |
1 |
2006 |
| Drug |
asg-22ce |
1 |
2011 |
| Drug |
asg-5me |
1 |
2010 |
| Drug |
aslan001 |
1 |
2012 |
| Drug |
aslan002( bms 777607) |
1 |
2012 |
| Drug |
asn007 rd |
1 |
2018 |
| Drug |
asn007: ascending doses |
1 |
2018 |
| Biological |
asonep (sonepcizumab |
1 |
2008 |
| Biological |
asonep (sonepcizumab/lt1009) |
1 |
2008 |
| Drug |
asp1650 |
1 |
2018 |
| Drug |
asp1951 |
1 |
2019 |
| Drug |
asp5878 |
1 |
2014 |
| Other |
assessment |
1 |
2015 |
| Behavioral |
assessment questionnaires |
1 |
2016 |
| Drug |
astx029 |
1 |
2018 |
| Drug |
astx295 |
1 |
2019 |
| Drug |
at-101 |
1 |
2006 |
| Drug |
atamestane |
1 |
2002 |
| Drug |
atezolizumab injection [tecentriq] |
1 |
2019 |
| Drug |
atezolizumab/bevacizumab |
1 |
2016 |
| Drug |
atg [thymoglobulin]) |
1 |
2008 |
| Biological |
atir |
1 |
2013 |
| Biological |
atir101 |
1 |
2015 |
| Drug |
atorvastatin calcium |
1 |
2012 |
| Drug |
atr kinase inhibitor azd6738 |
1 |
2018 |
| Other |
attention control supportive care |
1 |
2020 |
| Drug |
aurora b |
1 |
2010 |
| Drug |
aurora b/c kinase inhibitor gsk1070916a |
1 |
2010 |
| Device |
autolitt system |
1 |
2008 |
| Procedure |
autologous-autologous tandem hematopoietic stem cell transplantation |
1 |
2007 |
| Biological |
autologous car-t |
1 |
2017 |
| Biological |
autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes |
1 |
2014 |
| Biological |
autologous cd8 |
1 |
2017 |
| Biological |
autologous cd8/ slc45a2-specific t lymphocytes |
1 |
2017 |
| Biological |
autologous dc vaccine |
1 |
2019 |
| Drug |
autologous natural killer cells |
1 |
2019 |
| Biological |
autologous stem cell infusion |
1 |
2012 |
| Drug |
autologous stem cell transplantation |
1 |
2013 |
| Procedure |
autologous t cells |
1 |
2006 |
| Combination Product |
autologous tcm immunotherapy |
1 |
2018 |
| Drug |
autologous tumor cell vaccine |
1 |
2007 |
| Biological |
autologous tumor infiltrating lymphocytes ln-145 |
1 |
2018 |
| Procedure |
autophagy inhibition therapy |
1 |
2009 |
| Biological |
av-203 |
1 |
2012 |
| Biological |
av-299 |
1 |
2009 |
| Biological |
av-299 / gefitinib |
1 |
2009 |
| Biological |
av0113 dc-cit |
1 |
2015 |
| Drug |
avb-620 |
1 |
2017 |
| Drug |
ave0005 (aflibercept) |
1 |
2009 |
| Drug |
ave8062 |
1 |
2013 |
| Drug |
avelumab administration at 10mg |
1 |
2017 |
| Drug |
avelumab administration at 10mg/kg |
1 |
2017 |
| Drug |
avelumab injection |
1 |
2020 |
| Drug |
avelumab phase 1b |
1 |
2017 |
| Drug |
avelumab phase 2 |
1 |
2017 |
| Drug |
avid200 |
1 |
2019 |
| Biological |
avx701 |
1 |
2007 |
| Drug |
axumin pet scan |
1 |
2018 |
| Procedure |
az7550 |
1 |
2014 |
| Drug |
aza-tdcyd |
1 |
2017 |
| Drug |
azd 2281 |
1 |
2008 |
| Drug |
azd0466 |
1 |
2019 |
| Drug |
azd1152 part a |
1 |
2006 |
| Drug |
azd1152 part b |
1 |
2006 |
| Drug |
azd1208 |
1 |
2012 |
| Drug |
azd1390 |
1 |
2017 |
| Drug |
azd2461 |
1 |
2010 |
| Drug |
azd2811 |
1 |
2015 |
| Drug |
azd4547 |
1 |
2010 |
| Drug |
azd4573 |
1 |
2017 |
| Drug |
azd5153 |
1 |
2017 |
| Drug |
azd5363/olaparib/durvalumab |
1 |
2018 |
| Drug |
azd5438 |
1 |
2004 |
| Drug |
azd5991 |
1 |
2017 |
| Drug |
azd5991 / venetoclax |
1 |
2017 |
| Drug |
azd6738 |
1 |
2014 |
| Drug |
azd7648 |
1 |
2019 |
| Drug |
azd7762 |
1 |
2006 |
| Drug |
azd8330 |
1 |
2007 |
| Drug |
azd9150 |
1 |
2018 |
| Drug |
azd9150, durvalumab |
1 |
2017 |
| Drug |
azd9291 |
1 |
2015 |
| Drug |
azd9291 tablet dosing |
1 |
2014 |
| Drug |
azurin-derived cell-penetrating peptide p28 |
1 |
2013 |
| Drug |
b1: amg 386 10 mg |
1 |
2008 |
| Drug |
b1: amg 386 10 mg/kg / topotecan |
1 |
2008 |
| Drug |
b3: amg 386 15mg |
1 |
2008 |
| Drug |
b3: amg 386 15mg/kg / topotecan |
1 |
2008 |
| Drug |
baclofen |
1 |
2007 |
| Drug |
baclofen/amitriptyline/ketamine gel |
1 |
2007 |
| Drug |
bactrl-il-12 |
1 |
2019 |
| Drug |
bafetinib |
1 |
2010 |
| Drug |
bardoxolone methyl |
1 |
2007 |
| Other |
baseline geriatric screening |
1 |
2015 |
| Other |
baseline geriatric screening/assessment |
1 |
2015 |
| Behavioral |
baseline questionnaires |
1 |
2016 |
| Drug |
basiliximab |
1 |
2008 |
| Biological |
bat1306 |
1 |
2019 |
| Biological |
bat1306/bat8001 2.4mg/kg |
1 |
2019 |
| Biological |
bat1306/bat8001 3.6mg/kg |
1 |
2019 |
| Biological |
bat8001 2.4mg |
1 |
2019 |
| Biological |
bat8001 3.6mg |
1 |
2019 |
| Drug |
bavituximab |
1 |
2005 |
| Device |
baxter isolex 3001 stem cell selection system |
1 |
1999 |
| Drug |
bay1000394 |
1 |
2011 |
| Drug |
bay1217389 |
1 |
2015 |
| Drug |
bay1436032 |
1 |
2016 |
| Drug |
bay1834942 |
1 |
2018 |
| Drug |
bay1895344 |
1 |
2019 |
| Drug |
bay2757556 (larotrectinib, vitrakvi) |
1 |
2015 |
| Drug |
bay94-9343 (1.8 mg |
1 |
2011 |
| Drug |
bay94-9343 (1.8 mg/kg) |
1 |
2011 |
| Drug |
bay94-9343 (2.2 mg |
1 |
2011 |
| Drug |
bay94-9343 (2.2 mg/kg) |
1 |
2011 |
| Drug |
bay94-9343 (expansion) |
1 |
2011 |
| Drug |
bb-1701 |
1 |
2020 |
| Behavioral |
bbi intervention |
1 |
2015 |
| Drug |
bcnu |
1 |
2007 |
| Drug |
bdc-1001 |
1 |
2020 |
| Drug |
becatecarin |
1 |
2000 |
| Drug |
beclomethasone dipropionate |
1 |
2001 |
| Behavioral |
behavioral intervention |
1 |
2015 |
| Drug |
belinostat iv |
1 |
2016 |
| Drug |
belinostat, warfarin |
1 |
2011 |
| Biological |
bempegaldesleukin |
1 |
2018 |
| Drug |
benzoylphenylurea |
1 |
2001 |
| Drug |
bevacizumab, everolimus |
1 |
2010 |
| Drug |
bevacizumab, everolimus/lbh589 |
1 |
2010 |
| Drug |
bevacizumab/second-line chemotherapy |
1 |
2018 |
| Drug |
bez235 / mek162 |
1 |
2011 |
| Drug |
bgb-11417 |
1 |
2020 |
| Drug |
bgb-283 (lifirafenib) |
1 |
2019 |
| Drug |
bgb-3111/obinutuzumab |
1 |
2015 |
| Drug |
bgb-3245 |
1 |
2020 |
| Drug |
bgb-a1217 |
1 |
2019 |
| Drug |
bgb-a333 |
1 |
2017 |
| Drug |
bgb-a333/bgb-a317 |
1 |
2017 |
| Drug |
bgb-a425 |
1 |
2018 |
| Drug |
bgb-a445 |
1 |
2019 |
| Drug |
bi-weekly administration of arq 761 |
1 |
2011 |
| Drug |
bi 1701963 |
1 |
2019 |
| Drug |
bi 765063 |
1 |
2019 |
| Drug |
bi 891065 |
1 |
2017 |
| Drug |
bi 905711 |
1 |
2019 |
| Drug |
bibf 1120 / pld 30 mg/m2 / cbdca auc5 mg/ml*min |
1 |
2011 |
| Drug |
bibf 1120/ pld 30 mg/m2 / cbdca auc5 mg/ml*min |
1 |
2011 |
| Biological |
bicar-nk |
1 |
2019 |
| Biological |
bicar-nk/t cells (robo1 car-nk/t cells) |
1 |
2019 |
| Drug |
biib0121 |
1 |
2009 |
| Drug |
biib0121/antacid |
1 |
2009 |
| Drug |
biib015 |
1 |
2008 |
| Drug |
biib021/food |
1 |
2009 |
| Drug |
biib022 |
1 |
2007 |
| Drug |
biib028 |
1 |
2008 |
| Procedure |
bilateral neck dissection |
1 |
2018 |
| Procedure |
bilateral rectus sheath catheter |
1 |
2018 |
| Device |
biliary stent |
1 |
2012 |
| Drug |
bind-014 |
1 |
2011 |
| Other |
biological collection |
1 |
2019 |
| Other |
biological samples |
1 |
2016 |
| Other |
biological: humanized anti-pd-1 monoclonal antibody |
1 |
2017 |
| Other |
biological: humanized anti-pd-l1 monoclonal antibody |
1 |
2017 |
| Procedure |
biopsy collection |
1 |
2018 |
| Procedure |
biopsy/surgical resection of tumor/blood sampling |
1 |
2015 |
| Biological |
bioseal |
1 |
2017 |
| Device |
bipap |
1 |
2009 |
| Device |
biphasic positive airway pressure |
1 |
2018 |
| Drug |
bismuth tablets |
1 |
2009 |
| Drug |
bj-001 |
1 |
2020 |
| Drug |
bkm120-carbo |
1 |
2015 |
| Drug |
bkm120-cis |
1 |
2015 |
| Drug |
bkm120 (days 1-21) |
1 |
2011 |
| Drug |
bkm120 (days 1-21) / paclitaxel (day 1) / carboplatin (day 1) |
1 |
2011 |
| Drug |
bkm120 (days 1 - 28, ) |
1 |
2011 |
| Drug |
bkm120 (days 1 - 28, )/paclitaxel / carboplatin |
1 |
2011 |
| Drug |
bkm120 / mek162 |
1 |
2011 |
| Drug |
bkm120 days 1 - 21 |
1 |
2011 |
| Drug |
bkm120 days 1 - 21/paclitaxel / carboplatin |
1 |
2011 |
| Drug |
bkm120, paclitaxel |
1 |
2011 |
| Drug |
bkm120, paclitaxel / carboplatin |
1 |
2011 |
| Genetic |
blood |
1 |
2017 |
| Biological |
blood-stage infection of p.vivax |
1 |
2017 |
| Biological |
blood collection |
1 |
2016 |
| Procedure |
blood draw |
1 |
2018 |
| Genetic |
blood/tumor samples |
1 |
2017 |
| Biological |
bls-ilb-e710c |
1 |
2017 |
| Drug |
bls_ilb_710c 1000mg |
1 |
2014 |
| Drug |
bls_ils_e710c 1500mg |
1 |
2014 |
| Drug |
bls_ils_e710c 500mg |
1 |
2014 |
| Drug |
blz945 |
1 |
2016 |
| Drug |
bms-599626 |
1 |
2005 |
| Drug |
bms-690514 |
1 |
2006 |
| Drug |
bms-777607 |
1 |
2008 |
| Drug |
bms-833923 |
1 |
2009 |
| Biological |
bms-936558) |
1 |
2015 |
| Drug |
bms-986205 |
1 |
2017 |
| Drug |
bms-986226 |
1 |
2017 |
| Drug |
bn80927 |
1 |
2011 |
| Drug |
bnp7787 |
1 |
2002 |
| Behavioral |
bone health educational materials |
1 |
2013 |
| Procedure |
bone marrow transplantation |
1 |
2018 |
| Drug |
bos172722 |
1 |
2017 |
| Drug |
bos172738 |
1 |
2018 |
| Dietary Supplement |
bovine lactoferrin supplement |
1 |
2013 |
| Biological |
bpx-501 t cells |
1 |
2018 |
| Drug |
brd4 inhibitor plx51107 |
1 |
2019 |
| Other |
breast-q questionnaire |
1 |
2017 |
| Other |
breathing program |
1 |
2012 |
| Drug |
brentuximab vedotin |
1 |
2011 |
| Behavioral |
brief focus program |
1 |
2008 |
| Drug |
brivanib / cetuximab |
1 |
2005 |
| Drug |
brivanib alaninate |
1 |
2008 |
| Dietary Supplement |
broccoli |
1 |
2007 |
| Procedure |
bronchoscopic implantation |
1 |
2015 |
| Drug |
bryostatin 1 |
1 |
1999 |
| Drug |
bsi-201 |
1 |
2007 |
| Drug |
bsi-201 / carboplatin/paclitaxel |
1 |
2007 |
| Drug |
bsi-201 / gemcitabine |
1 |
2007 |
| Drug |
bsi-201 / temozolomide |
1 |
2007 |
| Drug |
bsi-201 / topotecan |
1 |
2007 |
| Drug |
btp-114 |
1 |
2016 |
| Combination Product |
budigalimab |
1 |
2020 |
| Drug |
bupivacaine |
1 |
2016 |
| Drug |
busulfan-cyclophosphamide as conditioning regimen before allogeneic hematopoietic stem cell transplantation |
1 |
2013 |
| Procedure |
busulfan pharmacokinetics |
1 |
2005 |
| Drug |
busulfan, |
1 |
2009 |
| Drug |
busulfan, cyclophosphamide |
1 |
2005 |
| Drug |
busulfan, cyclophosphamide/fludarabine |
1 |
2005 |
| Drug |
busulfan, melphalan |
1 |
2005 |
| Drug |
busulfan,/melphalan,/alemtuzumab |
1 |
2009 |
| Drug |
bvd-523 |
1 |
2013 |
| Drug |
bz (bortezomib) |
1 |
2011 |
| Drug |
c |
1 |
2012 |
| Drug |
c-myb as odn |
1 |
2008 |
| Drug |
c kinase inhibitor gsk1070916a |
1 |
2010 |
| Drug |
c1 |
1 |
2011 |
| Drug |
ca-18c3 |
1 |
2010 |
| Drug |
ca-4948 |
1 |
2017 |
| Drug |
ca102n |
1 |
2018 |
| Drug |
cabazitaxel |
1 |
2011 |
| Drug |
cabazitaxel (xrp6258) (rpr116258) |
1 |
2006 |
| Drug |
cabazitaxel xrp6258 |
1 |
2012 |
| Drug |
cabergoline |
1 |
2013 |
| Biological |
cabiralizumab |
1 |
2017 |
| Device |
cachexia acupuncture-a (peace classic needlesâ® ) |
1 |
2014 |
| Device |
cade colonoscopy using gi genius device |
1 |
2020 |
| Drug |
caelyx (doxorubicin) treatment sequence ab |
1 |
2013 |
| Drug |
caelyx (doxorubicin) treatment sequence ba |
1 |
2013 |
| Drug |
caelyx reference product (treatment a) |
1 |
2014 |
| Drug |
caelyx test product (treatment b) |
1 |
2014 |
| Drug |
caffeine |
1 |
2015 |
| Drug |
calcium |
1 |
1999 |
| Combination Product |
calcium electroporation |
1 |
2019 |
| Behavioral |
calm app meditation |
1 |
2018 |
| Biological |
calrlong36 peptide |
1 |
2018 |
| Drug |
campath |
1 |
2009 |
| Drug |
campath-1h |
1 |
2007 |
| Drug |
camptothecin (cpt) conjugated to a linear, cyclodextrin-based polymer |
1 |
2006 |
| Biological |
can04 |
1 |
2017 |
| Behavioral |
cancer educational materials |
1 |
2019 |
| Behavioral |
cancer: thriving |
1 |
2009 |
| Behavioral |
cancer: thriving/surviving online workshop |
1 |
2009 |
| Device |
cap-assisted chromoendoscopy |
1 |
2010 |
| Procedure |
cap treatment |
1 |
2017 |
| Drug |
capecitabine (xeloda), oxaliplatin |
1 |
2007 |
| Drug |
capecitabine (xeloda), oxaliplatin/bevacizumab (avastin) |
1 |
2007 |
| Drug |
capecitabine (xelodaâ®) |
1 |
2010 |
| Drug |
capecitabine 1000 mg |
1 |
2019 |
| Drug |
capecitabine 1000 mg/mâ² po bid |
1 |
2019 |
| Drug |
capecitabine oral product |
1 |
2018 |
| Drug |
capecitabine) |
1 |
2017 |
| Drug |
capecitabine, 5-fluorouracil prodrug; oral |
1 |
2008 |
| Drug |
capecitabine/cisplatin |
1 |
2010 |
| Drug |
capecitabine/cisplatin / sorafenib |
1 |
2010 |
| Drug |
capecitabine/oxaliplatin/bevacizumab/rad001 (xelox-a-ev) |
1 |
2009 |
| Drug |
capecitabine/sorafenib |
1 |
2008 |
| Drug |
capox (oxaliplatin |
1 |
2017 |
| Drug |
capox (oxaliplatin/capecitabine) |
1 |
2017 |
| Device |
capp-seq |
1 |
2016 |
| Procedure |
capsule endoscopy |
1 |
2009 |
| Drug |
capsule) |
1 |
2020 |
| Drug |
car-cldn18.2 t-cells |
1 |
2019 |
| Biological |
car-nk cells targeting nkg2d ligands |
1 |
2018 |
| Biological |
car-t cells |
1 |
2018 |
| Biological |
car-t cells recognizing epcam |
1 |
2016 |
| Biological |
car-t cells targeting epcam |
1 |
2018 |
| Combination Product |
car-t combining pd-1 knockout |
1 |
2018 |
| Biological |
car-t therapy for nectin4-positive malignant solid tumor |
1 |
2019 |
| Biological |
car.19 |
1 |
2017 |
| Drug |
carbendazim |
1 |
1999 |
| Other |
carbon c 11 alpha-methyltryptophan |
1 |
2018 |
| Radiation |
carbon ions therapy |
1 |
2016 |
| Device |
carbon monoxide test |
1 |
2016 |
| Drug |
carboplatin (day 1) |
1 |
2011 |
| Drug |
carboplatin (tc arm) |
1 |
2014 |
| Drug |
carboplatin / etoposide |
1 |
2016 |
| Drug |
carboplatin auc |
1 |
2016 |
| Drug |
carboplatin mtd |
1 |
2010 |
| Drug |
carboplatin) |
1 |
2005 |
| Drug |
carboplatin. |
1 |
2018 |
| Drug |
carboxyamidotriazole |
1 |
2001 |
| Device |
cardiopulmonary exercise testing (cpet) |
1 |
2012 |
| Other |
care as usual |
1 |
2011 |
| Other |
care manager outreach |
1 |
2011 |
| Other |
case management |
1 |
2012 |
| Drug |
caspofungin acetate |
1 |
2011 |
| Procedure |
caudal nerve block (cnb) |
1 |
2016 |
| Drug |
cb-103 |
1 |
2018 |
| Drug |
cb-839 |
1 |
2014 |
| Drug |
cb-cabo |
1 |
2014 |
| Drug |
cb-erl |
1 |
2014 |
| Procedure |
cbct thermometry method |
1 |
2013 |
| Drug |
cbd |
1 |
2014 |
| Drug |
cbdca auc5 mg |
1 |
2011 |
| Drug |
cbe |
1 |
2014 |
| Drug |
cbl0137 |
1 |
2013 |
| Drug |
cbp501 |
1 |
2007 |
| Drug |
cbp501/cisplatin |
1 |
2007 |
| Drug |
cc-115 |
1 |
2011 |
| Drug |
cc-122 |
1 |
2017 |
| Drug |
cc-220 |
1 |
2017 |
| Drug |
cc-4047 |
1 |
2007 |
| Behavioral |
cci; cancer care coordination instrument |
1 |
2018 |
| Drug |
ccs1477 |
1 |
2019 |
| Biological |
cd10 |
1 |
2020 |
| Biological |
cd123 |
1 |
2020 |
| Biological |
cd123-cd33 ccar t cells |
1 |
2019 |
| Device |
cd19 |
1 |
2017 |
| Biological |
cd19-car-t cells |
1 |
2019 |
| Biological |
cd19-directed car-t cells |
1 |
2015 |
| Procedure |
cd19-specific t cell infusion |
1 |
2009 |
| Biological |
cd19-star-t cells |
1 |
2019 |
| Biological |
cd19 car t |
1 |
2018 |
| Biological |
cd19 car t-cells |
1 |
2015 |
| Procedure |
cd19 depletion on clinimacs |
1 |
2005 |
| Drug |
cd20/cd22 dual targeted car t-cells |
1 |
2020 |
| Drug |
cd22 dual targeted car t-cells |
1 |
2020 |
| Procedure |
cd3 |
1 |
2005 |
| Procedure |
cd3/cd19 depletion on clinimacs |
1 |
2005 |
| Biological |
cd38 |
1 |
2020 |
| Biological |
cd4 |
1 |
2017 |
| Biological |
cd8 |
1 |
2017 |
| Procedure |
cd8-depleted pbsc after nonmyeloablative conditioning |
1 |
2008 |
| Biological |
cd8//cd4/ donor memory t-cells-expressing ha1-specific tcr |
1 |
2017 |
| Drug |
cdk inhibitor at7519 |
1 |
2015 |
| Drug |
cdx-1127 |
1 |
2011 |
| Biological |
cdx-1401 |
1 |
2009 |
| Biological |
cdx-1401 in combination with resiquimod and |
1 |
2009 |
| Biological |
cdx-1401 in combination with resiquimod and/or poly-iclc |
1 |
2009 |
| Drug |
cedazuridine |
1 |
2019 |
| Drug |
cediranib, azd2171, recentin |
1 |
2006 |
| Drug |
cefepime hydrochloride |
1 |
2011 |
| Device |
cellectraâ„¢-5p |
1 |
2011 |
| Biological |
cellular therapy |
1 |
2017 |
| Device |
cellvizio |
1 |
2014 |
| Drug |
cemiplimab regn2810 |
1 |
2017 |
| Radiation |
central nervous system (cns) prophylaxis radiation |
1 |
2005 |
| Drug |
cep-37440 |
1 |
2013 |
| Drug |
cep-9722 |
1 |
2009 |
| Device |
ceprate sc |
1 |
1999 |
| Drug |
ceralasertib |
1 |
2019 |
| Drug |
ceramide nanoliposome |
1 |
2016 |
| Drug |
cergutuzumab amunaleukin |
1 |
2015 |
| Other |
cervical papanicolaou test |
1 |
2012 |
| Drug |
cetirizine hcl 10 mg |
1 |
2019 |
| Drug |
cetirizine hcl 10 mg/ml |
1 |
2019 |
| Drug |
cetuximab (erbitux, c225) |
1 |
2006 |
| Drug |
cetuximab / irinotecan |
1 |
2005 |
| Other |
cetuximab chemotherapy |
1 |
2012 |
| Drug |
cetuximab injection |
1 |
2018 |
| Biological |
cetuximab: |
1 |
2003 |
| Device |
ceus (contrast-enhanced ultrasound) |
1 |
2015 |
| Drug |
cfi-400945 |
1 |
2013 |
| Drug |
cg5503) |
1 |
2010 |
| Drug |
cgm097 |
1 |
2013 |
| Drug |
cgx1321 |
1 |
2016 |
| Drug |
ch5132799 |
1 |
2010 |
| Drug |
checkpoint inhibitor |
1 |
2019 |
| Radiation |
chemoradiation |
1 |
2011 |
| Other |
chemoradiotherapy followed by surgery |
1 |
2019 |
| Drug |
chemotherapeutic regimen |
1 |
2019 |
| Drug |
chemotherapy by investigator’s choice |
1 |
2014 |
| Drug |
chemotherapy for hematologic malignancy |
1 |
2002 |
| Drug |
chemotherapy/antibodies |
1 |
2005 |
| Radiation |
chemotherapy/concomitant radiotherapy |
1 |
2017 |
| Drug |
chi lob 7 |
1 |
2012 |
| Drug |
chi lob 7/4 (a chimeric monoclonal antibody) |
1 |
2012 |
| Drug |
chiauranib |
1 |
2014 |
| Drug |
chidamide |
1 |
2017 |
| Drug |
chidamide/with r-gdp |
1 |
2017 |
| Biological |
chimeric antigen receptor t-cell therapy |
1 |
2018 |
| Procedure |
chinese acupuncture |
1 |
2004 |
| Drug |
chinese herb huanglian (coptis chinesis) |
1 |
2001 |
| Procedure |
chlorhexidine gluconate skin cleanser |
1 |
2013 |
| Combination Product |
chlorinated polyethylene elastomer |
1 |
2005 |
| Drug |
chlorogenic acid |
1 |
2014 |
| Drug |
chloroquine |
1 |
2014 |
| Drug |
chlorpromazine |
1 |
2017 |
| Drug |
chpp of cisplatin |
1 |
2007 |
| Procedure |
chpp with cisplatin |
1 |
1999 |
| Drug |
chr-2797 |
1 |
2008 |
| Drug |
chr-2797 (tosedostat) |
1 |
2008 |
| Drug |
chr-2845 |
1 |
2009 |
| Drug |
chr-3996 |
1 |
2008 |
| Drug |
ci-1040 |
1 |
2002 |
| Drug |
cialis |
1 |
2016 |
| Drug |
ciclopirox olamine |
1 |
2009 |
| Drug |
cidofovir 1% cream’s basis, 2gr, three times per week, during 4 weeks. |
1 |
2013 |
| Drug |
cidofovir gel |
1 |
2009 |
| Procedure |
circulating tumor cell blood draw |
1 |
2016 |
| Drug |
cisplatin (or alternative) |
1 |
2014 |
| Drug |
cisplatin (or alternative) - deintensified |
1 |
2017 |
| Drug |
cisplatin (or alternative) - standard |
1 |
2017 |
| Drug |
cisplatin / 5-fluorouracil (5fu) |
1 |
2016 |
| Biological |
cisplatin / celecoxib / dc vaccine |
1 |
2015 |
| Biological |
cisplatin / ckm / celecoxib / dc vaccine |
1 |
2015 |
| Drug |
cisplatin, thiosulfate |
1 |
2010 |
| Drug |
cisplatin/fluorouracil |
1 |
2019 |
| Device |
civasheet |
1 |
2016 |
| Biological |
ckm |
1 |
2015 |
| Device |
classical lymphadenectomy |
1 |
2005 |
| Other |
clinical trial kiosk |
1 |
2018 |
| Device |
clinicmacs |
1 |
2018 |
| Device |
clinimacs cd25 reagent device |
1 |
2008 |
| Device |
clinimacs cd34 reagent system |
1 |
2018 |
| Device |
clinimacsâ® cd34 reagent system |
1 |
2013 |
| Device |
clinimacsâ® tcrî±î² |
1 |
2017 |
| Device |
clinimacsâ® tcrî±î²/cd19/depletion system |
1 |
2017 |
| Biological |
cll1-cd33 ccar t cells |
1 |
2019 |
| Drug |
clofarabine (oral formulation) |
1 |
2005 |
| Drug |
clonidine |
1 |
2016 |
| Drug |
cloretazine |
1 |
2007 |
| Procedure |
closed stump |
1 |
2015 |
| Biological |
clostridium novyi-nt |
1 |
2018 |
| Biological |
clostridium novyi-nt spores |
1 |
2013 |
| Drug |
clr 131 |
1 |
2018 |
| Drug |
cm082 |
1 |
2018 |
| Drug |
cm082 tablet |
1 |
2013 |
| Biological |
cmvpp65-a*0201 peptide vaccine |
1 |
2015 |
| Biological |
cnct19 |
1 |
2019 |
| Drug |
cnf2024 |
1 |
2006 |
| Drug |
cnto 328; anti-interleukin-6 monoclonal antibody |
1 |
2009 |
| Drug |
cnto 95 |
1 |
2009 |
| Drug |
cnto 95/avastin |
1 |
2009 |
| Drug |
co-1.01 formulation a (aqueous suspension containing 15 mg |
1 |
2011 |
| Drug |
co-1.01 formulation a (aqueous suspension containing 15 mg/ml of drug solubilized in purified phospholipids) |
1 |
2011 |
| Drug |
co-1.01 formulation b (aqueous suspension containing 30 mg |
1 |
2011 |
| Drug |
co-1.01 formulation b (aqueous suspension containing 30 mg/ml of drug solubilized in purified phospholipids) |
1 |
2011 |
| Device |
co2 laser ablation |
1 |
2016 |
| Device |
co2 standard therapy |
1 |
2017 |
| Behavioral |
coach directed behavioral weight loss |
1 |
2015 |
| Device |
cobas hpv-dna test |
1 |
2017 |
| Device |
cobasâ® pcr female swab self-sampling |
1 |
2015 |
| Drug |
cobimetinib (combination treatment) |
1 |
2016 |
| Behavioral |
cognitive behavior therapy |
1 |
2017 |
| Behavioral |
cognitive behavioral mutli-symptom management(cbt) |
1 |
2017 |
| Behavioral |
cognitive existential therapy group 1 |
1 |
2016 |
| Other |
cognitive intervention |
1 |
2015 |
| Behavioral |
cogstate assessment battery |
1 |
2019 |
| Biological |
cohort 1 |
1 |
2013 |
| Drug |
cohort 1 anti-ox40 |
1 |
2012 |
| Biological |
cohort 2 |
1 |
2013 |
| Drug |
cohort 2 anti-ox40 |
1 |
2012 |
| Biological |
cohort 3 |
1 |
2013 |
| Drug |
cohort 3 anti-ox40 |
1 |
2012 |
| Drug |
colchicine |
1 |
2020 |
| Device |
cold knife |
1 |
2017 |
| Other |
collecting breath samples |
1 |
2013 |
| Biological |
collection of stool |
1 |
2017 |
| Biological |
collection of stool/serum samples |
1 |
2017 |
| Procedure |
colonic resection with d2 lymph node dissection |
1 |
2016 |
| Procedure |
colonic resection with d3 lymph node dissection |
1 |
2016 |
| Drug |
com701 |
1 |
2018 |
| Drug |
com701 with opdivo (nivolumab). |
1 |
2018 |
| Drug |
combination of local steroid injection(triamcinolone )with oral steroid administration(prednisone) |
1 |
2017 |
| Drug |
combination of sorafenib |
1 |
2009 |
| Drug |
combination of sorafenib/everolimus |
1 |
2009 |
| Drug |
combined administration of irinotecan |
1 |
2010 |
| Drug |
combined administration of irinotecan/rapamycin |
1 |
2010 |
| Drug |
combined chemotherapy with streptozotocin, 5-fluorouracil, |
1 |
1999 |
| Drug |
combined chemotherapy with streptozotocin, 5-fluorouracil,/doxorubicin |
1 |
1999 |
| Combination Product |
combined radiotherapy |
1 |
2019 |
| Combination Product |
combined radiotherapy/mr-hifu |
1 |
2019 |
| Other |
combined surgery |
1 |
2011 |
| Other |
combined surgery/radiation therapy |
1 |
2011 |
| Drug |
combretastatin a4 phosphate (ca4p) |
1 |
2006 |
| Behavioral |
commitment therapy |
1 |
2015 |
| Other |
communication aids |
1 |
2014 |
| Behavioral |
communication feedback form for patients with serious illness |
1 |
2013 |
| Other |
communication skills training |
1 |
2013 |
| placebo |
comparator: placebo (unspecified) |
1 |
2008 |
| Drug |
compound ac220 |
1 |
2010 |
| Other |
comprehensive smoking cessation intervention |
1 |
2014 |
| Device |
compression anastomosis device |
1 |
2010 |
| Radiation |
computed tomography perfusion imaging |
1 |
2016 |
| Other |
computer-assisted cognitive training |
1 |
2011 |
| Other |
computer-assisted intervention |
1 |
2010 |
| Other |
computer application |
1 |
2019 |
| Other |
computer reminders on clinical practice |
1 |
2015 |
| Device |
computerized tomography |
1 |
2016 |
| Biological |
conatumumab |
1 |
2011 |
| Radiation |
concomitant radiotherapy |
1 |
2017 |
| Drug |
concurrent rt |
1 |
2007 |
| Other |
conditioning regimen |
1 |
2005 |
| Drug |
conditioning regimen ii (tli 8 gy |
1 |
2008 |
| Drug |
conditioning regimen ii (tli 8 gy / atg [thymoglobulin]) |
1 |
2008 |
| Drug |
conditioning regimen tbi |
1 |
2008 |
| Drug |
conditioning regimen tbi / fludarabine |
1 |
2008 |
| Drug |
conditioning treatment “treosulfan-tmi” |
1 |
2019 |
| Device |
cone-beam ct-guided |
1 |
2015 |
| Device |
confocal endo-microscopy |
1 |
2013 |
| Radiation |
conformal radiation |
1 |
2015 |
| Radiation |
conformal wbrt |
1 |
2015 |
| Behavioral |
connect |
1 |
2016 |
| Drug |
consolidation chemotherapy |
1 |
2013 |
| Behavioral |
consultation by a trained physician |
1 |
2014 |
| Behavioral |
consultation by an untrained physician |
1 |
2014 |
| Behavioral |
consultation with pct doctor |
1 |
2017 |
| Procedure |
continuous hyperthermic peritoneal perfusion (chpp) with cisplatin |
1 |
2000 |
| Procedure |
continuous positive airway pressure |
1 |
2018 |
| Procedure |
contrast-enhanced ct |
1 |
2008 |
| Procedure |
contrast-enhanced magnetic resonance imaging |
1 |
2014 |
| Device |
contrast-enhanced mammogram |
1 |
2019 |
| Other |
contrast agent |
1 |
2019 |
| Drug |
contrast enhanced ultrasound with lumason |
1 |
2019 |
| Procedure |
conventional excisional breast biopsy |
1 |
2015 |
| Drug |
conventional intravenous fluid therapy |
1 |
2013 |
| Radiation |
conventional/hypofractionated |
1 |
2018 |
| Drug |
copanlisib (bay80-6946) |
1 |
2018 |
| Biological |
cord blood-derived expanded allogeneic natural killer cells |
1 |
2018 |
| Procedure |
cord blood infusion |
1 |
2011 |
| Procedure |
cord blood stem cell infusion |
1 |
2010 |
| Biological |
cord blood stem cells |
1 |
2019 |
| Other |
cord blood unit |
1 |
2016 |
| Biological |
cord transplant |
1 |
2007 |
| Procedure |
cordotomy |
1 |
2019 |
| Procedure |
core biopsy |
1 |
2019 |
| Drug |
cort125134 with nab-paclitaxel |
1 |
2016 |
| Other |
cosmetic assessment |
1 |
2015 |
| Behavioral |
counseling sessions |
1 |
2012 |
| Behavioral |
countering cognitive impairment |
1 |
2015 |
| Other |
courage with cancerâ„¢ (grace) |
1 |
2016 |
| Device |
covered biliary stents |
1 |
2014 |
| Device |
covered metal stent |
1 |
2015 |
| Drug |
cp-4055 |
1 |
2006 |
| Drug |
cp-4126 |
1 |
2008 |
| Drug |
cp-547,632 |
1 |
2003 |
| Drug |
cp-675,206 (tremelimumab) |
1 |
2006 |
| Drug |
cp-868,596 |
1 |
2009 |
| Drug |
cpi-0209 |
1 |
2019 |
| Drug |
cpi-1205 |
1 |
2018 |
| Drug |
cpt-11 |
1 |
2005 |
| Drug |
cpt-11 (irinotecan) |
1 |
2013 |
| Drug |
cpx-351 |
1 |
2018 |
| Drug |
cpx-pom |
1 |
2017 |
| Drug |
cra-24781 |
1 |
2007 |
| Procedure |
craniotomy |
1 |
2004 |
| Other |
cremophor |
1 |
2011 |
| Drug |
crizotinib (xalkori) |
1 |
2012 |
| Device |
crlm ablation group |
1 |
2016 |
| Procedure |
crlm resection group |
1 |
2016 |
| Device |
crs |
1 |
2017 |
| Drug |
crs-100 |
1 |
2006 |
| Procedure |
crs-hipec, control arm |
1 |
2016 |
| Procedure |
crs-hipec, experimental arm |
1 |
2016 |
| Device |
cryopen |
1 |
2017 |
| Drug |
cs-1008 (humanized anti-dr5 antibody) |
1 |
2006 |
| Drug |
cs1003 |
1 |
2018 |
| Drug |
cs3002 |
1 |
2019 |
| Drug |
cs3005 |
1 |
2020 |
| Radiation |
ct colonography |
1 |
2012 |
| Device |
ct of the brain |
1 |
2019 |
| Other |
ct scan |
1 |
2016 |
| Procedure |
ct/cbct thermometry method |
1 |
2013 |
| Drug |
ct7001 |
1 |
2017 |
| Drug |
ct7001 in combination with fulvestrant |
1 |
2017 |
| Diagnostic Test |
ctdna-analysis |
1 |
2019 |
| Biological |
ctx110 |
1 |
2019 |
| Drug |
cudc-101 |
1 |
2008 |
| Drug |
cudc-907 |
1 |
2016 |
| Behavioral |
cultural cbt |
1 |
2017 |
| Drug |
curcumin |
1 |
2015 |
| Drug |
cvm-1118 |
1 |
2018 |
| Drug |
cvm-1118 extended-release (er) capsules (200 mg |
1 |
2020 |
| Drug |
cvm-1118 extended-release (er) capsules (200 mg/capsule) |
1 |
2020 |
| Biological |
cvx-045 |
1 |
2009 |
| Biological |
cvx-060 |
1 |
2009 |
| Drug |
cx-072 |
1 |
2019 |
| Drug |
cxd101 |
1 |
2013 |
| Drug |
cxd101 in combination with nivolumab |
1 |
2019 |
| Drug |
cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic stem cell transplantation |
1 |
2013 |
| Drug |
cyclophosphamide (cy) |
1 |
2007 |
| Drug |
cyclophosphamide 50mg |
1 |
2015 |
| Drug |
cyclophosphamide. |
1 |
2005 |
| Drug |
cyclophosphamide/topotecan |
1 |
2008 |
| Drug |
cyclosporin |
1 |
2006 |
| Drug |
cyclosporin-a |
1 |
2007 |
| Drug |
cyclosporine ophthalmic emulsion |
1 |
2008 |
| Drug |
cypep-1 |
1 |
2020 |
| Drug |
cyproheptadine hydrochloride |
1 |
2003 |
| Drug |
cyt-0851 |
1 |
2019 |
| Genetic |
cytogenetic analysis |
1 |
2006 |
| Device |
cytology |
1 |
2014 |
| Drug |
cytovene (ganciclovir sodium) |
1 |
1999 |
| Drug |
dabrafenib/trametinib |
1 |
2016 |
| Drug |
dacarbazine |
1 |
2008 |
| Biological |
daclizumab |
1 |
2008 |
| Other |
daily sms text messaging |
1 |
2015 |
| Drug |
dalotuzumab |
1 |
2011 |
| Drug |
dalteparin |
1 |
2015 |
| Drug |
darbepoetin alfa - 2.25 mcg |
1 |
2005 |
| Drug |
darbepoetin alfa - 2.25 mcg/kg |
1 |
2005 |
| Drug |
darbepoetin alfa - 500mcg |
1 |
2005 |
| Drug |
darbepoetin alfa iv |
1 |
2002 |
| Drug |
darbepoetin alfa sc |
1 |
2002 |
| Drug |
darbepoetin alfa/epoetin alfa |
1 |
2005 |
| Drug |
dasatinib (bms-354825) |
1 |
2006 |
| Other |
data evaluation |
1 |
2015 |
| Drug |
daunorubicin |
1 |
2014 |
| Drug |
day) |
1 |
2005 |
| Biological |
dc-cik immunotherapy |
1 |
2013 |
| Combination Product |
dc-cik/with chemotherapy |
1 |
2019 |
| Biological |
dc1 vaccine |
1 |
2009 |
| Drug |
dcc-3014 |
1 |
2017 |
| Procedure |
dce-mri scan |
1 |
2008 |
| Drug |
debio 0123 |
1 |
2019 |
| Drug |
debio 1347 |
1 |
2019 |
| Drug |
decadron |
1 |
2016 |
| Drug |
decitabine (dtc arm) |
1 |
2014 |
| Procedure |
deep inspiration breath hold |
1 |
2018 |
| Drug |
deep neuromuscular blockade (nmb) |
1 |
2017 |
| Dietary Supplement |
defined green tea catechin extract |
1 |
2006 |
| Procedure |
delayed breast reconstruction |
1 |
2017 |
| Drug |
delayed metformin |
1 |
2014 |
| Device |
delphi screener |
1 |
2008 |
| Drug |
demcizumab |
1 |
2016 |
| Biological |
dendritic cell |
1 |
2020 |
| Biological |
dendritic cell vaccine therapy |
1 |
2012 |
| Biological |
dendritic cell/tumor fusion vaccine |
1 |
2020 |
| Drug |
denosumab (for the open-label treatment phase) |
1 |
2011 |
| Drug |
denosumab 120 mg |
1 |
2018 |
| Drug |
denosumab 120 mg/1.7 ml subcutaneous solution [xgeva] |
1 |
2018 |
| Device |
depletion system |
1 |
2017 |
| Drug |
detoxpc |
1 |
2001 |
| Drug |
dexamethasone acetate |
1 |
2011 |
| Drug |
dexanabinol |
1 |
2011 |
| Drug |
dexrazoxane hydrochloride |
1 |
2018 |
| Drug |
dextromethorphan |
1 |
2007 |
| Drug |
df1001 |
1 |
2019 |
| Drug |
dfp-14927 |
1 |
2019 |
| Drug |
diclofenac na gel |
1 |
2008 |
| Behavioral |
diet, fat-restricted |
1 |
1999 |
| Dietary Supplement |
dietary intervention |
1 |
2009 |
| Other |
dietary standard |
1 |
2013 |
| Behavioral |
dietary supplements |
1 |
1999 |
| Radiation |
diffusing alpha-emitter radiation therapy |
1 |
2020 |
| Procedure |
diffusion-weighted magnetic resonance imaging / pet ct |
1 |
2010 |
| Procedure |
diffusion tensor imaging |
1 |
2015 |
| Procedure |
diffusion weighted imaging |
1 |
2015 |
| Procedure |
diffusion weighted magnetic resonance imaging (dwmr) |
1 |
2012 |
| Other |
digital physical measures |
1 |
2019 |
| Other |
digital physical measures/survey assessments |
1 |
2019 |
| Drug |
digoxin tablet |
1 |
2020 |
| Biological |
dinutuximab |
1 |
2015 |
| Drug |
diphenhydramine |
1 |
2017 |
| Drug |
diphenhydramine 50 mg |
1 |
2019 |
| Drug |
diphenhydramine 50 mg/ml |
1 |
2019 |
| Drug |
diphenydramine |
1 |
2005 |
| Procedure |
direct electrocortical stimulation |
1 |
2016 |
| Procedure |
direct fluorescent oral visualization examination |
1 |
2016 |
| Device |
distal pancreatectomy sealing using ltw |
1 |
2017 |
| Drug |
divalproex sodium |
1 |
2019 |
| Drug |
dj-927 |
1 |
2004 |
| Drug |
dmuc4064a |
1 |
2014 |
| Drug |
dmxaa |
1 |
2009 |
| Drug |
dn-101 |
1 |
2003 |
| Drug |
dn1508052-01 |
1 |
2019 |
| Biological |
dna plasmid-encoding interleukin-12 |
1 |
2018 |
| Biological |
dna plasmid-encoding interleukin-12/hpv dna plasmids therapeutic vaccine medi0457 |
1 |
2018 |
| Biological |
dna vaccination |
1 |
2009 |
| Biological |
dnx-2401 |
1 |
2016 |
| Drug |
docetaxel-pnp |
1 |
2010 |
| Drug |
docetaxel (for 4 21-day cycles) after four 14-day cycles of doxorubicin |
1 |
2017 |
| Drug |
docetaxel (taxotere) |
1 |
2010 |
| Drug |
docetaxel, cisplatin, fluorouracil, bevacizumab, leucovorin |
1 |
2006 |
| Drug |
docetaxel, mitotic inhibitor; intravenous |
1 |
2009 |
| Drug |
docetaxel, oxaliplatin |
1 |
2006 |
| Drug |
dofequidar fumarate |
1 |
2000 |
| Biological |
donor-derived cik cells |
1 |
2019 |
| Biological |
donor lymphocyte preparation depleted of functional host alloreactive t-cells (atir) |
1 |
2009 |
| Biological |
donor memory t-cells-expressing ha1-specific tcr |
1 |
2017 |
| Biological |
donor natural killer cell infusion |
1 |
2009 |
| Procedure |
doppler ultrasound |
1 |
2013 |
| Radiation |
dose to prostate bed |
1 |
2017 |
| Radiation |
dose to prostate bed with integrated boost |
1 |
2017 |
| Radiation |
dosimetry-guided peptide receptor radiotherapy |
1 |
2015 |
| Other |
dot imaging |
1 |
2013 |
| Other |
double-labeled water |
1 |
2015 |
| Device |
double needle celiac neurolysis (dncn) |
1 |
2016 |
| Drug |
dovitinib |
1 |
2014 |
| Other |
dox 2 cycles - surgery - dox 2 cycles |
1 |
2013 |
| Other |
dox 4 cycles - surgery |
1 |
2013 |
| Drug |
doxil/caelyx (doxorubicin) treatment sequence ab |
1 |
2013 |
| Drug |
doxil/caelyx (doxorubicin) treatment sequence ba |
1 |
2013 |
| Drug |
doxil/caelyx reference product (treatment a) |
1 |
2014 |
| Drug |
doxil/caelyx test product (treatment b) |
1 |
2014 |
| Drug |
doxorubicin hcl liposome |
1 |
2007 |
| Drug |
doxorubicin hcl liposome; bevacizumab; carboplatin |
1 |
2008 |
| Drug |
doxorubicin hydrochloride injection |
1 |
2010 |
| Drug |
doxorubicin. |
1 |
2018 |
| Biological |
dpx-0907 consists of 7 tumor-specific hla-a2-restricted peptides, a universal t helper peptide, a polynucleotide adjuvant, a liposome |
1 |
2010 |
| Biological |
dpx-0907 consists of 7 tumor-specific hla-a2-restricted peptides, a universal t helper peptide, a polynucleotide adjuvant, a liposome/montanide isa51 vg |
1 |
2010 |
| Dietary Supplement |
drink |
1 |
2018 |
| Drug |
drug |
1 |
2012 |
| Biological |
drug: js004, recombinant humanized igg4îº monoclonal antibody specific to btla for injection intravenous infusion |
1 |
2020 |
| Drug |
drug: syha1801 |
1 |
2020 |
| Drug |
ds-1123 |
1 |
2016 |
| Drug |
ds-6051b |
1 |
2016 |
| Drug |
ds-7300a |
1 |
2019 |
| Drug |
ds-8895a |
1 |
2013 |
| Drug |
dsp-7888 dosing emulsion |
1 |
2017 |
| Procedure |
dual-energy computed tomography |
1 |
2018 |
| Biological |
duk-cpg-001 |
1 |
2015 |
| Procedure |
duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy |
1 |
2014 |
| Drug |
durvalumab / tremelimumab combination therapy |
1 |
2019 |
| Drug |
durvalumab; medi4736 |
1 |
2016 |
| Biological |
durvalumib |
1 |
2019 |
| Drug |
duvelisib |
1 |
2016 |
| Radiation |
dxa scanning |
1 |
2015 |
| Procedure |
dynamic area telethermometry (dat) |
1 |
2005 |
| Procedure |
dynamic susceptibility contrast-mri (dsc-mri) |
1 |
2018 |
| Behavioral |
e-pamphlet |
1 |
2017 |
| Biological |
e7 tcr cells |
1 |
2016 |
| Biological |
e7(detox) |
1 |
2005 |
| Drug |
e7016 |
1 |
2010 |
| Drug |
e7016 / tmz |
1 |
2010 |
| Drug |
e7080 |
1 |
2006 |
| Drug |
e7090 |
1 |
2014 |
| Drug |
e7130 |
1 |
2018 |
| Drug |
e7389 |
1 |
2003 |
| Drug |
e7449 |
1 |
2012 |
| Drug |
e7449 alone |
1 |
2012 |
| Drug |
e7449/carboplatin/paclitaxel |
1 |
2012 |
| Drug |
e7449/tmz |
1 |
2012 |
| Drug |
e7820 |
1 |
2013 |
| Drug |
eaca |
1 |
2014 |
| Other |
early palliative care consultation |
1 |
2011 |
| Behavioral |
early palliative care intervention |
1 |
2010 |
| Other |
early tumor response evaluation by mri volumetry |
1 |
2011 |
| Biological |
ebv-ctls |
1 |
2009 |
| Biological |
ebv-specific t cells |
1 |
2011 |
| Drug |
ec |
1 |
2016 |
| Drug |
ec d-3263 hcl |
1 |
2009 |
| Other |
ecography |
1 |
2016 |
| Drug |
ecteinascidin 743 |
1 |
2000 |
| Drug |
edetate calcium disodium |
1 |
2018 |
| Behavioral |
edmonton symptom assessment scale |
1 |
2015 |
| Biological |
edodekin alfa |
1 |
2017 |
| Drug |
edotecarin |
1 |
2003 |
| Other |
education |
1 |
2019 |
| Behavioral |
education information |
1 |
2015 |
| Other |
educational activity |
1 |
2019 |
| Other |
educational control |
1 |
2018 |
| Behavioral |
educational video tool |
1 |
2020 |
| Drug |
eflornithine |
1 |
2000 |
| Drug |
eflornithine hcl ointment |
1 |
2008 |
| Drug |
eft226 |
1 |
2019 |
| Drug |
egfr |
1 |
2019 |
| Drug |
egfr inhibitor |
1 |
2019 |
| Drug |
egfr/egfrviii inhibitor wsd0922-fu |
1 |
2019 |
| Biological |
egfr806-specific chimeric antigen receptor (car) t cell |
1 |
2018 |
| Biological |
egfrbi armed atc infusions |
1 |
2011 |
| Genetic |
egfrt |
1 |
2015 |
| Drug |
egfrviii inhibitor wsd0922-fu |
1 |
2019 |
| Behavioral |
ehr-based clinician jumpstart |
1 |
2020 |
| Drug |
ekb-569 |
1 |
2003 |
| Radiation |
elective target stereotacic spine radiosurgery |
1 |
2019 |
| Procedure |
electroacupuncture therapy |
1 |
2002 |
| Other |
electrocorticography |
1 |
2016 |
| Device |
electroporation |
1 |
2018 |
| Dietary Supplement |
elemental 028 extra liquid |
1 |
2017 |
| Other |
elos |
1 |
2018 |
| Drug |
em-1421 |
1 |
2005 |
| Drug |
ema-approved ati based targeted therapy |
1 |
2014 |
| Drug |
emb-01 |
1 |
2018 |
| Biological |
emd 640744 |
1 |
2009 |
| Biological |
emd525797 |
1 |
2011 |
| Drug |
emibetuzumab |
1 |
2014 |
| Drug |
emla |
1 |
2012 |
| Behavioral |
emotional skills |
1 |
2017 |
| Drug |
empirical vancomycin |
1 |
2005 |
| Device |
emr |
1 |
2019 |
| Device |
emr/esd |
1 |
2019 |
| Procedure |
en-bloc resection |
1 |
2014 |
| Drug |
encorafenib |
1 |
2019 |
| Procedure |
endobronchial ultrasound-guided transbronchial needle aspiration (ebus-tbna) |
1 |
2016 |
| Device |
endobronchial valve |
1 |
2011 |
| Device |
endocuff vision |
1 |
2017 |
| Device |
endomicroscope |
1 |
2006 |
| Procedure |
endomicroscopy |
1 |
2010 |
| Device |
endoringsâ„¢ |
1 |
2016 |
| Procedure |
endoscopic mucosal resection |
1 |
2010 |
| Procedure |
endoscopic stenting |
1 |
2007 |
| Procedure |
endoscopic sub-mucosal dissection |
1 |
2013 |
| Procedure |
endoscopic submucosal dissection |
1 |
2018 |
| Procedure |
endoscopic ultrasound guided fine needle biopsy |
1 |
2017 |
| Procedure |
endoscopically assisted colostomy with colopexy |
1 |
2014 |
| Other |
endurance |
1 |
2012 |
| Drug |
enfortumab vedotin (ev) |
1 |
2017 |
| Drug |
enoblituzumab |
1 |
2016 |
| Drug |
entecavir |
1 |
2012 |
| Other |
environmental music therapy |
1 |
2018 |
| Drug |
enzastaurin |
1 |
2006 |
| Other |
enzyme-linked immunosorbent assay |
1 |
2009 |
| Drug |
enzyme inhibitor therapy |
1 |
2017 |
| Drug |
eoc317 |
1 |
2018 |
| Behavioral |
eortc qlq-c30 questionnaire |
1 |
2015 |
| Behavioral |
eortc qlq-ov28 questionnaire |
1 |
2015 |
| Drug |
eos884448 |
1 |
2020 |
| Drug |
ep-100 |
1 |
2009 |
| Biological |
ep2101 |
1 |
2003 |
| Behavioral |
epac |
1 |
2016 |
| Drug |
epc2407 (crinobulin) |
1 |
2007 |
| Drug |
epic with fudr |
1 |
2013 |
| Drug |
epic with fudr/leucovorin |
1 |
2013 |
| Drug |
epinephrine |
1 |
2016 |
| Drug |
epirubicin hydrochloride |
1 |
2009 |
| Drug |
epirubicin, cisplatin, capecitabine |
1 |
2010 |
| Drug |
epirubicin, cisplatin, capecitabine, panitumumab |
1 |
2010 |
| Drug |
epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin |
1 |
2019 |
| Drug |
epirubicin, cyclophosphamide, paclitaxel, carboplatin |
1 |
2019 |
| Behavioral |
episodic future thinking |
1 |
2018 |
| Behavioral |
episodic recent thinking |
1 |
2018 |
| Drug |
epitinib |
1 |
2013 |
| Drug |
epo906 (epothilone b) |
1 |
2006 |
| Procedure |
eras protocol |
1 |
2019 |
| Biological |
erbitux (cetuximab) |
1 |
2002 |
| Procedure |
ercp with 10 french biliary plastic stent placement |
1 |
2011 |
| Procedure |
ercp with 11.5 french biliary plastic stent |
1 |
2011 |
| Device |
ercp with sems |
1 |
2015 |
| Device |
ercp with sems alone (standard of care) |
1 |
2015 |
| Device |
ercp with sems/radiofrequency ablation |
1 |
2015 |
| Drug |
eribulin-lf |
1 |
2013 |
| Combination Product |
eribulin ora |
1 |
2019 |
| Drug |
erlotinib po |
1 |
2009 |
| Drug |
erlotinib po/vidaza iv |
1 |
2009 |
| Drug |
ertapenem |
1 |
2007 |
| Drug |
ery974 |
1 |
2016 |
| Drug |
es101 |
1 |
2019 |
| Radiation |
escalated dose |
1 |
2016 |
| Behavioral |
escalation |
1 |
2019 |
| Drug |
escalation cohort: regorafenib (stivarga, bay73-4506) 100 mg |
1 |
2010 |
| Drug |
escalation cohort: regorafenib (stivarga, bay73-4506) 120 mg |
1 |
2010 |
| Drug |
escalation cohort: regorafenib (stivarga, bay73-4506) 140 mg |
1 |
2010 |
| Drug |
escalation cohort: regorafenib (stivarga, bay73-4506) 20 mg |
1 |
2010 |
| Drug |
escalation cohort: regorafenib (stivarga, bay73-4506) 40 mg |
1 |
2010 |
| Drug |
estrogen replacement therapy |
1 |
1999 |
| Drug |
estrogens |
1 |
1999 |
| Drug |
et743 |
1 |
2002 |
| Drug |
etanercept |
1 |
2005 |
| Drug |
etc-1922159 |
1 |
2015 |
| Drug |
ethanol |
1 |
2013 |
| Drug |
ethinyl estradiol |
1 |
2018 |
| Drug |
ethinyl estradiol/levonorgestrel |
1 |
2018 |
| Drug |
ethyl icosapentate |
1 |
2016 |
| Device |
eus-fna needle (beacon) |
1 |
2017 |
| Device |
eus guided radiofrequency ablation |
1 |
2019 |
| Drug |
evax-01-caf09b |
1 |
2018 |
| Device |
eve medical self-collection systemâ© |
1 |
2015 |
| Drug |
everolimus (rad001) |
1 |
2007 |
| Drug |
everolimus / bibf 1120 |
1 |
2011 |
| Drug |
everolimus/exemestane |
1 |
2014 |
| Drug |
evomela |
1 |
2017 |
| Procedure |
examination |
1 |
2008 |
| Drug |
exatecan mesylate |
1 |
2000 |
| Procedure |
excision of the lesion |
1 |
2008 |
| Procedure |
excisional therapy |
1 |
2002 |
| Behavioral |
exercise, nutritional optimization, |
1 |
2019 |
| Behavioral |
exercise, nutritional optimization,/psychoeducation |
1 |
2019 |
| Drug |
exisulind |
1 |
2002 |
| Drug |
exparel 1.33% (20ml volume) |
1 |
2014 |
| Procedure |
explantation |
1 |
2019 |
| Biological |
extension her-2 vaccine trial at obd |
1 |
2011 |
| Behavioral |
extensive focus program |
1 |
2008 |
| Radiation |
external beam proton radiation therapy. |
1 |
2017 |
| Radiation |
external beam radiotherapy |
1 |
2020 |
| Procedure |
extracellular contrast media (eccm) mri |
1 |
2008 |
| Procedure |
extracorporeal photopheresis |
1 |
2006 |
| Procedure |
extraperitoneal laparoscopic lymphadenectomy (eplnd) |
1 |
2011 |
| Other |
f-18-fluoromisonidazole |
1 |
2008 |
| Drug |
f-18 (bay85-8050) |
1 |
2009 |
| Drug |
f-18 fluorodeoxyglucose |
1 |
2017 |
| Drug |
f-18 fluoroethyltyrosine (fet) |
1 |
2019 |
| Drug |
f0002-adc |
1 |
2019 |
| Behavioral |
facilitator-based intervention |
1 |
2018 |
| Behavioral |
fact sheet |
1 |
2015 |
| Drug |
famitinib malate capsule |
1 |
2012 |
| Drug |
fasted treatment: axl1717 |
1 |
2012 |
| Other |
fasting mimicking diet |
1 |
2017 |
| Dietary Supplement |
fat emulsion |
1 |
2017 |
| Drug |
fate-nk100 |
1 |
2017 |
| Drug |
fcn-437 |
1 |
2019 |
| Device |
fdg pet |
1 |
2014 |
| Device |
fdg pet/ct |
1 |
2014 |
| Procedure |
fecal microbiota transplantation |
1 |
2020 |
| Drug |
fed treatment: axl1717 |
1 |
2012 |
| Drug |
fedratinib |
1 |
2020 |
| Drug |
fenretinide (4-hpr) |
1 |
2012 |
| Drug |
fenretinide (4-hpr)/intravenous safingol |
1 |
2012 |
| Drug |
fentanyl citrate |
1 |
2012 |
| Drug |
ff-10501-01 |
1 |
2014 |
| Drug |
ff-10832 gemcitabine liposome injection |
1 |
2018 |
| Drug |
ff-10850 topotecan liposome injection |
1 |
2019 |
| Drug |
fgf receptor |
1 |
2010 |
| Device |
fiducial markers placement |
1 |
2017 |
| Genetic |
fil-12 |
1 |
2015 |
| Drug |
filgrastim (g-csf) |
1 |
2004 |
| Radiation |
first-line bevacizumab |
1 |
2007 |
| Radiation |
first-line bevacizumab/chemotherapy |
1 |
2007 |
| Other |
first session |
1 |
2015 |
| Device |
fitbit |
1 |
2020 |
| Behavioral |
fitness test |
1 |
2016 |
| Biological |
fli1 type 1 lpx |
1 |
2016 |
| Drug |
flu-bu-cy |
1 |
2011 |
| Drug |
flucytosine (5-fc, ancotil) |
1 |
2018 |
| Drug |
fludarabine, busulfan, thymoglobuline |
1 |
2009 |
| Other |
fludeoxyglucose f-18 |
1 |
2018 |
| Radiation |
fludeoxyglucose f 18 dynomic contrast |
1 |
2010 |
| Procedure |
fluid loading of volulyte 300 ml |
1 |
2016 |
| Drug |
fluorine-19-fluoroded xyglucose |
1 |
2005 |
| Radiation |
fluorine f 18-fluoroazomycin arabinoside |
1 |
2017 |
| Radiation |
fluorine f 18 d-fmau |
1 |
2014 |
| Radiation |
fluorine f 18 sodium fluoride |
1 |
2009 |
| Other |
fluorophotometry |
1 |
2008 |
| Radiation |
fluorothymidine f-18 |
1 |
2014 |
| Drug |
fluorothymidine f 18 |
1 |
2012 |
| Drug |
fluvoxamine |
1 |
2012 |
| Drug |
fluzoparib |
1 |
2015 |
| Drug |
flx475 |
1 |
2018 |
| Drug |
fn-1501 |
1 |
2018 |
| Procedure |
focal leep |
1 |
2014 |
| Procedure |
focal treatment |
1 |
2012 |
| Procedure |
focused ultrasound |
1 |
2018 |
| Drug |
folfiri (irinotecan, 5-fluorouracil, |
1 |
2007 |
| Drug |
folfiri (irinotecan, 5-fluorouracil,/leucovorin) |
1 |
2007 |
| Drug |
folfiri regimen |
1 |
2007 |
| Drug |
folfox regimen (oxaliplatin |
1 |
2017 |
| Drug |
folfox regimen (oxaliplatin/leucovorin/5fu) |
1 |
2017 |
| Drug |
folfox/pac(ip) |
1 |
2016 |
| Drug |
folfox4 regimen |
1 |
2007 |
| Dietary Supplement |
folic acid |
1 |
2007 |
| Drug |
folinic acid / 5 fu |
1 |
2005 |
| Drug |
folinic acid) |
1 |
2016 |
| Other |
follow-up care |
1 |
2019 |
| Other |
follow-up colonoscopy |
1 |
2010 |
| Other |
follow-up for spontaneous regression of the lesion |
1 |
2008 |
| Drug |
fondaparinux |
1 |
2010 |
| Drug |
food |
1 |
2009 |
| Drug |
forodesine hydrochloride |
1 |
2009 |
| Drug |
fosaprepitant dimeglumine |
1 |
2018 |
| Drug |
fosbretabulin disodium |
1 |
1999 |
| Drug |
fostamatinib disodium |
1 |
2009 |
| Biological |
fpt155 |
1 |
2019 |
| Radiation |
fractionated stereotactic radiosurgery |
1 |
2019 |
| Radiation |
fractionated stereotactic radiosurgery (srs) |
1 |
2009 |
| Radiation |
fractionated total body irradiation (ftbi) |
1 |
2000 |
| Radiation |
fractionation |
1 |
2014 |
| Radiation |
frameless fractionated stereotactic radiation therapy |
1 |
2016 |
| Drug |
freeze-dried black raspberry powder |
1 |
2017 |
| Procedure |
fresh tissue from ovary |
1 |
2018 |
| Procedure |
frozen glove |
1 |
2009 |
| Drug |
fruquintinib (hmpl-013) |
1 |
2017 |
| Drug |
fruquintinib in combination with sintilimab |
1 |
2019 |
| Drug |
fs102 |
1 |
2014 |
| Drug |
ft-2102 |
1 |
2018 |
| Drug |
ft500 |
1 |
2019 |
| Behavioral |
functional assessment of cancer therapy - spiritual well-being scale |
1 |
2019 |
| Drug |
g-202 |
1 |
2010 |
| Procedure |
g-bm transplant |
1 |
2012 |
| Drug |
g-csf) |
1 |
1999 |
| Procedure |
g-pb transplant |
1 |
2012 |
| Device |
g1tksvna.53 producer cell line |
1 |
1999 |
| Drug |
g3139, oblimersen sodium, bcl-2 antisense oligonucleotide |
1 |
2007 |
| Biological |
gad-209-fsp high dose |
1 |
2019 |
| Biological |
gad-209-fsp low dose |
1 |
2019 |
| Drug |
gadobutrol |
1 |
2014 |
| Drug |
gadoxetate disodium |
1 |
2014 |
| Other |
gaido |
1 |
2019 |
| Other |
gait assessment test |
1 |
2020 |
| Drug |
gallium ga 68-edotreotide |
1 |
2016 |
| Drug |
gallium nitrate |
1 |
1999 |
| Drug |
galunisertib |
1 |
2011 |
| Drug |
gamma-secretase inhibitor ro4929097 |
1 |
2010 |
| Drug |
ganciclovir |
1 |
2008 |
| Drug |
ganetespib |
1 |
2015 |
| Biological |
gardasil |
1 |
2014 |
| Drug |
gardasil9 |
1 |
2018 |
| Procedure |
gastrectomy with d2 |
1 |
2005 |
| Procedure |
gastrectomy with d2/greater lymph node dissection |
1 |
2005 |
| Drug |
gastrectomy/ chemotherapy |
1 |
2005 |
| Drug |
gdc-0425 |
1 |
2011 |
| Drug |
gdc-0449 |
1 |
2008 |
| Drug |
gdc-0994 |
1 |
2013 |
| Drug |
gemcitabine-releasing intravesical system (gemris) |
1 |
2018 |
| Drug |
gemcitabine-releasing intravesical system (gemris)/tar-200 |
1 |
2018 |
| Drug |
gemcitabine - 21 day cycle |
1 |
2018 |
| Drug |
gemcitabine - 28 day cycle |
1 |
2018 |
| Drug |
gemcitabine / carboplatin |
1 |
2016 |
| Drug |
gemcitabine, ts-1 |
1 |
2007 |
| Drug |
gemzar |
1 |
2002 |
| Biological |
gen1042 |
1 |
2019 |
| Device |
gene gun vaccine |
1 |
2009 |
| Device |
general acupuncture-b (peace classic needlesâ®) |
1 |
2014 |
| Drug |
general anesthesia |
1 |
2016 |
| Drug |
general anesthesia alone |
1 |
2016 |
| Other |
genetic counseling |
1 |
2016 |
| Other |
genetic testing |
1 |
2016 |
| Genetic |
genetically-modified t cells |
1 |
2015 |
| Drug |
genomically directed monotherapy |
1 |
2014 |
| Drug |
genz-644282 (21-day dosing schedule) |
1 |
2009 |
| Drug |
genz-644282 (28-day dosing schedule) |
1 |
2009 |
| Biological |
geptanolimab injection 10mg |
1 |
2017 |
| Biological |
geptanolimab injection 10mg/kg |
1 |
2017 |
| Biological |
geptanolimab injection 10mg/kg, , q2w*6 |
1 |
2017 |
| Biological |
geptanolimab injection 1mg |
1 |
2017 |
| Biological |
geptanolimab injection 1mg/kg |
1 |
2017 |
| Biological |
geptanolimab injection 1mg/kg, q2w*6 |
1 |
2017 |
| Biological |
geptanolimab injection 280mg, q3w |
1 |
2017 |
| Biological |
geptanolimab injection 3mg |
1 |
2017 |
| Biological |
geptanolimab injection 3mg/kg |
1 |
2017 |
| Biological |
geptanolimab injection 3mg/kg, q2w |
1 |
2017 |
| Biological |
geptanolimab injection 3mg/kg, q2w*6 |
1 |
2017 |
| Other |
geriatric follow up |
1 |
2016 |
| Other |
geriatrician co-management |
1 |
2015 |
| Behavioral |
german pro-self(c) |
1 |
2009 |
| Behavioral |
german pro-self(c)/pain control program (pcp) |
1 |
2009 |
| Biological |
gi-6301 (yeast brachyury vaccine) |
1 |
2012 |
| Drug |
gilteritinib |
1 |
2015 |
| Drug |
gimatecanâ® (st-1481) |
1 |
2002 |
| Drug |
ginseng compound |
1 |
2015 |
| Drug |
givinostat |
1 |
2012 |
| Dietary Supplement |
glizigenâ® |
1 |
2018 |
| Dietary Supplement |
glizigenâ® / ocoxin-viusidâ® |
1 |
2018 |
| Device |
globo h ihc assay |
1 |
2018 |
| Drug |
glpg0187 |
1 |
2011 |
| Drug |
gls-010 |
1 |
2018 |
| Drug |
glse compound |
1 |
2015 |
| Drug |
glucarpidase |
1 |
2001 |
| Drug |
glufosfamide |
1 |
2005 |
| Drug |
glumetinib for tablet |
1 |
2017 |
| Drug |
glycopyrrolate |
1 |
2017 |
| Drug |
go-203-2c |
1 |
2011 |
| Behavioral |
go-excap mobile app |
1 |
2019 |
| Drug |
goal directed intravenous restrictive fluid therapy |
1 |
2013 |
| Behavioral |
goals of care initiative |
1 |
2019 |
| Drug |
goserelin |
1 |
2016 |
| Drug |
gpx-150 for injection |
1 |
2008 |
| Biological |
graft-versus-tumor induction therapy |
1 |
2004 |
| Procedure |
graft reconstruction |
1 |
2020 |
| Drug |
granisetron hydrochloride |
1 |
2006 |
| Drug |
granulocyte colony-stimulating factor (g-csf) |
1 |
2005 |
| Drug |
granulocyte colony stimulating factor |
1 |
2005 |
| Biological |
granulocyte macrophage colony-stimulating factor (gm-csf) |
1 |
2007 |
| Biological |
granulocytes |
1 |
2019 |
| Procedure |
greater lymph node dissection |
1 |
2005 |
| Device |
green indocianine |
1 |
2017 |
| Dietary Supplement |
green tea extract |
1 |
1999 |
| Other |
growing resiliency |
1 |
2016 |
| Other |
growing resiliency/courage with cancerâ„¢ (grace) |
1 |
2016 |
| Biological |
grt-c903 |
1 |
2019 |
| Biological |
grt-r904 |
1 |
2019 |
| Drug |
gs-1423 |
1 |
2019 |
| Drug |
gs-4224 |
1 |
2019 |
| Drug |
gs-9820 |
1 |
2012 |
| Biological |
gsk biologicals’ hpv-16 |
1 |
2006 |
| Biological |
gsk biologicals’ hpv-16/18 vaccine (cervarixâ„¢) |
1 |
2006 |
| Drug |
gsk1120212b (lower dmso content) |
1 |
2012 |
| Drug |
gsk1120212b (standard dmso content) |
1 |
2012 |
| Drug |
gsk1363089 (formerly xl880) |
1 |
2008 |
| Drug |
gsk21110183 |
1 |
2009 |
| Drug |
gsk2636771 |
1 |
2017 |
| Drug |
gsk3052230 |
1 |
2013 |
| Drug |
gst-hg161 |
1 |
2020 |
| Biological |
gti-2040 |
1 |
2004 |
| Drug |
gtx-006 (acapodene) |
1 |
2001 |
| Drug |
guarana extract |
1 |
2009 |
| Behavioral |
guided imagery with audio media |
1 |
2015 |
| Biological |
gx-188e |
1 |
2014 |
| Genetic |
gx-188e administered by electroporation |
1 |
2012 |
| Other |
h2ra |
1 |
2012 |
| Other |
h2ra/surgicel |
1 |
2012 |
| Drug |
hai abraxane |
1 |
2010 |
| Drug |
hai oxaliplatin |
1 |
2009 |
| Drug |
hal 0.2% with illumination |
1 |
2010 |
| Drug |
hal 1% with illumination |
1 |
2010 |
| Drug |
hal 5% with illumination |
1 |
2010 |
| Drug |
halofuginone hydrobromide |
1 |
2001 |
| Drug |
haloperidol decanoate |
1 |
2013 |
| Behavioral |
hand function test |
1 |
2019 |
| Biological |
hankâ„¢ for infusion |
1 |
2017 |
| Biological |
haplo |
1 |
2007 |
| Biological |
haplo hct <55 years old |
1 |
2016 |
| Biological |
haplo hct ≥55 |
1 |
2016 |
| Biological |
haplo hct ≥55 years old |
1 |
2016 |
| Biological |
haplo hct ≥55/< 65 years old |
1 |
2016 |
| Biological |
haplo hct ≥65 |
1 |
2016 |
| Biological |
haplo hct ≥65/≤75 years old |
1 |
2016 |
| Biological |
haplo/cord transplant |
1 |
2007 |
| Device |
haploidentical allogeneic transplantation |
1 |
2010 |
| Procedure |
haploidentical donor derived natural killer cell infusion |
1 |
2008 |
| Procedure |
haploidentical hematopoietic stem cell transplantation (hsct) |
1 |
2015 |
| Biological |
havrixâ„¢ |
1 |
2006 |
| Drug |
hb002.1t |
1 |
2018 |
| Drug |
hbm4003 |
1 |
2019 |
| Drug |
hcc child-pugh a expansion cohort: regorafenib 100 mg |
1 |
2010 |
| Drug |
hcc child-pugh b expansion cohort: regorafenib 100 mg |
1 |
2010 |
| Drug |
hdm201 |
1 |
2014 |
| Behavioral |
health coaching |
1 |
2015 |
| Behavioral |
health communication intervention |
1 |
2015 |
| Behavioral |
health talk |
1 |
2013 |
| Behavioral |
health talk/adventure-based training |
1 |
2013 |
| Other |
health telemonitoring |
1 |
2011 |
| Other |
healthy living |
1 |
2012 |
| Drug |
hec68498 |
1 |
2020 |
| Drug |
helixorâ® m |
1 |
2017 |
| Drug |
hematologic drug |
1 |
2019 |
| Other |
hematopoietic cell transplantation |
1 |
2006 |
| Biological |
hematopoietic stem cell transplant (hsct) |
1 |
2007 |
| Procedure |
hematopoietic stem cell transplantation (hsct) |
1 |
2007 |
| Drug |
hemay102 |
1 |
2019 |
| Procedure |
hepatic artery embolizations |
1 |
2007 |
| Drug |
hepatic artery infusion pump floxuridine |
1 |
2020 |
| Drug |
hepatic artery infusion pump floxuridine/dexamethasone |
1 |
2020 |
| Device |
hepatic artery infusion pump placement using the synchromed ii pump |
1 |
2020 |
| Device |
hepatic artery infusion pump placement using the synchromed ii pump/the codman tapered arterial catheter. |
1 |
2020 |
| Procedure |
hepatic resection |
1 |
2014 |
| Biological |
hepatitis a inactivated virus vaccine |
1 |
2005 |
| Biological |
hepatitis b vaccine |
1 |
2011 |
| Biological |
her-2 vaccine |
1 |
2011 |
| Biological |
her2-specific chimeric antigen receptor (car) t cell |
1 |
2018 |
| Biological |
her2-specific t cells |
1 |
2015 |
| Drug |
herceptin |
1 |
2012 |
| Biological |
hev vaccine |
1 |
2012 |
| Drug |
hgs1029 |
1 |
2008 |
| Drug |
hh2710 |
1 |
2019 |
| Radiation |
high-dose conformal radiation therapy |
1 |
2016 |
| Procedure |
high-resolution microendoscopy (hrme) |
1 |
2016 |
| Device |
high-resolution microendoscopy imaging |
1 |
2015 |
| Procedure |
high dose melphalan |
1 |
1999 |
| Procedure |
high dose melphalan/autologous bone marrow transplantation |
1 |
1999 |
| Procedure |
high field strength magnetic resonance imaging |
1 |
2008 |
| Device |
high flow nasal cannula |
1 |
2017 |
| Other |
high flow nasal cannula oxygen therapy |
1 |
2015 |
| Device |
high flow nasal cannula/low flow nasal cannula |
1 |
2017 |
| Device |
high flow oxygen therapy |
1 |
2017 |
| Device |
high intensity focused ultrasound |
1 |
2010 |
| Other |
high intensity interval training |
1 |
2019 |
| Other |
high intensity interval training exercise programme |
1 |
2016 |
| Procedure |
high resolution anal manometry |
1 |
2016 |
| Other |
high risk hpv dna testing |
1 |
2010 |
| Procedure |
highly conformal (crt) |
1 |
2005 |
| Drug |
highly selective fgfr1-3 inhibitor |
1 |
2019 |
| Drug |
hipec with mitomycin-c |
1 |
2013 |
| Radiation |
hippocampal avoidance wbrt |
1 |
2015 |
| Other |
histological technique |
1 |
2008 |
| Biological |
hla-a*2402 |
1 |
2013 |
| Biological |
hla-a2402/a0201 restricted peptides |
1 |
2013 |
| Drug |
hlx04 |
1 |
2018 |
| Drug |
hlx07 |
1 |
2018 |
| Drug |
hlx07/gemcitabine/cisplatin |
1 |
2018 |
| Drug |
hlx07/mfolfox6 |
1 |
2018 |
| Drug |
hlx07/paclitaxel/carboplatin |
1 |
2018 |
| Drug |
hlx20 |
1 |
2018 |
| Drug |
hlx22 |
1 |
2019 |
| Drug |
hm781-36b tablets |
1 |
2011 |
| Drug |
hm95573, cobimetinib |
1 |
2017 |
| Drug |
hmn14 (labetuzumab) |
1 |
2002 |
| Drug |
hmpl-306 |
1 |
2020 |
| Drug |
hmpl-453 |
1 |
2017 |
| Behavioral |
home-based high-intensity interval training |
1 |
2019 |
| Behavioral |
home-based moderate-intensity continuous exercise |
1 |
2019 |
| Other |
home exercise program |
1 |
2012 |
| placebo |
homeopathic placebo globules |
1 |
2012 |
| Drug |
hormone replacement therapy |
1 |
1999 |
| Procedure |
hormone therapy |
1 |
2002 |
| Other |
hospice video educational tool |
1 |
2017 |
| Biological |
hpn536 |
1 |
2019 |
| Drug |
hpv-16 vaccine |
1 |
2013 |
| Biological |
hpv dna plasmids therapeutic vaccine medi0457 |
1 |
2018 |
| Biological |
hpv dna plasmids therapeutic vaccine vgx-3100 |
1 |
2018 |
| Diagnostic Test |
hpv genotyping |
1 |
2018 |
| Other |
hpv self testing |
1 |
2014 |
| Device |
hpv test |
1 |
2014 |
| Biological |
hpv vaccine |
1 |
2012 |
| Drug |
hqp1351 |
1 |
2018 |
| Procedure |
hr pem scan |
1 |
2009 |
| Drug |
hs-10342 |
1 |
2019 |
| Biological |
hs-110 (viagenpumatucel-l) |
1 |
2019 |
| Biological |
hs-130 |
1 |
2019 |
| Drug |
hs-196 |
1 |
2017 |
| Biological |
hsc835 |
1 |
2011 |
| Biological |
hsp70 dna vaccine |
1 |
2005 |
| Drug |
hsp90 inhibitor auy 922 |
1 |
2010 |
| Drug |
hsp990 |
1 |
2009 |
| Biological |
hspe7 |
1 |
2003 |
| Genetic |
hsv-tk |
1 |
2007 |
| Biological |
hsv1716 |
1 |
2009 |
| Drug |
hti-1090 |
1 |
2017 |
| Drug |
huangqi guizhi wuwu decoction |
1 |
2020 |
| Device |
human intravital microscopy |
1 |
2019 |
| Biological |
human papillomavirus 16 |
1 |
2005 |
| Biological |
human papillomavirus 16/18 l1 virus-like particle/as04 vaccine |
1 |
2005 |
| Drug |
humanized anti-pd-1 monoclonal antibody |
1 |
2018 |
| Biological |
humanized anti-pd-1 monoclonal antibody toripalimab |
1 |
2016 |
| Drug |
humax-il8 |
1 |
2015 |
| Drug |
hwh340 tablet |
1 |
2018 |
| Drug |
hx009 |
1 |
2019 |
| Procedure |
hybrid apc |
1 |
2018 |
| Procedure |
hybrid argon plasma coagulation |
1 |
2019 |
| Drug |
hycamtin (topotecan) |
1 |
2009 |
| Drug |
hydralazine |
1 |
2006 |
| Drug |
hydralazine/magnesium valproate |
1 |
2006 |
| Drug |
hydrea |
1 |
2011 |
| Drug |
hydrocodone |
1 |
2018 |
| Drug |
hydromorphone |
1 |
2018 |
| Drug |
hydromorphone hydrochloride |
1 |
2018 |
| Drug |
hydroxychloroquine, 200mg twice dailiy |
1 |
2014 |
| Drug |
hydroxychloroquine, 400mg twice daily |
1 |
2014 |
| Drug |
hydroxyurea |
1 |
2007 |
| Drug |
hyper-cvad |
1 |
2010 |
| Drug |
hyperpolarized carbon c 13 pyruvate |
1 |
2019 |
| Drug |
hyperthermic intraperitoneal chemotherapy |
1 |
2019 |
| Procedure |
hyperthermic intraperitoneal chemotherapy with mmc |
1 |
2014 |
| Procedure |
hypnotherapy |
1 |
2019 |
| Radiation |
hypofractionated |
1 |
2018 |
| Radiation |
hypofractionated imrt using helical tomotherapy. |
1 |
2019 |
| Radiation |
hypofractionated index site radiation |
1 |
2018 |
| Radiation |
hypofractionated radiosurgery |
1 |
2012 |
| Radiation |
hypofractionated radiotherapy |
1 |
2015 |
| Radiation |
hypofractionated re-irradiation |
1 |
2016 |
| Radiation |
hypofractionation |
1 |
2014 |
| Procedure |
hypotonic partial nephrectomy |
1 |
2019 |
| Procedure |
hysteroscopic repeat curettage |
1 |
2018 |
| Drug |
i-131-clr1404 |
1 |
2009 |
| Drug |
i-dac (intermediate dose cytarabine) |
1 |
2015 |
| Drug |
ibandronate |
1 |
2009 |
| Drug |
ibi101 |
1 |
2018 |
| Drug |
ibi110 |
1 |
2019 |
| Drug |
ibi110/ sintilimab |
1 |
2019 |
| Drug |
ibi188, rituximab |
1 |
2018 |
| Drug |
ibi308 |
1 |
2016 |
| Drug |
ibi308 |
1 |
2016 |
| Drug |
ibi308 |
1 |
2016 |
| Drug |
ibi308\5-fu |
1 |
2016 |
| Drug |
ibi308 |
1 |
2016 |
| Drug |
ibi310 |
1 |
2018 |
| Drug |
ibi315 |
1 |
2019 |
| Biological |
ibi318 |
1 |
2019 |
| Drug |
ibrutinib 420 mg |
1 |
2017 |
| Drug |
ibrutinib 560 mg |
1 |
2017 |
| Drug |
ibrutinib 840 mg |
1 |
2017 |
| Drug |
ibuprofen |
1 |
2017 |
| Biological |
ic9 |
1 |
2017 |
| Biological |
ic9/car.19/il15-transduced cb-nk cells |
1 |
2017 |
| Drug |
icaritin |
1 |
2015 |
| Device |
icg fluorescence imaging |
1 |
2018 |
| Drug |
idarubicin |
1 |
2018 |
| Drug |
idelalisib |
1 |
2015 |
| Drug |
idh305 |
1 |
2015 |
| Drug |
idronoxil |
1 |
2001 |
| Drug |
idx-1197 |
1 |
2019 |
| Drug |
ifetroban sodium |
1 |
2018 |
| Drug |
ik-175 |
1 |
2019 |
| Drug |
il-2 |
1 |
2009 |
| Drug |
il-3 |
1 |
1999 |
| Biological |
il13rî±2-specific, hinge-optimized, 41bb-costimulatory car |
1 |
2014 |
| Biological |
il13rî±2-specific, hinge-optimized, 41bb-costimulatory car/truncated cd19-expressing autologous t lymphocytes |
1 |
2014 |
| Biological |
il15-transduced cb-nk cells |
1 |
2017 |
| Other |
illumination with ceramoptec laser |
1 |
2009 |
| Drug |
ilorasertib |
1 |
2015 |
| Drug |
im156 |
1 |
2017 |
| Biological |
im19 car-t |
1 |
2017 |
| Radiation |
image guided radiation therapy |
1 |
2012 |
| Device |
imaging 18f-fdg-pet |
1 |
2016 |
| Device |
imaging 18f-fdg-pet/ct |
1 |
2016 |
| Procedure |
imaging, adrenal acans |
1 |
2007 |
| Drug |
imatinib maintenance |
1 |
2014 |
| Drug |
imatinib/ptk/zk222584 |
1 |
2008 |
| Drug |
imc-001 |
1 |
2018 |
| Biological |
imc-11f8 |
1 |
2008 |
| Biological |
imc-11f8 i.v. |
1 |
2008 |
| Biological |
imc-18f1 |
1 |
2008 |
| Biological |
imc-3g3 |
1 |
2008 |
| Biological |
imc-tr1 |
1 |
2012 |
| Drug |
imetelstat |
1 |
2012 |
| Drug |
imetelstat sodium |
1 |
2011 |
| Drug |
imetelstat sodium (grn163l) |
1 |
2006 |
| Biological |
imf-001 |
1 |
2010 |
| Drug |
imgn388 |
1 |
2008 |
| Drug |
imgn632 |
1 |
2017 |
| Drug |
imipenem |
1 |
2018 |
| Procedure |
immediate breast reconstruction |
1 |
2017 |
| Drug |
immediate instillation of intravesical chemotherapy-epirubicin- |
1 |
2015 |
| Drug |
immune checkpoint inhibitor (ici) |
1 |
2019 |
| Drug |
immuno-oncology (io) therapy |
1 |
2019 |
| Procedure |
immunoablative hematopoietic pbsc transplant |
1 |
2005 |
| Drug |
immunotherapeutic agent |
1 |
2019 |
| Biological |
immunotherapy |
1 |
2008 |
| Radiation |
imrt |
1 |
2019 |
| Drug |
imsa101 |
1 |
2019 |
| Drug |
imx-110 |
1 |
2017 |
| Genetic |
in depth genomic sequencing |
1 |
2013 |
| Procedure |
in vitro-treated bone marrow transplantation |
1 |
1999 |
| Procedure |
in vitro-treated peripheral blood stem cell transplantation |
1 |
2001 |
| Biological |
in vitro expanded cytokine induced killer (cik) cells |
1 |
2010 |
| Drug |
incagn01949 |
1 |
2017 |
| Drug |
incagn02390 |
1 |
2018 |
| Drug |
incb001158 |
1 |
2019 |
| Drug |
incb018424 |
1 |
2008 |
| Drug |
incb024360 |
1 |
2010 |
| Drug |
incb028060 |
1 |
2010 |
| Drug |
incb040093 |
1 |
2013 |
| Drug |
incb040093 / itacitinib |
1 |
2013 |
| Drug |
incb053914 |
1 |
2015 |
| Drug |
incb057643 |
1 |
2016 |
| Drug |
incb081776 |
1 |
2018 |
| Drug |
incb086550 |
1 |
2018 |
| Biological |
incomplete freund’s adjuvant |
1 |
2019 |
| Drug |
incyclinide |
1 |
1999 |
| Drug |
indibulin |
1 |
2007 |
| Other |
indirect calorimetry |
1 |
2015 |
| Drug |
indoximod |
1 |
2015 |
| Drug |
induction trichemotherapy - folfirinox regimen |
1 |
2011 |
| Biological |
ineo-vac-p01 |
1 |
2018 |
| Drug |
infigratinib |
1 |
2020 |
| Biological |
influenza vaccine |
1 |
2016 |
| Behavioral |
informational brochure |
1 |
2012 |
| Behavioral |
informed assent |
1 |
2012 |
| Genetic |
infusion of 4h11-28z |
1 |
2015 |
| Genetic |
infusion of 4h11-28z/fil-12/egfrt/ genetically-modified t cells |
1 |
2015 |
| Biological |
infusion of 4scar-t specific to cd22 |
1 |
2020 |
| Biological |
infusion of 4scar-t specific to cd22/cd123/cd38/ cd10/cd20 |
1 |
2020 |
| Biological |
infusion of allogeneic cik cells |
1 |
2007 |
| Biological |
infusion of donor dendritic cells |
1 |
2007 |
| Biological |
infusion of donor lymphocytes |
1 |
2007 |
| Genetic |
infusion of modified car19 t-cells (4g7-card t-cells) |
1 |
2016 |
| Drug |
iniparib (sar240550-bsi-201) |
1 |
2011 |
| Drug |
iniparib (sar240550 - bsi-201) |
1 |
2010 |
| Behavioral |
initial fasting |
1 |
2013 |
| Procedure |
injecting air |
1 |
2011 |
| Biological |
injections of om-174 |
1 |
2013 |
| Drug |
inno-206 |
1 |
2011 |
| Biological |
ino-3106, ino-9012 |
1 |
2014 |
| Device |
inspiratory muscle training |
1 |
2019 |
| Other |
institutional standard of care |
1 |
2018 |
| Behavioral |
integrated psychological care |
1 |
2018 |
| Other |
integrative care |
1 |
2016 |
| Other |
intelligent electric bicycle (velis) sessions |
1 |
2017 |
| Other |
intensified follow-up schedule |
1 |
2019 |
| Radiation |
intensity-modulated radiation therapy (imrt) |
1 |
2019 |
| Procedure |
intensity modulated radiation therapy boost |
1 |
2005 |
| Radiation |
intensity modulated radiotherapy |
1 |
2016 |
| Radiation |
intensity modulated radiotherapy (imrt) - deintensified |
1 |
2017 |
| Radiation |
intensity modulated radiotherapy (imrt) - standard |
1 |
2017 |
| Behavioral |
interactive music therapy |
1 |
2018 |
| Behavioral |
interactive voice response (ivr) reminders |
1 |
2014 |
| Behavioral |
interactive voice response system |
1 |
2008 |
| Behavioral |
interdisciplinary rehabilitation |
1 |
2014 |
| Drug |
interferon |
1 |
2012 |
| Drug |
interferon-alpha |
1 |
2004 |
| Drug |
interferon-gamma |
1 |
2015 |
| Drug |
interferon-gamma/nivolumab |
1 |
2015 |
| Drug |
interferon alpha |
1 |
2002 |
| Drug |
interferon alpha-2b |
1 |
2008 |
| Drug |
interferon alpha 2b |
1 |
2009 |
| Drug |
interleukin-1 |
1 |
1999 |
| Drug |
interleukin-12 |
1 |
2020 |
| Drug |
interleukin-2 (il-2) |
1 |
2008 |
| Biological |
interleukin 2 |
1 |
1999 |
| Other |
internet mobile technology |
1 |
2018 |
| Device |
interstitial light emitting diodes |
1 |
2007 |
| Other |
interventional arm: early best palliative care |
1 |
2013 |
| Other |
interviews |
1 |
2016 |
| Biological |
intra-lesional vaccine administration |
1 |
2009 |
| Procedure |
intrabone cord blood infusion |
1 |
2009 |
| Biological |
intramuscular vaccination |
1 |
2009 |
| Device |
intraoperative cerebral microdialysis using m dialysis 107 pump |
1 |
2019 |
| Device |
intraoperative cerebral microdialysis using m dialysis 107 pump/71 high cut-off brain microdialysis catheter |
1 |
2019 |
| Radiation |
intraoperative radiotherapy |
1 |
2011 |
| Drug |
intravenous (iv) sea-cd40 |
1 |
2015 |
| Drug |
intravenous artesunate |
1 |
2015 |
| Drug |
intravenous safingol |
1 |
2012 |
| Drug |
investigational agent |
1 |
2019 |
| Device |
investigational imaging device |
1 |
2017 |
| Drug |
investigator’s choice of platinum agent |
1 |
2017 |
| Drug |
investigator’s choice of treatment |
1 |
2011 |
| Other |
investigator choice therapy |
1 |
2018 |
| Radiation |
involved target stereotacic spine radiosurgery |
1 |
2019 |
| Drug |
iodine-123 |
1 |
2018 |
| Drug |
ionis-stat3rx |
1 |
2012 |
| Drug |
ip-001 |
1 |
2019 |
| Device |
ip catheter insertion |
1 |
2015 |
| Drug |
ipatasertib |
1 |
2015 |
| Drug |
iph2201 |
1 |
2015 |
| Biological |
iph5201 |
1 |
2020 |
| Biological |
iph5401 |
1 |
2018 |
| Biological |
iph5401/durvalumab |
1 |
2018 |
| Drug |
ipi-504, docetaxel |
1 |
2008 |
| Drug |
ipi-549 |
1 |
2018 |
| Drug |
ipi-926 |
1 |
2008 |
| Drug |
ipilimumab injection [yervoy] |
1 |
2018 |
| Drug |
ipn60090 |
1 |
2019 |
| Drug |
ipn60090 single administration |
1 |
2019 |
| Device |
ipolysite â® mini sã©rie 3108 |
1 |
2018 |
| Device |
ipolysite â® mini sã©rie 3108/polysite â® standard, sã©rie 4108. |
1 |
2018 |
| Procedure |
ire treatment |
1 |
2016 |
| Drug |
irinotecan (administered with |
1 |
2007 |
| Drug |
irinotecan (administered with/without cetuximab) |
1 |
2007 |
| Drug |
irinotecan (cpt-11) |
1 |
1999 |
| Drug |
irinotecan (irinotecan cell pharmâ®) |
1 |
2014 |
| Drug |
irinotecan / 5 fu / folinic acid |
1 |
2005 |
| Drug |
irinotecan hydrochloride injection(camptoâ®ï¼‰ |
1 |
2019 |
| Drug |
irinotecan, zd1839, vincristine, cefixime, cefpodoxime. |
1 |
2005 |
| Drug |
irofulven |
1 |
1999 |
| Drug |
iron isomaltoside 1000 |
1 |
2010 |
| Drug |
iron sulphate |
1 |
2010 |
| Biological |
irx-2 |
1 |
2017 |
| Biological |
isa 101 |
1 |
2015 |
| Biological |
isa101b |
1 |
2017 |
| Drug |
isavuconazonium sulfate - intravenous |
1 |
2017 |
| Drug |
isavuconazonium sulfate - oral |
1 |
2017 |
| Drug |
iso-fludelone |
1 |
2011 |
| Procedure |
isolated hepatic portal |
1 |
1999 |
| Procedure |
isolated hepatic portal/arterial perfusion |
1 |
1999 |
| Drug |
isotretinoin |
1 |
2005 |
| Drug |
isotretinoin (accutane) |
1 |
2002 |
| Drug |
isovue-200 |
1 |
2016 |
| Procedure |
issue of information booklet |
1 |
2005 |
| Biological |
isu104 |
1 |
2018 |
| Drug |
itraconazole (sporanox) |
1 |
2015 |
| Drug |
iv anti-thymocyte globuline |
1 |
2014 |
| Drug |
iv bisphosphonate q 4 weeks |
1 |
2005 |
| Drug |
iv busulfan |
1 |
2014 |
| Drug |
iv fludarabine |
1 |
2014 |
| Drug |
iv fluorescein administration |
1 |
2015 |
| Drug |
iv iron dextran |
1 |
2006 |
| Drug |
iv thiotepa |
1 |
2014 |
| Device |
ivct |
1 |
2017 |
| Drug |
ixazomib 2.5 mg |
1 |
2011 |
| Drug |
ixazomib 4 mg capsule a |
1 |
2011 |
| Drug |
ixazomib 4 mg capsule b |
1 |
2011 |
| Biological |
jcar017 |
1 |
2017 |
| Biological |
jetpeiâ„¢ |
1 |
2018 |
| Drug |
ji-101 |
1 |
2009 |
| Drug |
jk-1201i |
1 |
2020 |
| Drug |
jnj-26483327 |
1 |
2008 |
| Drug |
jnj-26854165 |
1 |
2008 |
| Drug |
jpi-547 |
1 |
2018 |
| Drug |
jsi-1187 |
1 |
2020 |
| Drug |
jtx-4014 |
1 |
2018 |
| Drug |
ka2507 |
1 |
2016 |
| Drug |
karenitecin (bnp1350) |
1 |
2003 |
| Drug |
kareniticin |
1 |
2007 |
| Drug |
kareniticin/cyclophosphamide |
1 |
2007 |
| Drug |
kaz954 |
1 |
2020 |
| Drug |
kd033 for injection |
1 |
2020 |
| Drug |
ketamine gel |
1 |
2007 |
| Other |
ketogenic diet |
1 |
2017 |
| Drug |
keyhole limpet hemocyanin |
1 |
2007 |
| Drug |
keytruda |
1 |
2020 |
| Drug |
kg) |
1 |
2011 |
| Biological |
kg, , q2w*6 |
1 |
2017 |
| Biological |
kg, q2w |
1 |
2017 |
| Biological |
kg, q2w*6 |
1 |
2017 |
| Drug |
khk2455 |
1 |
2016 |
| Biological |
klh day 1 |
1 |
2012 |
| Biological |
klh day 29 |
1 |
2012 |
| Biological |
kn026 |
1 |
2019 |
| Biological |
kn026/with kn046 |
1 |
2019 |
| Biological |
kn044 |
1 |
2019 |
| Drug |
ko-539 |
1 |
2019 |
| Drug |
ko-947 |
1 |
2017 |
| Drug |
kpg-818 |
1 |
2020 |
| Drug |
kpt-9274 |
1 |
2016 |
| Drug |
krn5500 |
1 |
2001 |
| Drug |
krn951 |
1 |
2009 |
| Drug |
kw-2450 |
1 |
2009 |
| Drug |
kx2-361 |
1 |
2014 |
| Drug |
kx2-391 |
1 |
2008 |
| Drug |
l-leucyl-l-leucine methyl ester (llme) |
1 |
2007 |
| Drug |
l-lv (dl-lv) |
1 |
2013 |
| Drug |
l-phenylalanine mustard |
1 |
2007 |
| Drug |
l-selenomethionine |
1 |
2002 |
| placebo |
l-selenomethionine placebo |
1 |
2002 |
| Drug |
l19-il2 |
1 |
2013 |
| Drug |
l19il2 |
1 |
2010 |
| Other |
laboratory assay |
1 |
2005 |
| Biological |
lactobacillus plantarum strain 299 |
1 |
2017 |
| Biological |
lactobacillus plantarum strain 299v |
1 |
2017 |
| Drug |
lamivudine |
1 |
2012 |
| Drug |
lanreotide |
1 |
2016 |
| Drug |
lanreotide autogel 120 mg |
1 |
2015 |
| Procedure |
laparoscopic distal pancreatectomy |
1 |
2019 |
| Procedure |
laparoscopic interval debulking surgery |
1 |
2014 |
| Procedure |
laparoscopic liver resection |
1 |
2012 |
| Device |
laparoscopic narrow band imaging |
1 |
2013 |
| Procedure |
laparoscopic) |
1 |
2014 |
| Drug |
lapatinib/sorafenib |
1 |
2009 |
| Procedure |
large loop excision of the transformation zone |
1 |
2016 |
| Drug |
larotrectinib (vitravki, bay2757556) |
1 |
2015 |
| Device |
laser |
1 |
2013 |
| Procedure |
laser acupuncture |
1 |
2020 |
| Behavioral |
later entry group |
1 |
2010 |
| Procedure |
layered closure technique |
1 |
2018 |
| Drug |
lbh589, paclitaxel, carboplatin, bevacizumab |
1 |
2007 |
| Drug |
ldac |
1 |
2014 |
| Drug |
le-dt |
1 |
2010 |
| Drug |
ledipasvir |
1 |
2019 |
| Drug |
ledipasvir / sofosbuvir oral product |
1 |
2019 |
| Device |
leep |
1 |
2017 |
| Device |
leep/cold knife |
1 |
2017 |
| Drug |
len (lenalidomide) |
1 |
2011 |
| Drug |
lenvatinib/pembrolizumab |
1 |
2019 |
| Drug |
lerafaon |
1 |
2001 |
| Drug |
lerafaon-etu |
1 |
2005 |
| Drug |
letermovir |
1 |
2019 |
| Drug |
letrozole / temsirolimus (cci-779) |
1 |
2003 |
| Drug |
letrozole 2.5 mg |
1 |
2015 |
| Drug |
leucovorin (calcium folinate |
1 |
2016 |
| Drug |
leucovorin (lv) |
1 |
2015 |
| Drug |
leucovorin) |
1 |
2007 |
| Drug |
leuprolide acetate |
1 |
2011 |
| Drug |
levofloxacin |
1 |
2000 |
| Drug |
levoleucovorin |
1 |
2018 |
| Drug |
levoleucovorin 200 mg |
1 |
2012 |
| Drug |
levoleucovorin 200 mg/m2 |
1 |
2012 |
| Drug |
levoleucovorin 60 mg |
1 |
2012 |
| Drug |
levoleucovorin 60 mg/m2 |
1 |
2012 |
| Drug |
levonorgestrel |
1 |
2018 |
| Device |
levonorgestrel-releasing intrauterine system(lng-ius) |
1 |
2017 |
| Drug |
levorphanol |
1 |
2018 |
| Drug |
lgx818 |
1 |
2012 |
| Drug |
lhc165 |
1 |
2017 |
| Drug |
lidocaine |
1 |
2013 |
| Drug |
lidocaine 1% |
1 |
2015 |
| Procedure |
limited surgical evaluation |
1 |
2012 |
| Other |
linear array hpv genotyping assay |
1 |
2013 |
| Drug |
liposomal bupivacaine |
1 |
2016 |
| Drug |
liposome entrapped paclitaxel easy to use |
1 |
2004 |
| Drug |
liposome entrapped paclitaxel easy to use (lep-etu) |
1 |
2004 |
| Drug |
lipotecan |
1 |
2008 |
| Other |
liquid chromatography |
1 |
2010 |
| Biological |
lisocabtagene maraleucel |
1 |
2018 |
| Device |
litebook |
1 |
2012 |
| Drug |
lithium |
1 |
2017 |
| Radiation |
liver radiation therapy |
1 |
2018 |
| Procedure |
liver transplant |
1 |
2019 |
| Behavioral |
living with hope program |
1 |
2010 |
| Procedure |
lletz cone |
1 |
2012 |
| Procedure |
llnd |
1 |
2018 |
| Drug |
lm716 |
1 |
2013 |
| Drug |
lmb-100 |
1 |
2016 |
| Device |
local hyperthermia at 37℃ |
1 |
2017 |
| Device |
local hyperthermia at 44℃ |
1 |
2017 |
| Radiation |
local radiotherapy |
1 |
2014 |
| Drug |
lonsurf |
1 |
2018 |
| Drug |
lor-253 hcl |
1 |
2011 |
| Drug |
lorlatinib |
1 |
2018 |
| Biological |
lorvotuzumab mertansine |
1 |
2015 |
| Procedure |
low-intensity bodywork therapy |
1 |
2002 |
| Drug |
low dose ara-c (ldac) |
1 |
2014 |
| Drug |
low dose chemotherapy |
1 |
2013 |
| Diagnostic Test |
low dose ct |
1 |
2016 |
| Drug |
low dose cytarabine |
1 |
2013 |
| Combination Product |
low dose irradiation |
1 |
2018 |
| Combination Product |
low dose irradiation / nivolumab / ipilimumab / aspirin |
1 |
2018 |
| Radiation |
low dose total body irradiation |
1 |
2013 |
| Device |
low flow nasal cannula |
1 |
2017 |
| Procedure |
lower-limb drainage isotopic intraoperative detection |
1 |
2013 |
| Drug |
lpm3480226 |
1 |
2019 |
| Procedure |
lptme |
1 |
2016 |
| Biological |
lt1009) |
1 |
2008 |
| Combination Product |
lum imaging system |
1 |
2019 |
| Procedure |
lung function imaging |
1 |
2007 |
| Drug |
lupron |
1 |
2018 |
| Drug |
lurtotecan liposome |
1 |
2000 |
| Drug |
luspatercept |
1 |
2017 |
| Drug |
lv |
1 |
2016 |
| Biological |
lvgn6051 |
1 |
2019 |
| Drug |
ly01610 ( irinotecan hydrochloride liposome injection ) |
1 |
2019 |
| Drug |
ly01610 ( irinotecan hydrochloride liposome injection ) with 5-fu(fluorouracil injection) |
1 |
2019 |
| Drug |
ly2157299 |
1 |
2012 |
| Drug |
ly2228820 |
1 |
2011 |
| Drug |
ly2275796 |
1 |
2009 |
| Drug |
ly2334737 |
1 |
2012 |
| Drug |
ly2495655 |
1 |
2012 |
| Drug |
ly2603618 |
1 |
2011 |
| Drug |
ly2784544 |
1 |
2012 |
| Drug |
ly2835219 |
1 |
2011 |
| Drug |
ly2875358 |
1 |
2011 |
| Drug |
ly2875358 / erlotinib |
1 |
2011 |
| Drug |
ly2875358 at part a highest dose |
1 |
2011 |
| Drug |
ly2875358 at part a highest dose / trametinib |
1 |
2011 |
| Drug |
ly2880070 |
1 |
2015 |
| Drug |
ly293111 |
1 |
2000 |
| Drug |
ly3076226 |
1 |
2015 |
| Drug |
ly3127804 |
1 |
2015 |
| Drug |
ly3164530 |
1 |
2014 |
| Drug |
ly3200882 |
1 |
2016 |
| Drug |
ly3295668 |
1 |
2017 |
| Drug |
ly3434172 |
1 |
2019 |
| Drug |
ly3475070 |
1 |
2019 |
| Drug |
ly573636 |
1 |
2010 |
| Drug |
ly573636-sodium |
1 |
2010 |
| Drug |
ly900003 |
1 |
2002 |
| Drug |
ly900009 - dose confirmation phase (part b) |
1 |
2010 |
| Drug |
ly900009 - dose escalation phase (part a) |
1 |
2010 |
| Drug |
lycopene 30mg |
1 |
2011 |
| Procedure |
lymphadenectomy (lne) |
1 |
2008 |
| Drug |
lymphodepletion with cyclophosphamide |
1 |
2015 |
| Drug |
lymphodepletion with fludarabine |
1 |
2015 |
| Drug |
lyso-thermosensitive liposomal doxorubicin |
1 |
2015 |
| Biological |
lzm009,recombinant humanized anti-pd-1 monoclonal antibody for injection |
1 |
2017 |
| Drug |
m1774 |
1 |
2019 |
| Drug |
m3541 |
1 |
2017 |
| Drug |
m3814 |
1 |
2018 |
| Drug |
m4344 |
1 |
2014 |
| Drug |
m4n |
1 |
2003 |
| Biological |
m57-klh peptide vaccine |
1 |
2019 |
| Drug |
m6620 |
1 |
2014 |
| Drug |
m7583 |
1 |
2016 |
| Drug |
m8891 |
1 |
2017 |
| Drug |
mâ² iv |
1 |
2019 |
| Drug |
mâ² po bid |
1 |
2019 |
| Drug |
mabp1 |
1 |
2009 |
| Drug |
mac-321 |
1 |
2003 |
| Device |
macy catheter |
1 |
2018 |
| Drug |
magnesium sulfate |
1 |
2014 |
| Drug |
magnesium valproate |
1 |
2006 |
| Procedure |
magnetic compressive anastomosis |
1 |
2018 |
| Drug |
maintainance therapy of intravesical chemotherapy-epirubicin- |
1 |
2015 |
| Drug |
maintenance instillations |
1 |
2018 |
| Drug |
maitake mushroom extract compound |
1 |
2015 |
| Biological |
mammaglobin-a dna vaccine |
1 |
2014 |
| Device |
management of therapy complications fitbit zip (portable pedometer device) |
1 |
2015 |
| Drug |
maraviroc 300 mg |
1 |
2013 |
| Drug |
marqibo |
1 |
2010 |
| Procedure |
marrow transplant |
1 |
2010 |
| Procedure |
mass closure technique |
1 |
2018 |
| Procedure |
massage therapy |
1 |
2014 |
| Other |
masterful supportive care |
1 |
2020 |
| Device |
matched sibling allogeneic transplantation |
1 |
2011 |
| Drug |
max-10181 |
1 |
2019 |
| Drug |
max-40279-01 |
1 |
2019 |
| Biological |
mb-102 |
1 |
2019 |
| Drug |
mbg453 |
1 |
2015 |
| Other |
mc5-a scrambler therapy |
1 |
2020 |
| Drug |
mcs110 |
1 |
2012 |
| Drug |
mdg1011 |
1 |
2018 |
| Drug |
mdm2 |
1 |
2018 |
| Drug |
mdm2/mdmx inhibitor alrn-6924 |
1 |
2018 |
| Drug |
mdmx inhibitor alrn-6924 |
1 |
2018 |
| Biological |
mdx-1106 |
1 |
2007 |
| Drug |
me-143 |
1 |
2011 |
| Drug |
me-344 |
1 |
2012 |
| Biological |
me tarp vaccine |
1 |
2015 |
| Behavioral |
meaning centered psychotherapy for latinos |
1 |
2019 |
| Behavioral |
meaning centered psychotherapy for latinos for waitlist control patients |
1 |
2019 |
| Drug |
mebendazole |
1 |
2015 |
| Drug |
medi-573 |
1 |
2011 |
| Drug |
medi-575 |
1 |
2010 |
| Biological |
medi0639 |
1 |
2012 |
| Biological |
medi0680 |
1 |
2014 |
| Drug |
medi0680 (amp-514) |
1 |
2013 |
| Biological |
medi1191 |
1 |
2019 |
| Biological |
medi1873 |
1 |
2015 |
| Drug |
medi3617 |
1 |
2010 |
| Biological |
medi4736 (durvalumab) / tremelimumab |
1 |
2017 |
| Biological |
medi5395 |
1 |
2019 |
| Biological |
medi5752 |
1 |
2018 |
| Biological |
medi6383 |
1 |
2014 |
| Biological |
medi6383/medi4736 |
1 |
2014 |
| Biological |
medi9090 |
1 |
2016 |
| Biological |
medi9447 |
1 |
2015 |
| Drug |
medi9447 (oleclumab) |
1 |
2018 |
| Biological |
medi9447/medi4736 |
1 |
2015 |
| Other |
media intervention |
1 |
2019 |
| Other |
medical chart review |
1 |
2019 |
| Procedure |
medical examination |
1 |
2019 |
| Other |
mediterranean diet |
1 |
2019 |
| Drug |
mek inhibitor |
1 |
2019 |
| Drug |
mek162 / raf265 |
1 |
2011 |
| Drug |
melphalan hydrochloride |
1 |
2016 |
| Drug |
melphalan, |
1 |
2009 |
| Drug |
memantine hydrochloride |
1 |
2019 |
| Other |
memory intervention |
1 |
2016 |
| Drug |
menadione topical lotion |
1 |
2011 |
| Device |
mendec spine bone cement |
1 |
2018 |
| Biological |
mesothelin-directed car-t cells |
1 |
2018 |
| Device |
mesothelin expression |
1 |
2016 |
| Drug |
metformin xr |
1 |
2014 |
| Drug |
methionine |
1 |
2009 |
| Drug |
methotrexate 1 gm injection |
1 |
2020 |
| Drug |
methylene blue |
1 |
2018 |
| Drug |
metoprolol |
1 |
2012 |
| Drug |
metronomic cyclophosphamide |
1 |
2012 |
| Radiation |
mf-ssrs |
1 |
2015 |
| Drug |
mfgr1877s |
1 |
2011 |
| Drug |
mfolfox6 regimen |
1 |
2019 |
| Drug |
mg005 |
1 |
2018 |
| Biological |
mga012 |
1 |
2018 |
| Biological |
mgc018 |
1 |
2018 |
| Drug |
mgcd516 |
1 |
2014 |
| Biological |
mgd013 |
1 |
2017 |
| Biological |
mgd013 in combination with margetuximab |
1 |
2017 |
| Drug |
mgn1703 |
1 |
2016 |
| Drug |
mibi-tc99m |
1 |
2018 |
| Drug |
mibi-tc99m/iodine-123 |
1 |
2018 |
| Device |
microwave ablation with acculis accu2i pmta applicator |
1 |
2016 |
| Drug |
midalzolam |
1 |
2007 |
| Procedure |
mild soap skin cleanser |
1 |
2013 |
| Biological |
milsâ„¢ - nsclc |
1 |
2019 |
| Device |
miltenyi biotec clinimacs device |
1 |
2008 |
| Device |
miltenyi clinimacs |
1 |
2005 |
| Device |
mimig system |
1 |
2014 |
| Behavioral |
mind-body exercises |
1 |
2018 |
| Procedure |
mind-body intervention procedure |
1 |
2017 |
| Behavioral |
mind-body psychotherapy group |
1 |
2005 |
| Other |
mindful movement |
1 |
2012 |
| Other |
mindful movement/breathing program |
1 |
2012 |
| Drug |
mirabegron |
1 |
2014 |
| Drug |
miracle mouthwash |
1 |
2014 |
| Drug |
miracle mouthwash/hydrocortisone |
1 |
2014 |
| Device |
mirasol platelets (mir plts) |
1 |
2016 |
| Drug |
mirtazapine |
1 |
2007 |
| Drug |
mithramycin |
1 |
2016 |
| Drug |
mitomycins |
1 |
2015 |
| Drug |
mitoxantrone packaged edv (engeneic delivery vehicle) |
1 |
2016 |
| Biological |
mix vaccine |
1 |
2017 |
| Drug |
mk-0646 |
1 |
2008 |
| Drug |
mk-0752 |
1 |
2011 |
| Biological |
mk-1308 |
1 |
2017 |
| Drug |
mk-1308a |
1 |
2017 |
| Drug |
mk-1775 |
1 |
2008 |
| Drug |
mk-3475 (an antibody that blocks negative signals to t cells) |
1 |
2019 |
| Biological |
mk-4621 |
1 |
2018 |
| Biological |
mk-4621/jetpeiâ„¢ |
1 |
2018 |
| Drug |
mk-5890 |
1 |
2018 |
| Drug |
mk-8353 |
1 |
2018 |
| Drug |
mk2206 every other day |
1 |
2010 |
| Drug |
mk2206 once weekly |
1 |
2010 |
| Drug |
ml fentanyl. |
1 |
2014 |
| Drug |
ml of drug solubilized in purified phospholipids) |
1 |
2011 |
| Drug |
ml*min |
1 |
2011 |
| Device |
mlc tracking |
1 |
2015 |
| Drug |
mln0264 |
1 |
2012 |
| Drug |
mln2480 |
1 |
2014 |
| Drug |
mln8237 (alisertib) |
1 |
2010 |
| Drug |
mln9708 |
1 |
2014 |
| Drug |
mm-121 (sar256212) |
1 |
2011 |
| Drug |
mm-398 |
1 |
2015 |
| Procedure |
moderate-intensity |
1 |
2002 |
| Procedure |
moderate-intensity/low-intensity bodywork therapy |
1 |
2002 |
| Drug |
moderate neuromuscular blockade (nmb) |
1 |
2017 |
| Other |
modification in acquisition protocol |
1 |
2017 |
| Procedure |
modified barium swallow (mbs) |
1 |
2017 |
| Drug |
modified folfirinox |
1 |
2011 |
| Biological |
modified vaccinia virus ankara vaccine expressing p53 |
1 |
2015 |
| Drug |
modufolin |
1 |
2014 |
| Device |
modulated tens |
1 |
2016 |
| Biological |
mogamulizumab (kw-0761) |
1 |
2014 |
| Biological |
mogamulizumab / nivolumab |
1 |
2016 |
| Biological |
mogamulizumab: kw-0761, nivolumab: (ono-4538 |
1 |
2015 |
| Biological |
mogamulizumab: kw-0761, nivolumab: (ono-4538/bms-936558) |
1 |
2015 |
| Genetic |
molecular diagnostic method |
1 |
2006 |
| Drug |
monoclonal antibody 3a1 |
1 |
1999 |
| Drug |
monoclonal antibody 95-5-49 |
1 |
1999 |
| Drug |
monoclonal antibody 95-6-22 |
1 |
1999 |
| Biological |
monoclonal antibody cal |
1 |
2003 |
| Procedure |
monocolour inking specimens |
1 |
2016 |
| Drug |
montanide |
1 |
2008 |
| Other |
montanide isa 51 vg |
1 |
2009 |
| Biological |
montanide isa51 vg |
1 |
2010 |
| Drug |
morab-003 |
1 |
2010 |
| Drug |
morab-004 |
1 |
2013 |
| Drug |
morab-004 (monoclonal antibody to tem1) |
1 |
2009 |
| Drug |
morab-202 |
1 |
2017 |
| Drug |
morphine sulfate |
1 |
2018 |
| Drug |
motexafin gadolinium injection |
1 |
2004 |
| Drug |
mp-470 |
1 |
2009 |
| Drug |
mp0310 (amg 506) |
1 |
2019 |
| Drug |
mpc-6827 |
1 |
2006 |
| Biological |
mpeg-r-crisantaspase |
1 |
2012 |
| Drug |
mpt0e028 |
1 |
2015 |
| Device |
mr |
1 |
2020 |
| Procedure |
mri-based angiogram |
1 |
2005 |
| Device |
mri-guided sbrt |
1 |
2015 |
| Procedure |
mri contrast agent combidex (ferumoxtran-10) |
1 |
2005 |
| Procedure |
mri guided intensity modulated radiotherapy (imrt) planning |
1 |
2017 |
| Biological |
mrna-2416 |
1 |
2017 |
| Biological |
mrna-2752 |
1 |
2018 |
| Biological |
mrna-2752 / durvalumab |
1 |
2018 |
| Biological |
mrna-4157 |
1 |
2017 |
| Drug |
mrx-2843 |
1 |
2018 |
| Drug |
mrx0518 |
1 |
2018 |
| Drug |
msb0254 injection |
1 |
2020 |
| Drug |
msc1936369b (pimasertib) |
1 |
2011 |
| Drug |
msc2363318a |
1 |
2013 |
| Drug |
msc2363318a/tamoxifen |
1 |
2013 |
| Drug |
msc2363318a/trastuzumab |
1 |
2013 |
| Drug |
mtc-dox for injection |
1 |
2002 |
| Drug |
mtl-cebpa |
1 |
2019 |
| Drug |
mtor inhibitor) |
1 |
2011 |
| Drug |
mtx 1 |
1 |
2013 |
| Drug |
mtx 2 |
1 |
2013 |
| Biological |
multi-epitope folate receptor alpha-loaded dendritic cell vaccine |
1 |
2014 |
| Device |
multi-modal precision ablation |
1 |
2017 |
| Genetic |
multi-targeted next generation sequencing |
1 |
2018 |
| Procedure |
multicolour inking specimens |
1 |
2016 |
| Drug |
multikinase inhibitor at9283 |
1 |
2009 |
| Behavioral |
multimedia psychoeducational intervention |
1 |
2014 |
| Drug |
multiple dose azd2014 |
1 |
2015 |
| Drug |
muromonab |
1 |
2007 |
| Drug |
muscadine grape skin extract |
1 |
2015 |
| Other |
music |
1 |
2014 |
| Behavioral |
music-based meditation |
1 |
2018 |
| Procedure |
mutation carrier screening |
1 |
2017 |
| Biological |
mva-209-fsp high dose |
1 |
2019 |
| Biological |
mva-209-fsp low dose |
1 |
2019 |
| Biological |
mvt-5873 |
1 |
2016 |
| Drug |
mycobacterial cell wall-dna complex |
1 |
2006 |
| Drug |
mycofenolate mofetil |
1 |
2009 |
| Drug |
mycophenolate mofetil (mmf) |
1 |
2007 |
| Procedure |
myeloablative haploidentical stem cell transplant |
1 |
2012 |
| Drug |
myeloid growth factor |
1 |
2015 |
| Procedure |
myeloid progenitor cell transplantation |
1 |
2014 |
| Drug |
nab-paclitaxel (paclitaxel-albumin) |
1 |
2016 |
| Drug |
nab-paclitaxel (paclitaxel-albumin) / carboplatin |
1 |
2016 |
| Drug |
nab-paclitaxel (paclitaxel-albumin) / gemcitabine |
1 |
2016 |
| Drug |
nab paclitaxel |
1 |
2017 |
| Drug |
nab paclitaxel. |
1 |
2018 |
| Drug |
nadroparin calcium |
1 |
2010 |
| Device |
naf pet |
1 |
2014 |
| Device |
naf pet/ct |
1 |
2014 |
| Device |
naf pet/mri |
1 |
2014 |
| Drug |
nanodoce (direct injection) |
1 |
2018 |
| Drug |
nanodoce (intravesical instillation) - induction |
1 |
2018 |
| Drug |
nanodoce (intravesical instillation) - induction/maintenance instillations |
1 |
2018 |
| Drug |
nanodoce (intravesical instillation) - visit 2 instillation |
1 |
2018 |
| Drug |
nanoliposomal irinotecan |
1 |
2018 |
| Drug |
nanopacâ® |
1 |
2017 |
| Drug |
nanosomal docetaxel lipid suspension |
1 |
2013 |
| Drug |
napabucasin |
1 |
2020 |
| Drug |
naphazoline |
1 |
2017 |
| Other |
nasal smears were taken in all the patients. laparotomies were performed in all patients. |
1 |
2019 |
| Procedure |
natural orifice specimen extraction surgery |
1 |
2020 |
| Device |
navifus system |
1 |
2018 |
| Procedure |
navigated transcranial magnetic stimulation |
1 |
2019 |
| Drug |
nbtxr3 |
1 |
2018 |
| Procedure |
ncrt |
1 |
2018 |
| Procedure |
near-infrared fluorescence imaging |
1 |
2018 |
| Drug |
nedisertib |
1 |
2019 |
| Device |
needle angle measurement |
1 |
2010 |
| Drug |
nelarabine |
1 |
2010 |
| Drug |
nelfinavir |
1 |
2011 |
| Other |
neoadjuvant chemoradiotherapy |
1 |
2018 |
| Drug |
neoadjuvant chemotherapy (paclitaxel |
1 |
2005 |
| Drug |
neoadjuvant chemotherapy (paclitaxel/carboplatin) |
1 |
2005 |
| Other |
neoadjuvant radiotherapy |
1 |
2019 |
| Other |
neoadjuvant radiotherapy/chemoradiotherapy followed by surgery |
1 |
2019 |
| Biological |
neoantigen reactive t cells(nrts) |
1 |
2017 |
| Biological |
neotcr-p1 adoptive cell therapy |
1 |
2019 |
| Drug |
nerofe |
1 |
2012 |
| Procedure |
nerve-sparing radical hysterectomy |
1 |
2015 |
| Drug |
nesvacumab (regn910 |
1 |
2012 |
| Drug |
nesvacumab (regn910/ sar307746) |
1 |
2012 |
| Drug |
nev801 |
1 |
2016 |
| Diagnostic Test |
next gen sequencing report |
1 |
2019 |
| Drug |
nhs-il-12 |
1 |
2011 |
| Biological |
nhs-il12 |
1 |
2020 |
| Drug |
niacin er |
1 |
2016 |
| Drug |
nicordâ® (omidubicel) |
1 |
2016 |
| Drug |
nicotine |
1 |
1999 |
| Drug |
nicotine replacement |
1 |
2019 |
| Drug |
nilotinib / paclitaxel |
1 |
2015 |
| Drug |
nimorazole. |
1 |
2019 |
| Drug |
nimotuzumab (theracim h-r3) |
1 |
2006 |
| Drug |
nintedanib |
1 |
2015 |
| Drug |
nir178 |
1 |
2020 |
| Device |
niris 1300e |
1 |
2012 |
| Device |
nitinol |
1 |
2009 |
| Drug |
nivolumab/entinostat |
1 |
2019 |
| Drug |
njh395 |
1 |
2018 |
| Combination Product |
nk |
1 |
2019 |
| Biological |
nk-dli |
1 |
2015 |
| Biological |
nk-dli / duk-cpg-001 |
1 |
2015 |
| Biological |
nk cell enriched-dli only |
1 |
2015 |
| Combination Product |
nk/with chemotherapy |
1 |
2019 |
| Drug |
nkp-1339 |
1 |
2011 |
| Drug |
nktr-214 |
1 |
2016 |
| Drug |
nlg802 |
1 |
2017 |
| Drug |
nms-03305293 |
1 |
2019 |
| Drug |
nms-1286937 |
1 |
2009 |
| Other |
no-transfuse |
1 |
2016 |
| Other |
no intervention |
1 |
2004 |
| Procedure |
no lymphadenectomy (lne) |
1 |
2008 |
| Radiation |
no partial breast irradiation |
1 |
2018 |
| Other |
no peer comparison email |
1 |
2020 |
| Other |
no results of brief geriatric assessments |
1 |
2019 |
| Procedure |
no touch (nt) |
1 |
2017 |
| Other |
no vaccination |
1 |
2017 |
| Other |
non-invasive positive pressure ventilation (nippv) |
1 |
2015 |
| Procedure |
non-myeloablative hematopoietic cell transplantation |
1 |
2005 |
| Device |
non-power injectable port (cook vital mini port) |
1 |
2014 |
| Procedure |
non-tbi regime |
1 |
2015 |
| Drug |
noni extract |
1 |
2002 |
| Procedure |
normal fluid volume |
1 |
2012 |
| Drug |
normal saline , cisplatin , 5-fu |
1 |
2016 |
| Procedure |
normotonic partial nephrectomy |
1 |
2019 |
| Procedure |
notes |
1 |
2016 |
| Drug |
nov140101 (idx-1197) |
1 |
2017 |
| Drug |
nov1601(chc2014) |
1 |
2019 |
| Device |
novel 22-gauge core biopsy needle |
1 |
2012 |
| Device |
novel 22-gauge core biopsy needle / standard biopsy needle |
1 |
2012 |
| Device |
novilase interstitial laser therapy |
1 |
2011 |
| Drug |
nozin |
1 |
2019 |
| Drug |
np-g2-044 |
1 |
2017 |
| Drug |
npi-0052 on days 1, 4, 8, 11 every 21 days |
1 |
2008 |
| Drug |
npi-0052 on days 1, 8, 15 every 28 days |
1 |
2008 |
| Drug |
ns-9 [poly i: poly c] |
1 |
2004 |
| Drug |
nsclc expansion cohort: regorafenib 100 mg |
1 |
2010 |
| Drug |
nuc-3373 |
1 |
2018 |
| Drug |
nuc-3373 / irinotecan |
1 |
2018 |
| Drug |
nuc-3373 / irinotecan / cetuximab |
1 |
2018 |
| Drug |
nuc-3373 / leucovorin |
1 |
2018 |
| Drug |
nuc-3373 / oxaliplatin |
1 |
2018 |
| Drug |
nuc-3373 / oxaliplatin / bevacizumab |
1 |
2018 |
| Drug |
nuc-3373 / oxaliplatin / panitumumab |
1 |
2018 |
| Behavioral |
nudge |
1 |
2019 |
| Behavioral |
nurse-led care |
1 |
2014 |
| Other |
nurse case management |
1 |
2009 |
| Other |
nurse telephone contact |
1 |
2015 |
| Dietary Supplement |
nutrison |
1 |
2016 |
| Other |
nutritional assessment |
1 |
2017 |
| Dietary Supplement |
nutritional supplementation |
1 |
2017 |
| Other |
nutritional support |
1 |
2019 |
| Drug |
nv1020 |
1 |
2005 |
| Biological |
ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine |
1 |
2016 |
| Drug |
nyh100p |
1 |
2020 |
| Drug |
nyh817g |
1 |
2020 |
| Drug |
nyh817g/nyh100p |
1 |
2020 |
| Drug |
nzv930 |
1 |
2020 |
| Drug |
obatoclax mesylate (gx15-070ms) |
1 |
2007 |
| Drug |
obi-888 |
1 |
2018 |
| Drug |
obi-999 |
1 |
2019 |
| Drug |
oblimersen (genasense) |
1 |
2007 |
| Biological |
oblimersen sodium |
1 |
2003 |
| Drug |
obp-801 |
1 |
2015 |
| Other |
observation |
1 |
2014 |
| Other |
observation/standard therapy |
1 |
2014 |
| Drug |
octreotate |
1 |
2014 |
| Drug |
octreotide-lar |
1 |
2009 |
| Drug |
octreotide lar |
1 |
2012 |
| Drug |
odm-207 |
1 |
2017 |
| Drug |
odm 203 |
1 |
2014 |
| Drug |
ogx-427 1000 mg |
1 |
2011 |
| Drug |
ogx-427 600 mg |
1 |
2011 |
| Biological |
oh2 injection |
1 |
2020 |
| Drug |
oki-179 |
1 |
2019 |
| Drug |
okt-3 |
1 |
2005 |
| Other |
okt3 |
1 |
2009 |
| Drug |
olaparib oral capsule |
1 |
2019 |
| Drug |
olaparib tablets |
1 |
2013 |
| Drug |
olaparib treatment a |
1 |
2018 |
| Drug |
olaparib treatment b |
1 |
2018 |
| Drug |
olaparib treatment c |
1 |
2018 |
| Drug |
olaparib treatment d |
1 |
2018 |
| Biological |
olaratumab |
1 |
2010 |
| Device |
olympus |
1 |
2014 |
| Drug |
omacetaxine |
1 |
2008 |
| Drug |
omacetaxine mepesuccinate |
1 |
2013 |
| Dietary Supplement |
omega-3 fatty acids |
1 |
2017 |
| Drug |
omeprazol |
1 |
2012 |
| Drug |
omiganan (cls001) topical gel |
1 |
2015 |
| Drug |
omp-131r10 |
1 |
2015 |
| Biological |
omp-18r5 |
1 |
2011 |
| Drug |
omp-21m18 |
1 |
2008 |
| Drug |
omp-305b83 |
1 |
2014 |
| Biological |
omp-54f28 |
1 |
2012 |
| Drug |
omp-59r5 |
1 |
2011 |
| Drug |
onartuzumab |
1 |
2015 |
| Drug |
onc201 |
1 |
2017 |
| Biological |
oncolytic measles virus encoding thyroidal sodium iodide symporter |
1 |
2016 |
| Procedure |
oncoplastic approach excisional breast biopsy |
1 |
2015 |
| Biological |
oncr-177 |
1 |
2020 |
| Drug |
ondansetron hydrochloride |
1 |
2018 |
| Behavioral |
online health management program |
1 |
2015 |
| Procedure |
only pulmonary metastasectomy |
1 |
2017 |
| Drug |
ono-4578 |
1 |
2017 |
| Drug |
ono-7436 |
1 |
2005 |
| Drug |
ono-7475 |
1 |
2018 |
| Drug |
ono-7475 / ono-4538 |
1 |
2018 |
| Biological |
ont-10 |
1 |
2012 |
| Drug |
opb-111077 |
1 |
2014 |
| Drug |
opb-31121 |
1 |
2009 |
| Procedure |
open distal pancreatectomy |
1 |
2019 |
| Procedure |
open liver resection |
1 |
2012 |
| Device |
optical tomography using near infrared diffused light assisted with ultrasound |
1 |
2016 |
| Procedure |
optional biopsy |
1 |
2014 |
| Procedure |
optional research biopsy |
1 |
2016 |
| Drug |
optison |
1 |
2005 |
| Biological |
or poly-iclc |
1 |
2009 |
| Drug |
oradoxel |
1 |
2016 |
| Drug |
oral 5-azacitidine |
1 |
2013 |
| Procedure |
oral biopsy |
1 |
2016 |
| Drug |
oral contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol) |
1 |
2016 |
| Drug |
oral dfp-11207 |
1 |
2014 |
| Dietary Supplement |
oral immunonutrition |
1 |
2014 |
| Drug |
oral steroid administration(prednisone) |
1 |
2017 |
| Drug |
oral topotecan |
1 |
2006 |
| Drug |
orantinib |
1 |
2001 |
| Drug |
oratecan |
1 |
2014 |
| Drug |
oratopo |
1 |
2019 |
| Drug |
osi-7904l |
1 |
2005 |
| Drug |
osimertinib; azd9291 |
1 |
2016 |
| Other |
osteopathic manipulative treatment |
1 |
2017 |
| Drug |
ots167iv |
1 |
2013 |
| Device |
over- the- scope full- thickness resection device |
1 |
2019 |
| Device |
overstitch endoscopic suturing system |
1 |
2011 |
| Drug |
oxaliplatin , capecitabine |
1 |
2016 |
| Drug |
oxaliplatin / 5-fluorouracil (5fu) / leucovorin (calcium folinate/folinic acid) |
1 |
2016 |
| Drug |
oxaliplatin, capecitabine |
1 |
2005 |
| Drug |
oxazolidine |
1 |
2017 |
| Drug |
oxi4503 |
1 |
2009 |
| Drug |
oxidative phosphorylation inhibitor iacs-010759 |
1 |
2017 |
| Drug |
oxycodone cr |
1 |
2010 |
| Procedure |
oxygen |
1 |
2015 |
| Drug |
oxymorphone |
1 |
2018 |
| Drug |
oxymorphone hydrochloride |
1 |
2018 |
| Biological |
p-psma-101 car-t cells |
1 |
2020 |
| Drug |
p276-00 |
1 |
2006 |
| Drug |
p28 |
1 |
2009 |
| Drug |
pac-1 |
1 |
2015 |
| Drug |
pac-1 compound |
1 |
2017 |
| Drug |
pac-cb |
1 |
2014 |
| Drug |
pac(ip) |
1 |
2016 |
| Drug |
paclitaxel-based chemotherapeutic regimens |
1 |
2016 |
| Device |
paclitaxel-eluting metal stent |
1 |
2015 |
| Drug |
paclitaxel (day 1) |
1 |
2011 |
| Drug |
paclitaxel / carboplatin |
1 |
2016 |
| Drug |
paclitaxel for injection (taxol) |
1 |
2004 |
| Drug |
paclitaxel. |
1 |
2018 |
| Drug |
paclitaxel/carboplatin (tc arm) |
1 |
2014 |
| Behavioral |
pain assessment |
1 |
2017 |
| Behavioral |
pain control program (pcp) |
1 |
2009 |
| Procedure |
pain therapy |
1 |
2018 |
| Drug |
palbociclib oral capsule [ibrance] |
1 |
2019 |
| Other |
palliative care support |
1 |
2014 |
| Other |
palliative homecare nursing |
1 |
2011 |
| Radiation |
palliative radiotherapy |
1 |
2014 |
| Radiation |
palliative radiotherapy (rt) |
1 |
2017 |
| Drug |
palonosetron |
1 |
2017 |
| Drug |
pamiparib |
1 |
2016 |
| Drug |
pamiparib 20 |
1 |
2019 |
| Drug |
pamiparib 20, 40, 60 mg po twice daily (bid) |
1 |
2019 |
| Drug |
pamiparib 20/40 mg po bid |
1 |
2019 |
| Drug |
pan-erbb tyrosine kinase inhibitor |
1 |
2019 |
| Other |
pancreatic adenocarcinoma diagnosis |
1 |
2014 |
| Procedure |
pancreatic duct occlusion with neoprene |
1 |
2018 |
| Procedure |
pancreaticojejunostomy |
1 |
2012 |
| Procedure |
pancreato-jejunal anastomosis |
1 |
2018 |
| Drug |
panher |
1 |
2004 |
| Drug |
panitumumab-irdye800 |
1 |
2018 |
| Drug |
panitumumab (abx-egf) |
1 |
2004 |
| Drug |
panobinostat |
1 |
2009 |
| Drug |
panobinostat (lbh589) |
1 |
2009 |
| Drug |
panolosetron |
1 |
2013 |
| Drug |
pantoprazole high dose |
1 |
2019 |
| Drug |
pantoprazole low dose |
1 |
2019 |
| Drug |
pantoprazole sodium for injection |
1 |
2010 |
| Drug |
parp inhibitor |
1 |
2019 |
| Drug |
parp inhibitor/anti-pd-l1 |
1 |
2019 |
| Drug |
parsaclisib |
1 |
2013 |
| Drug |
part a: dose escalation of cantrixil |
1 |
2016 |
| Drug |
part b: expansion cohort of cantrixil |
1 |
2016 |
| Procedure |
partial nephrectomy |
1 |
2019 |
| Drug |
pasireotide |
1 |
2013 |
| Drug |
pasireotide lar |
1 |
2016 |
| Drug |
pasireotide long acting release (lar) |
1 |
2010 |
| Drug |
patient controlled opioid analgesia (pca) |
1 |
2018 |
| Procedure |
patient monitoring |
1 |
2019 |
| Behavioral |
patient navigation program |
1 |
2019 |
| Other |
patient questionaires |
1 |
2014 |
| Other |
patients who have surgery at 12 weeks after radiotherapy |
1 |
2009 |
| Other |
patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy |
1 |
2009 |
| Drug |
patupilone / midalzolam |
1 |
2007 |
| Drug |
patupilone/omeprazole |
1 |
2007 |
| Drug |
pazopanib gw786034 |
1 |
2013 |
| Biological |
pbcar3-phosphopeptide |
1 |
2013 |
| Biological |
pbi-shrna stmn1 lp |
1 |
2012 |
| Biological |
pbi-shrnaâ„¢ ews |
1 |
2016 |
| Biological |
pbi-shrnaâ„¢ ews/fli1 type 1 lpx |
1 |
2016 |
| Drug |
pci-32765 |
1 |
2012 |
| Device |
pcle |
1 |
2015 |
| Device |
pcle guided evaluation |
1 |
2009 |
| Drug |
pd-0325901 |
1 |
2019 |
| Drug |
pd-1 antibody |
1 |
2019 |
| Biological |
pd-1 antibody expressing mesocar-t cells |
1 |
2018 |
| Biological |
pd-1 knockout |
1 |
2018 |
| Drug |
pd-1 mab |
1 |
2018 |
| Drug |
pd-1 monoclonal antibody injection |
1 |
2020 |
| Drug |
pd-l1 inhibitor |
1 |
2019 |
| Drug |
pd-l1 peptide: pd-l1 long(19-27) peptide sequence: fmtywhllnaftvtvpkdl |
1 |
2019 |
| Biological |
pd-l1 t-hank |
1 |
2019 |
| Drug |
pd 0360324 |
1 |
2015 |
| Drug |
pd1 inhibitor |
1 |
2019 |
| Drug |
pdm08 |
1 |
2011 |
| Biological |
pds0101 |
1 |
2020 |
| Dietary Supplement |
peas |
1 |
2007 |
| Other |
pediatric early warning scoring system |
1 |
2019 |
| Other |
pediatric early warning scoring system/resuscitation curriculum |
1 |
2019 |
| Other |
pediquest response |
1 |
2018 |
| Other |
peep |
1 |
2017 |
| Other |
peer comparison email |
1 |
2020 |
| Drug |
peg-rhg-csf |
1 |
2016 |
| Drug |
pegasys |
1 |
2011 |
| Drug |
pegintron |
1 |
2011 |
| Drug |
pegylated g-csf |
1 |
2015 |
| Drug |
pegylated l-asparaginase |
1 |
2011 |
| Drug |
pegylated liposomal doxorubicin (pld) |
1 |
2019 |
| Drug |
pegylated liposomal doxorubicin hydrochloride |
1 |
2019 |
| Drug |
pegylated liposomal doxorubicin/carboplatin |
1 |
2005 |
| Drug |
pegylated recombinant human endostatin(peg-endo) |
1 |
2020 |
| Drug |
pelitinib |
1 |
2004 |
| Procedure |
pelvic surgery |
1 |
2016 |
| Drug |
pembrolizumab 200 mg q3w |
1 |
2017 |
| Drug |
pembrolizumab 25 mg |
1 |
2018 |
| Drug |
pembrolizumab 25 mg/1 ml intravenous solution [keytruda] |
1 |
2018 |
| Drug |
pemetrexed (alimta) in combination with gemcitabine (gemzar) |
1 |
2002 |
| Drug |
pemetrexed 500 mg |
1 |
2019 |
| Drug |
pemetrexed 500 mg/mâ² iv |
1 |
2019 |
| Drug |
pemetrexed/cisplatin |
1 |
2010 |
| Drug |
penclomedine |
1 |
1999 |
| Drug |
pentostatin |
1 |
2006 |
| Drug |
peox-based polymer encapsulated paclitaxel fid-007 |
1 |
2018 |
| Biological |
pep-3-klh |
1 |
2008 |
| Biological |
pep-3-klh conjugate vaccine |
1 |
2008 |
| Biological |
pep-3 vaccine |
1 |
2008 |
| Biological |
pepidh1m vaccine |
1 |
2014 |
| Biological |
pepinemab |
1 |
2017 |
| Biological |
peptide receptor radionuclide therapy (prrt) using 177lu-dota0-tyr3-octreotate |
1 |
2018 |
| Biological |
peptides |
1 |
2016 |
| Procedure |
percutaneous placement of device in liver metastases |
1 |
2007 |
| Procedure |
percutaneous tumor cryoablation |
1 |
2009 |
| Procedure |
perfusion-weighted magnetic resonance imaging |
1 |
2005 |
| Procedure |
perfusion magnetic resonance imaging |
1 |
2015 |
| Drug |
perifosine / temsirolimus |
1 |
2010 |
| Combination Product |
perioperative capox-bevacizumab |
1 |
2016 |
| Combination Product |
perioperative folfiri-bevacizumab |
1 |
2016 |
| Combination Product |
perioperative folfox-bevacizumab |
1 |
2016 |
| Other |
perioperative folfox4 |
1 |
2012 |
| Other |
perioperative folfox4/cetuximab chemotherapy |
1 |
2012 |
| Behavioral |
perioperative rehabilitation program |
1 |
2016 |
| Other |
perioperative simplified folfox-4 chemotherapy |
1 |
2012 |
| Other |
perioperative systemic therapy |
1 |
2016 |
| Biological |
peripheral blood lymphocyte therapy |
1 |
1999 |
| Procedure |
peripheral blood progenitor cell transplant |
1 |
1999 |
| Genetic |
peripheral blood progenitor cells carrying mdr1 |
1 |
1999 |
| Procedure |
peripheral blood stem cell transplant |
1 |
2010 |
| Drug |
personalized vaccine |
1 |
2018 |
| Drug |
pertuzumab (combination treatment) |
1 |
2016 |
| Procedure |
pet ct |
1 |
2010 |
| Procedure |
pet scan |
1 |
2017 |
| Drug |
pet tracer (bay94-9392) |
1 |
2010 |
| Device |
pet/ct of the brain |
1 |
2019 |
| Device |
pet/mr |
1 |
2020 |
| Biological |
pexa-vec |
1 |
2016 |
| Drug |
pf-00299804 |
1 |
2008 |
| Drug |
pf-03446962 |
1 |
2007 |
| Drug |
pf-03814735 |
1 |
2007 |
| Drug |
pf-04518600/pf-05082566 |
1 |
2014 |
| Drug |
pf-04554878 |
1 |
2008 |
| Drug |
pf-06647020 |
1 |
2014 |
| Drug |
pf-06647020 q2w |
1 |
2014 |
| Drug |
pf-06647020 q3w |
1 |
2014 |
| Drug |
pf-06647020/with avelumab |
1 |
2014 |
| Drug |
pf-06801591 |
1 |
2019 |
| Drug |
pf-06804103 |
1 |
2017 |
| Drug |
pf-06939999 |
1 |
2019 |
| Drug |
pf00562271 |
1 |
2008 |
| Drug |
pg2 |
1 |
2011 |
| Drug |
pg545 |
1 |
2014 |
| Biological |
pgv001 |
1 |
2017 |
| Drug |
pha-848125ac |
1 |
2011 |
| Procedure |
pharmacokinetic sampling - az5140 |
1 |
2014 |
| Procedure |
pharmacokinetic sampling - az5140/az7550 |
1 |
2014 |
| Procedure |
pharmacokinetic sampling - azd9291 |
1 |
2014 |
| Drug |
pharmacological ascorbate |
1 |
2016 |
| Drug |
phenytoin |
1 |
2005 |
| Behavioral |
phone call |
1 |
2016 |
| Behavioral |
phone calls |
1 |
2016 |
| Drug |
phosphate binders |
1 |
2010 |
| Radiation |
photon beam radiation therapy |
1 |
2020 |
| Other |
physical activity measurement |
1 |
2016 |
| Other |
physical exercise |
1 |
2019 |
| Procedure |
physician-collected sampling |
1 |
2015 |
| Other |
physiotherapy |
1 |
2017 |
| Drug |
pi3k inhibitor bkm120 |
1 |
2011 |
| Drug |
pi3k inhibitor gdc-0084 |
1 |
2019 |
| Drug |
pi3kbeta inhibitor azd8186 |
1 |
2017 |
| Procedure |
piecemeal resection |
1 |
2014 |
| Procedure |
pigtail catheter |
1 |
2020 |
| Behavioral |
pill diary |
1 |
2016 |
| Device |
pillcamâ® colon capsule |
1 |
2014 |
| Device |
pillow |
1 |
2008 |
| Drug |
pimasertib |
1 |
2013 |
| Drug |
pimasertib capsule (part a) |
1 |
2013 |
| Drug |
pimasertib capsule (part b |
1 |
2013 |
| Drug |
pimasertib capsule (part b/trial extension phase) |
1 |
2013 |
| Drug |
pimasertib tablet (part a) |
1 |
2013 |
| Drug |
piperacillin-tazobactam |
1 |
1999 |
| Drug |
piperacillin sodium |
1 |
1999 |
| Dietary Supplement |
piperine extract (standardized) |
1 |
2015 |
| Biological |
pirs2-phosphopeptide |
1 |
2013 |
| Biological |
pirs2-phosphopeptide) |
1 |
2013 |
| Other |
pk testing |
1 |
2010 |
| placebo |
placebo (for aflibercept) |
1 |
2007 |
| placebo |
placebo acupressure band |
1 |
2011 |
| placebo |
placebo control |
1 |
2013 |
| placebo |
placebo ointment without illumination |
1 |
2010 |
| placebo |
placebo sar302503 |
1 |
2013 |
| placebo |
placebo tablets |
1 |
2009 |
| placebo |
placebo tens |
1 |
2016 |
| placebo |
placebo to denosumab |
1 |
2011 |
| placebo |
placebo to zoledronic acid |
1 |
2011 |
| placebo |
placebo, vehicle control |
1 |
2009 |
| Drug |
placlitaxel |
1 |
2011 |
| Other |
plasmodium immunotherapy |
1 |
2019 |
| Other |
platelet transfusion |
1 |
2014 |
| Drug |
platinum-doublet chemotherapy |
1 |
2017 |
| Drug |
platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania |
1 |
2017 |
| Drug |
pld 30 mg |
1 |
2011 |
| Drug |
plerixafor |
1 |
2017 |
| Drug |
plx2853 |
1 |
2017 |
| Drug |
plx8394 |
1 |
2015 |
| Drug |
pm01183 |
1 |
2009 |
| Drug |
pm02734 |
1 |
2009 |
| Drug |
pm02734/erlotinib |
1 |
2009 |
| Drug |
pm060184 |
1 |
2011 |
| Biological |
pngvl3-hicd vaccine |
1 |
2007 |
| Biological |
pngvl4a-sig |
1 |
2005 |
| Biological |
pngvl4a-sig/e7(detox)/hsp70 dna vaccine |
1 |
2005 |
| Drug |
pof |
1 |
2016 |
| Device |
poinpoint-ir9000 |
1 |
2018 |
| Drug |
poly-gamma glutamic acid |
1 |
2013 |
| Drug |
poly iclc |
1 |
2017 |
| Device |
polysite â® standard, sã©rie 4108. |
1 |
2018 |
| Drug |
pomalidomide 0.5 mg |
1 |
2010 |
| Drug |
ponatinib |
1 |
2008 |
| Drug |
ponatinib hydrochloride |
1 |
2014 |
| Drug |
posaconazole |
1 |
2008 |
| Behavioral |
positive psychology intervention |
1 |
2018 |
| Procedure |
positron emission tomography (pet) |
1 |
2019 |
| Procedure |
positron emission tomography (pet) scan |
1 |
2005 |
| Drug |
postoperative chemotherapy |
1 |
2020 |
| Drug |
postoperative dwell with paclitaxel |
1 |
2000 |
| Drug |
postoperative dwell with paclitaxel/5-fu |
1 |
2000 |
| Other |
postoperative risk stratification |
1 |
2015 |
| Device |
power injectable port (angiodynamics smart port ct mini) |
1 |
2014 |
| Other |
ppi |
1 |
2012 |
| Drug |
pralatrexate injection |
1 |
2007 |
| Drug |
pralsetinib |
1 |
2020 |
| Drug |
pralsetinib (blu-667) |
1 |
2017 |
| Drug |
prednisone/prednisolone |
1 |
2007 |
| Drug |
premedication |
1 |
2013 |
| Drug |
preoperative dose intense chemotherapy (flac |
1 |
1999 |
| Drug |
preoperative dose intense chemotherapy (flac/g-csf) |
1 |
1999 |
| Drug |
preoperative hyperbaric oxygen |
1 |
2015 |
| Other |
preoperative liver stiffness measurement |
1 |
2011 |
| Radiation |
preoperative radiation |
1 |
2016 |
| Other |
preoperative risk stratification |
1 |
2015 |
| Drug |
preparative regimen |
1 |
2011 |
| Behavioral |
prescribed activity |
1 |
2017 |
| Other |
preventative dietary intervention |
1 |
2010 |
| Device |
prf on drg |
1 |
2017 |
| Procedure |
primary repair |
1 |
2020 |
| Procedure |
primovist mri |
1 |
2008 |
| Behavioral |
print educational intervention |
1 |
2014 |
| Drug |
probenecid |
1 |
2001 |
| Behavioral |
problem-solving intervention |
1 |
2015 |
| Drug |
procarbazine hydrochloride |
1 |
1999 |
| Procedure |
production of genetically-modified t cells |
1 |
2015 |
| Drug |
proflavine, high resolution imaging |
1 |
2013 |
| Drug |
progesterone |
1 |
2005 |
| Drug |
progestins |
1 |
1999 |
| Other |
program of geriatric |
1 |
2016 |
| Other |
program of geriatric/social intervention associated techniques of domotic/remote assistance |
1 |
2016 |
| Drug |
prolonged glucocorticosteroid (prednisone) regimen |
1 |
2019 |
| Drug |
promitil |
1 |
2012 |
| Drug |
prophylactic growth factors; subcutaneous |
1 |
2009 |
| Drug |
prophylactic vancomycin |
1 |
2005 |
| Drug |
propranolol |
1 |
2013 |
| Drug |
propranolol hydrochloride |
1 |
2013 |
| Biological |
prostvac-f/tricom |
1 |
2014 |
| Biological |
prostvac-v/tricom |
1 |
2014 |
| Genetic |
protein analysis |
1 |
2008 |
| Biological |
protmune |
1 |
2016 |
| Radiation |
proton beam radiation |
1 |
2010 |
| Other |
proton beam radiation using pencil beam scanning |
1 |
2019 |
| Other |
proton radiotherapy |
1 |
2010 |
| Radiation |
protons |
1 |
2016 |
| Other |
psycho-educational intervention |
1 |
2017 |
| Behavioral |
psychoeducation |
1 |
2019 |
| Behavioral |
psychosocial rehabilitation course |
1 |
2010 |
| Other |
psychosocial support for caregiver |
1 |
2011 |
| Behavioral |
psychotherapy |
1 |
2020 |
| Drug |
pt-112 injection |
1 |
2014 |
| Drug |
pt2977 |
1 |
2016 |
| Drug |
pthrp (1-36) |
1 |
2007 |
| Drug |
ptk |
1 |
2008 |
| Drug |
ptk787 |
1 |
2008 |
| Drug |
ptk787/zk222584/bevacizumab |
1 |
2008 |
| Biological |
ptvg-hp plasmid dna vaccine |
1 |
2015 |
| Drug |
ptx-100 |
1 |
2019 |
| Drug |
ptx-35 |
1 |
2020 |
| Drug |
pu-h71 |
1 |
2011 |
| Procedure |
pulmonary metastasectomy |
1 |
2017 |
| Drug |
pwcb |
1 |
2016 |
| Drug |
pwo |
1 |
2016 |
| Drug |
pwt-143 |
1 |
2015 |
| Drug |
pwt33597 mesylate |
1 |
2011 |
| Drug |
px-12 |
1 |
2008 |
| Drug |
pyrotinib |
1 |
2015 |
| Drug |
pyruvate (13c) |
1 |
2016 |
| Drug |
pzp115891, pci-24781 |
1 |
2012 |
| Drug |
quadrivalent hpv vaccine |
1 |
2019 |
| Biological |
quadrivalent influenza vaccine |
1 |
2016 |
| Other |
quality of life assessment |
1 |
2014 |
| Behavioral |
quality of life counseling |
1 |
2016 |
| Procedure |
quantitative sensory testing |
1 |
2020 |
| Behavioral |
questionnaire, educational material |
1 |
2015 |
| Procedure |
r0 resection |
1 |
2014 |
| Drug |
r306465 |
1 |
2008 |
| Drug |
r331333 (referred to as jns024 er |
1 |
2010 |
| Drug |
r331333 (referred to as jns024 er/cg5503) |
1 |
2010 |
| Drug |
rad001 (xelox-a-ev) |
1 |
2009 |
| Drug |
rad140 |
1 |
2017 |
| Radiation |
radiation therapy treatment planning |
1 |
2018 |
| Radiation |
radiation therapy treatment planning/simulation |
1 |
2018 |
| Device |
radiation: diffusing alpha radiation emitters therapy (dart) |
1 |
2018 |
| Procedure |
radical colorectal resection |
1 |
2016 |
| Procedure |
radical proctectomy with total mesorectal excision |
1 |
2011 |
| Procedure |
radical prostatectomy |
1 |
2011 |
| Radiation |
radiochemotherapy |
1 |
2014 |
| Radiation |
radiochemotherapy cap 50 |
1 |
2011 |
| Radiation |
radiochemotherapy cap 60 |
1 |
2011 |
| Device |
radiofrequency ablation (barrxâ„¢) |
1 |
2014 |
| Device |
radiofrequency ablation (rfa) using the halo ablation system |
1 |
2013 |
| Device |
radiofrequency ablation of dysplastic mucosa (halo) |
1 |
2012 |
| Procedure |
radiofrequency ablation under eus |
1 |
2014 |
| Procedure |
radiofrequency tumor ablation |
1 |
2008 |
| Radiation |
radiosurgery / wbrt |
1 |
2005 |
| Radiation |
radiosurgery dose escalation |
1 |
2011 |
| Procedure |
radiotherapy, dose fractionation |
1 |
2005 |
| Drug |
raf265 |
1 |
2011 |
| Drug |
ralimetinib |
1 |
2016 |
| Drug |
raltitrexed |
1 |
2016 |
| Biological |
ramucirumab (imc-1121b) |
1 |
2012 |
| Biological |
ras peptide cancer vaccine |
1 |
2001 |
| Drug |
rasburicase |
1 |
2007 |
| Drug |
rasburicase (sr29142) |
1 |
2005 |
| Drug |
ravuconazole |
1 |
2003 |
| Biological |
rbbx-01 |
1 |
2009 |
| Drug |
rbn-2397 |
1 |
2019 |
| Drug |
rc48-adc |
1 |
2016 |
| Drug |
rc88 |
1 |
2019 |
| Radiation |
re-irradiation |
1 |
2018 |
| Procedure |
real acupressure band |
1 |
2011 |
| Procedure |
real rtms(20 hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days |
1 |
2014 |
| Procedure |
real rtms(20 hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week) |
1 |
2014 |
| Biological |
recombinant albumin fusion protein sephb4-hsa |
1 |
2012 |
| Biological |
recombinant human endostatin |
1 |
2000 |
| Drug |
recombinant human erythropoietin (rhuepo) |
1 |
2005 |
| Biological |
recombinant human interleukin-15 (rhil-15) |
1 |
2013 |
| Drug |
recombinant humanized bispecific monoclonal antibody mbs301 |
1 |
2019 |
| Biological |
recombinant interferon alfa |
1 |
1999 |
| Biological |
recombinant interferon alfa-2b |
1 |
2007 |
| Biological |
recombinant interferon gamma |
1 |
1999 |
| Biological |
recombinant interleukin-11 |
1 |
1999 |
| Biological |
recombinant interleukin-12 |
1 |
1999 |
| Procedure |
rectus sheath block |
1 |
2018 |
| Procedure |
reduced fluid volume |
1 |
2012 |
| Procedure |
reduced intensity haplodentical stem cell transplant |
1 |
2012 |
| Procedure |
reduced intensity stem cell transplantation |
1 |
2009 |
| Device |
reference platelets (ref plts) |
1 |
2016 |
| Procedure |
regional lymph node dissection |
1 |
2011 |
| Drug |
regn2810 |
1 |
2017 |
| Drug |
regn2810 (maintenance) |
1 |
2018 |
| Drug |
regn2810 (monotherapy) |
1 |
2018 |
| Drug |
regn3767 |
1 |
2016 |
| Drug |
regn421(sar153192) |
1 |
2009 |
| Radiation |
reirradiation |
1 |
2019 |
| Device |
rejuvenair |
1 |
2015 |
| Behavioral |
relaxation |
1 |
2017 |
| Behavioral |
relaxation/talking group |
1 |
2017 |
| Other |
remote assistance |
1 |
2016 |
| Procedure |
removal of ovarian vessels |
1 |
2005 |
| Procedure |
removal of pet-positive lymph nodes |
1 |
2016 |
| Procedure |
removal of tumor |
1 |
2010 |
| Procedure |
removal of tumor/tissue |
1 |
2010 |
| Procedure |
remove tumor only |
1 |
2010 |
| Combination Product |
repetitive epipac-ox |
1 |
2017 |
| Procedure |
repetitive transcranial magnetic stimulation |
1 |
2017 |
| Procedure |
research blood draw |
1 |
2016 |
| Biological |
resiquimod |
1 |
2009 |
| Procedure |
respiratory therapy |
1 |
2015 |
| Procedure |
resting energy expenditure |
1 |
2018 |
| Other |
results of the brief geriatric assessment |
1 |
2019 |
| Other |
resuscitation curriculum |
1 |
2019 |
| Drug |
retifanlimab / incb001158 |
1 |
2019 |
| Behavioral |
revie âš• |
1 |
2019 |
| Radiation |
rfa interventions |
1 |
2019 |
| Combination Product |
rfa, bevacizumab |
1 |
2018 |
| Combination Product |
rfa, bevacizumab/second-line chemotherapy |
1 |
2018 |
| Drug |
rgx-104 |
1 |
2016 |
| Drug |
rgx-202-01 |
1 |
2018 |
| Drug |
rhenium (re 188 p2045, bay86-5284) |
1 |
2004 |
| Biological |
rhumab |
1 |
1999 |
| Drug |
ridaforolimus 100 mg |
1 |
2009 |
| Drug |
ridaforolimus 40 mg |
1 |
2009 |
| Drug |
riluzole |
1 |
2011 |
| Biological |
rintatolimod |
1 |
2014 |
| Other |
risk-based, escalating levels of care |
1 |
2015 |
| Other |
risk-based, escalating levels of co-management |
1 |
2015 |
| Other |
risk-based, escalating levels of monitoring |
1 |
2015 |
| Drug |
ritonavir |
1 |
2017 |
| Drug |
rituxanâ„¢ |
1 |
2007 |
| Drug |
rituxanâ® (rituximab) |
1 |
2019 |
| Drug |
rituximab for patients with b-cell malignancies |
1 |
2006 |
| Drug |
rly-1971 |
1 |
2020 |
| Biological |
rna-loaded dendritic cell vaccine |
1 |
2008 |
| Genetic |
rna analysis |
1 |
2008 |
| Drug |
rnr inhibitor coh29 |
1 |
2014 |
| Drug |
ro5045337 |
1 |
2008 |
| Drug |
ro5217790 |
1 |
2009 |
| Drug |
ro5503781 |
1 |
2011 |
| Drug |
ro5509554 |
1 |
2011 |
| Drug |
ro6870810 |
1 |
2013 |
| Drug |
ro7172508 |
1 |
2018 |
| Drug |
ro7247669 |
1 |
2019 |
| Drug |
ro7284755 |
1 |
2020 |
| Drug |
ro7296682 |
1 |
2019 |
| Biological |
robo1 car-nk cells |
1 |
2019 |
| Procedure |
robotic single port surgery |
1 |
2016 |
| Procedure |
robotic single port surgery/notes |
1 |
2016 |
| Drug |
rocuronium |
1 |
2017 |
| Drug |
roflumilast |
1 |
2013 |
| Drug |
rogaratinib (bay1163877) |
1 |
2018 |
| Drug |
romiplostim |
1 |
2014 |
| Drug |
roniciclib (bay 1000394) |
1 |
2015 |
| Drug |
roniciclib (bay1000394) |
1 |
2010 |
| Drug |
ropidoxuridine |
1 |
2016 |
| Behavioral |
routine care |
1 |
2014 |
| Drug |
rovalpituzumab tesirine |
1 |
2016 |
| Procedure |
rreversible electroporation (ire) |
1 |
2015 |
| Drug |
rrx-001 |
1 |
2016 |
| Drug |
rta 402 |
1 |
2007 |
| Device |
runkeeper app |
1 |
2015 |
| Drug |
rx108 |
1 |
2018 |
| Drug |
rxc004 |
1 |
2018 |
| Drug |
rxdx-105 |
1 |
2013 |
| Drug |
s-1 de-escalation |
1 |
2014 |
| Drug |
s ckd602 |
1 |
2005 |
| Device |
sacral nerve stimulator |
1 |
2019 |
| Device |
sacral nerve stimulator battery |
1 |
2019 |
| Drug |
safingol |
1 |
2004 |
| Genetic |
sait301 |
1 |
2014 |
| Genetic |
salivary kit |
1 |
2012 |
| Device |
salvage stereotactic radiosurgery arm |
1 |
2006 |
| Drug |
sandostatin lar depot |
1 |
2013 |
| Drug |
sar245408 (xl147) |
1 |
2011 |
| Drug |
sar245409 (pi3k |
1 |
2011 |
| Drug |
sar245409 (pi3k/mtor inhibitor) |
1 |
2011 |
| Drug |
sar260301 |
1 |
2012 |
| Drug |
sar302503 |
1 |
2012 |
| Drug |
sar302503 (tg101348) |
1 |
2013 |
| Drug |
sar307746) |
1 |
2012 |
| Drug |
sar428926 |
1 |
2015 |
| Biological |
sar439459 |
1 |
2017 |
| Drug |
sar566658 |
1 |
2010 |
| Drug |
sarcnu |
1 |
1999 |
| Drug |
sargramostim (gm-csf) |
1 |
2008 |
| Drug |
savolitinib |
1 |
2017 |
| Drug |
sb-485232 |
1 |
2004 |
| Drug |
sb-743921 |
1 |
2005 |
| Drug |
sb939 |
1 |
2008 |
| Radiation |
sbrt-pathy (sbrt-based partial tumor irradiation targeting hypoxic segment) |
1 |
2019 |
| Radiation |
sbrt treatment |
1 |
2013 |
| Drug |
scb-313 |
1 |
2018 |
| Drug |
scb01a |
1 |
2010 |
| Behavioral |
screening interview |
1 |
2016 |
| Procedure |
screening method |
1 |
2012 |
| Biological |
scri-carb7h3(s); b7h3-specific chimeric antigen receptor (car) t cel |
1 |
2019 |
| Procedure |
sct |
1 |
2019 |
| Drug |
sdx-7320 |
1 |
2016 |
| Biological |
second generation 4-1bbî¶ egfr806-egfrt |
1 |
2018 |
| Biological |
second generation 4-1bbî¶ egfr806-egfrt/a second generation 4 1bbî¶ cd19-her2tg |
1 |
2018 |
| Other |
second session |
1 |
2015 |
| Behavioral |
secondary fasting |
1 |
2013 |
| Procedure |
segmental resection |
1 |
2020 |
| Behavioral |
self-administered acupressure |
1 |
2018 |
| Behavioral |
self-control weight loss |
1 |
2015 |
| Behavioral |
self-help |
1 |
2018 |
| Behavioral |
self-help materials |
1 |
2016 |
| Other |
self-test arm |
1 |
2009 |
| Drug |
selpercatinib |
1 |
2017 |
| Drug |
semaxanib |
1 |
2000 |
| Diagnostic Test |
semi whole-body mri |
1 |
2018 |
| Device |
sems(self-expandable metallic stent) |
1 |
2016 |
| Behavioral |
sens model |
1 |
2013 |
| Biological |
serum samples |
1 |
2017 |
| Drug |
sevoflurane |
1 |
2013 |
| Radiation |
sf-ssrs |
1 |
2015 |
| Drug |
sf1126 |
1 |
2009 |
| Drug |
sgi-110 |
1 |
2017 |
| Genetic |
sgt-53 |
1 |
2007 |
| Genetic |
sgt-94 |
1 |
2012 |
| Drug |
sh3051 capsule treatment |
1 |
2020 |
| Other |
sham control |
1 |
2018 |
| Procedure |
sham rtms (same parameters but with coil elevated/angled away from the head) every day for 10 consecutive days (5 days/week). |
1 |
2014 |
| Procedure |
sham rtms (same parameters but with coil elevated/angled away from the head)every day for ten consecutive days (5 days/week). |
1 |
2014 |
| Device |
shear-wave elastography |
1 |
2014 |
| Drug |
short glucocorticosteroid (prednisone) regimen |
1 |
2019 |
| Other |
shorter pict |
1 |
2017 |
| Drug |
shp2 allosteric inhibitor |
1 |
2019 |
| Drug |
shr-1316 |
1 |
2019 |
| Drug |
shr-a1403 |
1 |
2019 |
| Drug |
shr1459 |
1 |
2018 |
| Drug |
shr2554 |
1 |
2018 |
| Drug |
shr3162 |
1 |
2016 |
| Drug |
sildenafil citrate |
1 |
2015 |
| Drug |
simmitecan hydrochloride for injection |
1 |
2013 |
| Radiation |
simulation |
1 |
2018 |
| Radiation |
single fraction stereotactic radiosurgery |
1 |
2019 |
| Device |
single needle celiac neurolysis (sncn) |
1 |
2016 |
| Device |
sir spheres intra-arterial hepatic |
1 |
2005 |
| Biological |
sirna-transfected peripheral blood mononuclear cells apn401 |
1 |
2017 |
| Drug |
sirolimus (rapamycin) |
1 |
2010 |
| Drug |
sirolimus, cyclophosphamide, topotecan |
1 |
2012 |
| Radiation |
sirt with y-90 |
1 |
2020 |
| Drug |
sitravatinib |
1 |
2018 |
| Drug |
ski-606 |
1 |
2009 |
| Drug |
ski-606 (bosutinib) |
1 |
2006 |
| Other |
skin biopsy |
1 |
2013 |
| Procedure |
skin biopsy (optional) |
1 |
2012 |
| Drug |
sl-401 |
1 |
2014 |
| Drug |
sl-801 |
1 |
2015 |
| Drug |
slc-0111 |
1 |
2014 |
| Drug |
slc-391 |
1 |
2019 |
| Biological |
slc45a2-specific t lymphocytes |
1 |
2017 |
| Procedure |
sln mapping |
1 |
2016 |
| Procedure |
sln mapping/removal of pet-positive lymph nodes |
1 |
2016 |
| Drug |
sm08502 |
1 |
2017 |
| Behavioral |
smart intervention |
1 |
2018 |
| Drug |
sn2310 injectable emulsion |
1 |
2006 |
| Drug |
sndx-6352 |
1 |
2017 |
| Drug |
sns-314 |
1 |
2007 |
| Drug |
snx-5422 mesylate hsp90 inhibitor |
1 |
2008 |
| Other |
social-health care intervention |
1 |
2018 |
| Other |
social intervention associated techniques of domotic |
1 |
2016 |
| Drug |
sodium bicarbonate |
1 |
2015 |
| Drug |
sodium stibogluconate |
1 |
2008 |
| Drug |
sofosbuvir oral product |
1 |
2019 |
| Drug |
solumedrol |
1 |
2005 |
| Drug |
som230 |
1 |
2008 |
| Device |
sonopet ultrasonic aspirator |
1 |
2016 |
| Drug |
sonovue |
1 |
2018 |
| Drug |
sorafenib/with hydroxychloroquine |
1 |
2012 |
| Biological |
sotatercept |
1 |
2012 |
| Drug |
sotorasib |
1 |
2019 |
| Drug |
sox neoadjuvant |
1 |
2020 |
| Drug |
sox neoadjuvant/postoperative chemotherapy |
1 |
2020 |
| Other |
sox postoperative chemotherapy |
1 |
2015 |
| Dietary Supplement |
soy protein isolate |
1 |
2003 |
| Drug |
sp-2577 seclidemstat |
1 |
2019 |
| Diagnostic Test |
spanom (identifying msi status from ctdna) |
1 |
2018 |
| Other |
spark |
1 |
2018 |
| Radiation |
spatially fractionated radiation therapy |
1 |
2014 |
| Other |
specialized pathology review (germany only) |
1 |
2011 |
| Behavioral |
specialized symptom management |
1 |
2016 |
| Behavioral |
specialized symptom management/supportive care |
1 |
2016 |
| Diagnostic Test |
spect |
1 |
2013 |
| Diagnostic Test |
spect with 99mtc-1-thio-d-glucose |
1 |
2020 |
| Diagnostic Test |
spect/ct |
1 |
2013 |
| Radiation |
spine radiosurgery |
1 |
2017 |
| Procedure |
spiritual therapy |
1 |
2011 |
| Drug |
spironolactone |
1 |
2012 |
| Drug |
spleen tyrosine kinase inhibitor tak-659 |
1 |
2018 |
| Biological |
sqz-pbmc-hpv |
1 |
2019 |
| Drug |
sr-t100 gel with 2.3% of sm in solanum undatum plant extract |
1 |
2012 |
| Drug |
srf388 |
1 |
2020 |
| Drug |
srf617 |
1 |
2020 |
| Drug |
st1968 |
1 |
2012 |
| Drug |
sta-9090 |
1 |
2008 |
| Drug |
sta-9090 (ganetespib) with docetaxel |
1 |
2010 |
| Procedure |
standard-of-care intensity modulated radiotherapy (imrt) planning |
1 |
2017 |
| Drug |
standard-of-care therapy |
1 |
2014 |
| Other |
standard-stimulated cohort |
1 |
2019 |
| Drug |
standard adjuvant systemic chemotherapy |
1 |
2014 |
| Device |
standard biopsy needle |
1 |
2012 |
| Behavioral |
standard cbt |
1 |
2017 |
| Device |
standard colonoscopy |
1 |
2016 |
| Radiation |
standard dose |
1 |
2016 |
| Device |
standard endoscopic evaluation |
1 |
2009 |
| Procedure |
standard external beam radiation therapy |
1 |
2013 |
| Other |
standard fall care |
1 |
2014 |
| Behavioral |
standard health educational booklet |
1 |
2015 |
| Other |
standard hydration |
1 |
2019 |
| Procedure |
standard of care brain biopsy |
1 |
2018 |
| Procedure |
standard of care brain biopsy/tumor removal |
1 |
2018 |
| Procedure |
standard of care procedure as described in arm |
1 |
2011 |
| Other |
standard postoperative care |
1 |
2015 |
| Drug |
standard supportive therapy |
1 |
2018 |
| Device |
standard white-light laparoscopy |
1 |
2013 |
| Behavioral |
standardized care |
1 |
2013 |
| Behavioral |
standardized care (intervention i) |
1 |
2013 |
| Behavioral |
standardized care / woman-pro ii program (intervention ii) |
1 |
2013 |
| Procedure |
standardized endoscopic treatment of local residual neoplasia |
1 |
2013 |
| Device |
stapling device |
1 |
2012 |
| Drug |
stat3 inhibitor wp1066 |
1 |
2013 |
| Device |
steel |
1 |
2009 |
| Procedure |
stem cell infusion |
1 |
2011 |
| Procedure |
stem cell reinfusion |
1 |
2015 |
| Procedure |
stem cell transplantation, hematopoietic |
1 |
2009 |
| Biological |
stem cells |
1 |
2012 |
| Drug |
stemexâ® |
1 |
2007 |
| Device |
stenting by ercp (endoscopic retrograde cholangiopancreatography) |
1 |
2016 |
| Radiation |
stereotactic ablative body radiosurgery (sabr) |
1 |
2014 |
| Radiation |
stereotactic ablative radiotherapy |
1 |
2016 |
| Radiation |
stereotactic ablative radiotherapy (sabr) |
1 |
2016 |
| Radiation |
stereotactic body radiation treatments |
1 |
2015 |
| Radiation |
stereotactic fractionation |
1 |
2014 |
| Radiation |
stereotactic hypofractionated radioablation |
1 |
2017 |
| Radiation |
stereotactic radiosurgery using the cyberknife system. |
1 |
2012 |
| Procedure |
stereotactic radiotherapy (srt) |
1 |
2005 |
| Procedure |
stereotactic radiotherapy (srt)/highly conformal (crt) |
1 |
2005 |
| Procedure |
stereotactic surgery (srs) |
1 |
2004 |
| Drug |
sterile compound c31510 for injection |
1 |
2010 |
| Procedure |
sterotactic radiosurgery |
1 |
2007 |
| Drug |
sti571 (glivecâ®) |
1 |
2011 |
| Other |
stratification |
1 |
2016 |
| Other |
strengthening |
1 |
2012 |
| Drug |
streptozocin |
1 |
2008 |
| Other |
stretching |
1 |
2012 |
| Behavioral |
study diaries |
1 |
2012 |
| Drug |
study part 1: krp203 |
1 |
2013 |
| Drug |
study part 2: krp203 higher dose |
1 |
2013 |
| Drug |
study part 2: krp203 lower dose |
1 |
2013 |
| Drug |
su011248; gemcitabine |
1 |
2008 |
| Drug |
su5416 |
1 |
2000 |
| Drug |
su5416/carboplatin |
1 |
2000 |
| Drug |
subcutaneous (sc) sea-cd40 |
1 |
2015 |
| placebo |
subcutaneous injection saline placebo |
1 |
2018 |
| Drug |
succimer |
1 |
2018 |
| Drug |
sulfatinib |
1 |
2014 |
| Drug |
sulindac |
1 |
2006 |
| Drug |
sunitinib / folfox |
1 |
2008 |
| Drug |
sunitinib, pemetrexed |
1 |
2008 |
| Drug |
sunscreen |
1 |
2012 |
| Procedure |
superior mesenteric artery first (sma) |
1 |
2017 |
| Other |
supportive care regimens |
1 |
2019 |
| Behavioral |
supportive therapy group 2 |
1 |
2016 |
| Radiation |
supr |
1 |
2018 |
| Procedure |
surgery / wbrt |
1 |
2005 |
| Procedure |
surgery after neoadjuvant therapy |
1 |
2016 |
| Procedure |
surgery alone |
1 |
2011 |
| Other |
surgery followed by adjuvant radiotherapy |
1 |
2019 |
| Other |
surgery followed by adjuvant radiotherapy/chemoradiotherapy |
1 |
2019 |
| Other |
surgery followed by folfox4 chemotherapy |
1 |
2012 |
| Procedure |
surgery/hyperthermic intraperitoneal chemotherapy with mmc |
1 |
2014 |
| Procedure |
surgical resection of tumor |
1 |
2015 |
| Other |
surgicel |
1 |
2012 |
| Drug |
surufatinib/humanized anti-pd-1 monoclonal antibody |
1 |
2018 |
| Other |
survey assessments |
1 |
2019 |
| Other |
surveys |
1 |
2018 |
| Behavioral |
surviving online workshop |
1 |
2009 |
| Behavioral |
survivorship education |
1 |
2015 |
| Procedure |
susceptibility weighted imaging |
1 |
2008 |
| Biological |
svn53-67 |
1 |
2019 |
| Biological |
svn53-67/m57-klh peptide vaccine |
1 |
2019 |
| Behavioral |
swallowing questionnaire |
1 |
2017 |
| Procedure |
swetz |
1 |
2012 |
| Drug |
sy-5609 |
1 |
2020 |
| Drug |
syb c-0501 |
1 |
2018 |
| Drug |
sym004 |
1 |
2013 |
| Drug |
sym015 |
1 |
2016 |
| Behavioral |
symptom questionnaires |
1 |
2017 |
| Biological |
syn004 |
1 |
2020 |
| Biological |
syn125 |
1 |
2020 |
| Drug |
systematic chemotherapy |
1 |
2005 |
| Drug |
systematic chemotherapy/antibodies |
1 |
2005 |
| Drug |
systemic chemotherapy |
1 |
2005 |
| Drug |
systemic chemotherapy for colorectal liver metastases |
1 |
2020 |
| Drug |
systemic chemotherapy for intrahepatic cholangiocarcinoma |
1 |
2020 |
| Drug |
systemic chemotherapy/antibodies |
1 |
2005 |
| Procedure |
t cell |
1 |
2007 |
| Biological |
t cell-depleted donor lymphocyte infusion |
1 |
2015 |
| Biological |
t cells (robo1 car-nk |
1 |
2019 |
| Biological |
t cells) |
1 |
2019 |
| Combination Product |
t601/5-fc |
1 |
2019 |
| Drug |
tab004, recombinant humanized igg4îº monoclonal antibody specific to btla for injection |
1 |
2019 |
| Drug |
tab08 |
1 |
2016 |
| Biological |
tabelecleucel |
1 |
2018 |
| Combination Product |
tace/autologous tcm immunotherapy |
1 |
2018 |
| Drug |
tadalafil |
1 |
2013 |
| Drug |
taest16001 |
1 |
2017 |
| Drug |
tagitol v, lo so, readi-cat 2 |
1 |
2005 |
| Biological |
tagraxofusp-erzs |
1 |
2020 |
| Other |
tailored education intervention |
1 |
2014 |
| Behavioral |
tailored printout |
1 |
2015 |
| Drug |
tak-164 |
1 |
2018 |
| Drug |
tak-165 |
1 |
2002 |
| Drug |
tak-441 |
1 |
2010 |
| Drug |
tak-573 |
1 |
2019 |
| Drug |
tak-659 |
1 |
2013 |
| Biological |
tak-701 |
1 |
2009 |
| Drug |
tak-733 |
1 |
2009 |
| Drug |
tak-981 |
1 |
2018 |
| Drug |
tak228 |
1 |
2018 |
| Drug |
taladegib |
1 |
2010 |
| Drug |
talaporfin sodium |
1 |
2007 |
| Drug |
talazoparib phase 1b |
1 |
2017 |
| Drug |
talazoparib phase 2 |
1 |
2017 |
| Drug |
talazoparib tosylate |
1 |
2014 |
| Drug |
talimogene laherparepvec |
1 |
2015 |
| Behavioral |
talking group |
1 |
2017 |
| Drug |
talotrexin ammonium |
1 |
2004 |
| Procedure |
tamis |
1 |
2017 |
| Drug |
tamoxifen 20 mg |
1 |
2019 |
| Drug |
tamoxifen citrate |
1 |
2007 |
| Biological |
tanibirumab |
1 |
2012 |
| Drug |
tar-200 |
1 |
2018 |
| Drug |
tarceva, erlotinib, osi-774 |
1 |
2005 |
| Other |
targeted t-cell armed with bispecific antibody (decitabine) |
1 |
2019 |
| Drug |
targeted therapy |
1 |
2014 |
| Drug |
targeted therapy based on molecular profiling |
1 |
2014 |
| Drug |
tariquidar |
1 |
2003 |
| Drug |
tas-102 tablets |
1 |
2013 |
| Drug |
tas-102 with a light tracer dose of [14c] tpi |
1 |
2013 |
| Drug |
tas-102 with a light tracer dose of [14c]ftd |
1 |
2013 |
| Drug |
tas-114 |
1 |
2012 |
| Drug |
tas-114 / s-1 |
1 |
2012 |
| Drug |
tas-116 |
1 |
2016 |
| Drug |
tas-120 |
1 |
2014 |
| Procedure |
tatme |
1 |
2016 |
| Drug |
taxane |
1 |
2011 |
| Drug |
taxol w |
1 |
2007 |
| Drug |
tazarotene |
1 |
2007 |
| Drug |
tazobactam sodium |
1 |
1999 |
| Biological |
tb-403 |
1 |
2008 |
| Biological |
tbi-1401(hf10) |
1 |
2015 |
| Procedure |
tbi regime |
1 |
2015 |
| Drug |
tbi, systemic chemotherapy |
1 |
2005 |
| Drug |
tbi, systemic chemotherapy/antibodies as follows: |
1 |
2005 |
| Device |
tc-325 |
1 |
2019 |
| Drug |
tc 99m ec20 |
1 |
2012 |
| Drug |
tcd-717 |
1 |
2010 |
| Other |
tdf |
1 |
2014 |
| Genetic |
tdt-mediated dutp nick end labeling assay |
1 |
2008 |
| Radiation |
technetium tc-99m albumin aggregated |
1 |
2013 |
| Drug |
technetium tc-99m dtpa |
1 |
2013 |
| Drug |
telaglenastat hydrochloride |
1 |
2019 |
| Drug |
telaglenestat (cb-839) |
1 |
2019 |
| Drug |
telatinib mesylate |
1 |
2017 |
| Other |
telehealth |
1 |
2016 |
| Other |
telephone arm |
1 |
2009 |
| Behavioral |
telephone coaching/phone calls |
1 |
2016 |
| Drug |
telisotuzumab vedotin |
1 |
2014 |
| Biological |
telomerase: 540-548 peptide vaccine |
1 |
2003 |
| Drug |
telotristat etiprate |
1 |
2018 |
| Biological |
tem1 monoclonal antibody morab-004 |
1 |
2012 |
| Drug |
temozolomide/hycamtin (topotecan) |
1 |
2009 |
| Drug |
temsirolimus (cci-779) |
1 |
2003 |
| Drug |
temsirolimus, pazopanib |
1 |
2010 |
| Drug |
tenalisib |
1 |
2018 |
| Drug |
tesetaxel |
1 |
2020 |
| Drug |
testosterone |
1 |
2009 |
| Biological |
tetanus-diphtheria toxoid (td) |
1 |
2014 |
| Biological |
tetanus day 1 |
1 |
2012 |
| Biological |
tetanus day 29 |
1 |
2012 |
| Biological |
tetanus toxoid |
1 |
2008 |
| Biological |
tetanus vaccine |
1 |
2017 |
| Drug |
tetrahydrouridine (thu) |
1 |
2009 |
| Drug |
tew-7197 |
1 |
2014 |
| Behavioral |
text messages |
1 |
2019 |
| Drug |
teysuno (s1) in combination with epirubicin |
1 |
2016 |
| Drug |
teysuno (s1) in combination with epirubicin/oxaliplatin |
1 |
2016 |
| Drug |
tezacitabine |
1 |
2003 |
| Drug |
tezacitabine (fmdc) |
1 |
2003 |
| Other |
tezel method of breast volume measurement |
1 |
2015 |
| Biological |
tg6002 |
1 |
2018 |
| Biological |
tgfbeta resistant her2 |
1 |
2009 |
| Biological |
tgfbeta resistant her2/ebv-ctls |
1 |
2009 |
| Drug |
thalomid |
1 |
2005 |
| Device |
the codman tapered arterial catheter. |
1 |
2020 |
| Other |
the family talk intervention |
1 |
2018 |
| Procedure |
the observer mobility scale |
1 |
2012 |
| Genetic |
therapeutic 4scar19 cells |
1 |
2017 |
| Biological |
therapeutic angiotensin-(1-7) |
1 |
2007 |
| Biological |
therapeutic autologous dendritic cells |
1 |
2008 |
| Biological |
therapeutic autologous lymphocytes |
1 |
2008 |
| Other |
therapeutic exercise |
1 |
2019 |
| Other |
therapeutic exercise/education |
1 |
2019 |
| Drug |
therapeutic hydrocortisone |
1 |
2012 |
| Biological |
therapeutic immune globulin |
1 |
2008 |
| Procedure |
therapeutic procedure |
1 |
2014 |
| Procedure |
therapeutic resection of the lesion |
1 |
2009 |
| Procedure |
therapeutic surgical procedure |
1 |
2014 |
| Procedure |
therapeutic touch |
1 |
2012 |
| Device |
therasphere, yttrium-90 glass microspheres |
1 |
2010 |
| Procedure |
thermal ablation therapy |
1 |
2016 |
| Other |
thermal comfort questionnaire |
1 |
2018 |
| Device |
thermocoagulator |
1 |
2017 |
| Other |
thermography imaging |
1 |
2016 |
| Drug |
thioguanine |
1 |
1999 |
| Drug |
thioplexâ® |
1 |
2007 |
| Drug |
thioureidobutyronitrile |
1 |
2012 |
| Behavioral |
third through sixth sessions |
1 |
2015 |
| Drug |
thor-707 |
1 |
2019 |
| Device |
thoracic drain tube 24 fr. |
1 |
2018 |
| Procedure |
thoracoscopy |
1 |
2019 |
| Other |
til |
1 |
2019 |
| Drug |
tinostamustine |
1 |
2015 |
| Drug |
tislelizumab (bgb-a317) |
1 |
2018 |
| Drug |
tislelizumab 200 mg, iv |
1 |
2019 |
| Drug |
tisotumab vedotin |
1 |
2019 |
| Procedure |
tissue |
1 |
2010 |
| Procedure |
tissue collection |
1 |
2019 |
| Other |
tissue sample storage |
1 |
2009 |
| Other |
titrated pain management |
1 |
2008 |
| Drug |
tivantinib (arq 197) capsule |
1 |
2010 |
| Drug |
tivantinib (arq 197) capsule d, oral |
1 |
2010 |
| Drug |
tivantinib (arq 197) tablet |
1 |
2010 |
| Drug |
tivozanib |
1 |
2010 |
| Drug |
tivozanib (av-951) |
1 |
2010 |
| Drug |
tivozanib (av-951)/capecitabine (xelodaâ®) |
1 |
2010 |
| Drug |
tj004309 |
1 |
2019 |
| Drug |
tj004309 injection |
1 |
2020 |
| Drug |
tki258 (dovitinib) |
1 |
2009 |
| Drug |
tlc178 |
1 |
2016 |
| Drug |
tld-1 |
1 |
2017 |
| Drug |
tlr9 agonist sd-101 |
1 |
2019 |
| Procedure |
tme |
1 |
2018 |
| Procedure |
tme/llnd |
1 |
2018 |
| Procedure |
tme/ncrt |
1 |
2018 |
| Drug |
tno155 |
1 |
2020 |
| Other |
tobacco cessation counseling |
1 |
2019 |
| Drug |
tocosol paclitaxel |
1 |
2004 |
| Drug |
tolipalimab |
1 |
2019 |
| Radiation |
tomotherapy |
1 |
2010 |
| Drug |
topical abi-1968 |
1 |
2018 |
| Drug |
topical fluorouracil |
1 |
2017 |
| Drug |
topical imiquimod therapy |
1 |
2009 |
| Drug |
topotecan, temozolomide |
1 |
2006 |
| Drug |
topotecan/pazopanib |
1 |
2014 |
| Drug |
topotecan/taxotere |
1 |
2005 |
| Drug |
toremifene |
1 |
2002 |
| Drug |
toremifene 20 mg |
1 |
2005 |
| Biological |
toripalimab, recombinant humanized anti-pd-1 monoclonal antibody |
1 |
2018 |
| Radiation |
total body radiation (tbi) |
1 |
2007 |
| Drug |
total lymphoid irradiation/anti-thymocyte globulin |
1 |
2012 |
| Procedure |
total mediastinal lymph node dissection |
1 |
2017 |
| Procedure |
total mediastinal lymph node dissection/pulmonary metastasectomy |
1 |
2017 |
| Drug |
tp-0184 |
1 |
2018 |
| Drug |
tp-1287 |
1 |
2018 |
| Drug |
tp-3654 |
1 |
2018 |
| Drug |
tpi 287 injection |
1 |
2005 |
| Drug |
tpx-0022 |
1 |
2019 |
| Drug |
tpx-0046 |
1 |
2019 |
| Drug |
tq-b3234 |
1 |
2016 |
| Drug |
tq05105 |
1 |
2020 |
| Drug |
tqb2450 |
1 |
2019 |
| Drug |
tqb3804 |
1 |
2019 |
| Biological |
tr1801-adc |
1 |
2019 |
| Other |
tracheal aspirates |
1 |
2019 |
| Other |
tracheal aspirates/nasal smears were taken in all the patients. laparotomies were performed in all patients. |
1 |
2019 |
| Device |
traditional polyethylene stent insertion (cotton huibregtse) |
1 |
2012 |
| Procedure |
traditional robotic-assisted surgery |
1 |
2020 |
| Other |
training with feedback |
1 |
2016 |
| Drug |
tranexamic acid |
1 |
2018 |
| Procedure |
transanal endoscopic microsurgery |
1 |
2018 |
| Procedure |
transcranial direct current stimulation |
1 |
2019 |
| Procedure |
transoral robotic surgery (tors) with neck dissection |
1 |
2019 |
| Drug |
trastuzumab deruxtecan |
1 |
2018 |
| Drug |
trastuzumab/docetaxel (for 4 21-day cycles) after four 14-day cycles of doxorubicin/cyclophosphamide |
1 |
2017 |
| Drug |
trastuzumab/pertuzumab (combination treatment) |
1 |
2016 |
| Drug |
trc 105 |
1 |
2011 |
| Drug |
trc105/bevacizumab |
1 |
2011 |
| Behavioral |
treadmill walking (proof-of-concept) |
1 |
2019 |
| Behavioral |
treadmill walking dose-finding |
1 |
2019 |
| Behavioral |
treadmill walking dose-finding / escalation |
1 |
2019 |
| Behavioral |
treadmill walking phase 1b: dose-expansion |
1 |
2019 |
| Other |
treatment |
1 |
2013 |
| Drug |
treatment a - azd1775 administered under fasted conditions |
1 |
2017 |
| Drug |
treatment b - azd1775 administered under fed conditions. |
1 |
2017 |
| Biological |
treatment group |
1 |
2002 |
| Drug |
treatment with arq 197 in combination with gemcitabine |
1 |
2009 |
| Drug |
treatment with arq 197 in combination with sorafenib |
1 |
2009 |
| Drug |
tremelimumab / durvalumab |
1 |
2016 |
| Drug |
tremelimumab combination therapy |
1 |
2019 |
| Device |
trf on drg |
1 |
2017 |
| Drug |
trial extension phase) |
1 |
2013 |
| Drug |
triapine |
1 |
2006 |
| Device |
trichloroacetic acid 85% (tca) |
1 |
2020 |
| Drug |
trichostatin a |
1 |
2019 |
| Drug |
triciribine |
1 |
2008 |
| Biological |
tricom |
1 |
2014 |
| Drug |
trientine |
1 |
2010 |
| Drug |
trientine mtd |
1 |
2010 |
| Drug |
trilaciclib |
1 |
2016 |
| Biological |
trivalent influenza vaccine |
1 |
2016 |
| Drug |
trpv6 calcium channel inhibitor sor-c13 |
1 |
2018 |
| Biological |
truncated cd19-expressing autologous t lymphocytes |
1 |
2014 |
| Device |
trusbx |
1 |
2019 |
| Drug |
trx-818 capsules |
1 |
2015 |
| Biological |
trx518 |
1 |
2010 |
| Drug |
tsd-001 |
1 |
2017 |
| Drug |
tsr-022 |
1 |
2016 |
| Drug |
tsr-033, an anti-lag-3 antibody |
1 |
2016 |
| Drug |
tsr-042, an anti-pd-1 antibody |
1 |
2016 |
| Drug |
tti-101 |
1 |
2017 |
| Drug |
tti-621 |
1 |
2016 |
| Drug |
tti-621/nivolumab |
1 |
2016 |
| Drug |
tti-621/rituximab |
1 |
2016 |
| Combination Product |
ttx-030 |
1 |
2020 |
| Combination Product |
ttx-030, budigalimab |
1 |
2020 |
| Combination Product |
ttx-030, budigalimab/docetaxel |
1 |
2020 |
| Combination Product |
ttx-030, budigalimab/mfolfox6 |
1 |
2020 |
| Combination Product |
ttx-030/budigalimab |
1 |
2020 |
| Combination Product |
ttx-030/mfolfox6 |
1 |
2020 |
| Drug |
tumor-specific tcr-t cells |
1 |
2019 |
| Biological |
tumor associated antigen lymphocytes (taa-t) |
1 |
2014 |
| Other |
tumor biopsies. |
1 |
2014 |
| Procedure |
tumor biopsy |
1 |
2012 |
| Procedure |
tumor biopsy (optional) |
1 |
2016 |
| Biological |
tumor cell lysate vaccine therapy |
1 |
1999 |
| Biological |
tumor fusion vaccine |
1 |
2020 |
| Procedure |
tumor removal |
1 |
2018 |
| Genetic |
tumor samples |
1 |
2017 |
| Biological |
tumoral specific genetic alterations |
1 |
2015 |
| Drug |
tvb-2640 |
1 |
2014 |
| Drug |
two consecutive weeks administration of arq 761 with one week of rest |
1 |
2011 |
| Drug |
u3-1287 (amg888) |
1 |
2008 |
| Drug |
u3-1565 |
1 |
2011 |
| Biological |
ucart19 |
1 |
2016 |
| Biological |
ucart19/allo-501 follow-up |
1 |
2016 |
| Device |
ultracision |
1 |
2005 |
| Device |
ultrasound |
1 |
2016 |
| Procedure |
ultrasound-guided teci |
1 |
2019 |
| Procedure |
ultrasound imaging |
1 |
2008 |
| Other |
ultrasound therapy |
1 |
2015 |
| Device |
uncovered biliary stents |
1 |
2014 |
| Other |
unenhanced monitoring |
1 |
2015 |
| Procedure |
unilateral neck dissection |
1 |
2018 |
| Procedure |
unmanipulated pbsc after nonmyeloablative conditioning |
1 |
2008 |
| Behavioral |
unnamed consumer-based app meditation |
1 |
2018 |
| Procedure |
upper gastrointestinal endoscopy |
1 |
2013 |
| Procedure |
upper gastrointestinal endoscopy/doppler ultrasound |
1 |
2013 |
| Drug |
ursodeoxycholic acid |
1 |
2008 |
| Drug |
ursodiol |
1 |
2012 |
| Other |
usda diet |
1 |
2019 |
| Other |
usual cancer care |
1 |
2018 |
| Behavioral |
uv4.me |
1 |
2017 |
| Behavioral |
uv4.me2 |
1 |
2017 |
| Biological |
v212 |
1 |
2010 |
| Biological |
v941 |
1 |
2019 |
| Biological |
vaccination |
1 |
2017 |
| Biological |
vaccine therapy |
1 |
2014 |
| Procedure |
vaginal packing |
1 |
2017 |
| Device |
vaginal self-sampling brush |
1 |
2016 |
| Drug |
vancomycin |
1 |
1999 |
| Drug |
vancomycin oral capsule |
1 |
2019 |
| Drug |
vandetanib 300 mg |
1 |
2007 |
| Drug |
vanucizumab |
1 |
2016 |
| Device |
vapotherm |
1 |
2009 |
| Biological |
vb10.16 immunotherapy (dna vaccine) |
1 |
2015 |
| Genetic |
vcn-01 |
1 |
2014 |
| Biological |
ve800 |
1 |
2019 |
| Drug |
vehicle topical gel |
1 |
2015 |
| Drug |
vemurafenib/cobimetinib (combination treatment) |
1 |
2016 |
| Other |
venous blood samples |
1 |
2020 |
| Behavioral |
verbal support |
1 |
2018 |
| Biological |
vgx 3100 |
1 |
2011 |
| Drug |
vidaza |
1 |
2014 |
| Drug |
vidaza iv |
1 |
2009 |
| Other |
video-conference quality of life counseling |
1 |
2016 |
| Procedure |
video-strobe procedure |
1 |
2017 |
| Behavioral |
video chat sessions |
1 |
2016 |
| Behavioral |
video decision aid |
1 |
2010 |
| Other |
video presentation |
1 |
2017 |
| Other |
videos |
1 |
2016 |
| Procedure |
videoscopic ilioinguinal dissection |
1 |
2015 |
| Biological |
vigil |
1 |
2018 |
| Drug |
vinblastine/sirolimus |
1 |
2010 |
| Drug |
vincristine (cellcristinâ®) |
1 |
2014 |
| Drug |
vinorelbine, cyclophosphamide |
1 |
2009 |
| Drug |
vinorelbine, cyclophosphamide/interferon alpha 2b |
1 |
2009 |
| Drug |
vinorelbine, paclitaxel, nab-paclitaxel , docetaxel, capecitabine |
1 |
2014 |
| Procedure |
virtual reality distraction |
1 |
2008 |
| Procedure |
visual inspection with acetic acid |
1 |
2014 |
| Procedure |
visual inspection with lugol’s iodine |
1 |
2014 |
| Procedure |
visual oral screening examination |
1 |
2016 |
| Device |
vital portâ®minititanium |
1 |
2018 |
| Dietary Supplement |
vitamin b12 |
1 |
2007 |
| Drug |
vitamin c |
1 |
2019 |
| Drug |
vitamin d |
1 |
1999 |
| Dietary Supplement |
vitamin d3 analogue ilx23-7553 |
1 |
2000 |
| Dietary Supplement |
vitamin e |
1 |
2003 |
| Drug |
vitamin e î´-tocotrienol |
1 |
2009 |
| Drug |
vitamin supplements |
1 |
2009 |
| Radiation |
vmat |
1 |
2018 |
| Drug |
vnp20009 |
1 |
2000 |
| Drug |
volatile agent |
1 |
2017 |
| Radiation |
volumetric arc therapy (vmat) |
1 |
2017 |
| Procedure |
volumetric incentive spirometry |
1 |
2012 |
| Radiation |
volumetric modulated arc therapy |
1 |
2012 |
| Drug |
voriconazole (dosing according to the spc) |
1 |
2009 |
| Drug |
vorinostat (suberoylanilide hydroxamic acid [saha]) in combination with pemetrexed |
1 |
2005 |
| Drug |
vorinostat (suberoylanilide hydroxamic acid [saha]) in combination with pemetrexed/cisplatin |
1 |
2005 |
| Drug |
vorinostat, suberoylanilide hydroxamic acid (saha) |
1 |
2005 |
| Drug |
voruciclib |
1 |
2018 |
| Drug |
vosaroxin |
1 |
2005 |
| Drug |
vp-16 |
1 |
2000 |
| Drug |
vrx-3996 |
1 |
2017 |
| Biological |
vsv-ifnî²-nis |
1 |
2016 |
| Biological |
vsv-ifnî²-nis/avelumab |
1 |
2016 |
| Drug |
vt1021 |
1 |
2017 |
| Drug |
vx-006: 0,5mg |
1 |
2014 |
| Drug |
vx-006: 10mg |
1 |
2014 |
| Drug |
vx-006: 1mg |
1 |
2014 |
| Drug |
vx-006: 5mg |
1 |
2014 |
| Drug |
vx-970 (m6620) |
1 |
2015 |
| Drug |
vx15 |
1 |
2011 |
| Drug |
vx15/2503 |
1 |
2011 |
| Drug |
w0101 - cohort a1 |
1 |
2017 |
| Drug |
w0101 - cohort a2 |
1 |
2017 |
| Drug |
w0101 - expansion phase |
1 |
2017 |
| Other |
waiting list |
1 |
2019 |
| Device |
wallflexâ„¢ biliary partially-covered stent |
1 |
2008 |
| Drug |
warfarin |
1 |
2015 |
| Radiation |
wbi |
1 |
2018 |
| Device |
wearable exercise tracker watch |
1 |
2017 |
| Procedure |
week) |
1 |
2014 |
| Drug |
weekly carboplatin |
1 |
2007 |
| Drug |
weekly carboplatin/taxol w/concurrent rt |
1 |
2007 |
| Other |
whole-body electromyostimulation |
1 |
2018 |
| Device |
whole brain radiation therapy arm |
1 |
2006 |
| Radiation |
whole brain radiation therapy with hippocampal avoidance |
1 |
2015 |
| Drug |
whole human anti-pd-l1 antibody injection (ldp) |
1 |
2019 |
| Device |
winged perimeter biliary stent insertion (viaduct) |
1 |
2012 |
| Drug |
with avelumab |
1 |
2014 |
| Biological |
with kn046 |
1 |
2019 |
| Drug |
with r-gdp |
1 |
2017 |
| Other |
withdrawal of immunosuppression |
1 |
2009 |
| Other |
withdrawal of immunosuppression/donor lymphocyte infusion |
1 |
2009 |
| Drug |
without cetuximab) |
1 |
2007 |
| Procedure |
without suction |
1 |
2011 |
| Behavioral |
woman-pro ii program (intervention ii) |
1 |
2013 |
| Behavioral |
workshop |
1 |
2015 |
| Biological |
wt-1 |
1 |
2008 |
| Biological |
wt2725 |
1 |
2012 |
| Drug |
wx-uk1 in combination with capecitabine |
1 |
2004 |
| Drug |
x-82 |
1 |
2011 |
| Other |
xelox postoperative chemotherapy |
1 |
2015 |
| Drug |
xentuzumab |
1 |
2017 |
| Drug |
xl092 |
1 |
2019 |
| Drug |
xl184 |
1 |
2005 |
| Drug |
xl999 |
1 |
2009 |
| Drug |
xmab24306 |
1 |
2020 |
| Drug |
xnw7201 tablets |
1 |
2019 |
| Device |
xpedeâ„¢ bone cement |
1 |
2018 |
| Device |
y-90 microspheres |
1 |
2016 |
| Drug |
yl-13027 |
1 |
2019 |
| Drug |
ym155 |
1 |
2010 |
| Behavioral |
yoga questionnaire |
1 |
2017 |
| Behavioral |
yoga therapy |
1 |
2011 |
| Other |
yttrium-90 |
1 |
2019 |
| Device |
yttrium-90 microsphere radioembolization |
1 |
2018 |
| Radiation |
yttrium y 90-edotreotide |
1 |
2000 |
| Drug |
zalypsis |
1 |
2010 |
| Drug |
zd1694 (tomudex) |
1 |
1999 |
| Drug |
zd4054 (zibotentan) |
1 |
2009 |
| Drug |
zd4054 10 mg |
1 |
2003 |
| Drug |
zd4054 15 mg |
1 |
2003 |
| Drug |
zd4054 22.5 mg |
1 |
2003 |
| Drug |
zd6474 |
1 |
2002 |
| Drug |
zevalin radioimmunotherapy |
1 |
2002 |
| Drug |
zidovudine |
1 |
2004 |
| Drug |
zimberelimab |
1 |
2020 |
| Drug |
zio-101 |
1 |
2007 |
| Drug |
zio-101 (darinaparsin) |
1 |
2007 |
| Drug |
zio-201 |
1 |
2007 |
| Drug |
zo-nantax |
1 |
2011 |
| Drug |
zr-dfo-pertuzumab pet |
1 |
2017 |
| Drug |
zr-dfo-pertuzumab pet/ct |
1 |
2017 |
| Drug |
zstk474 |
1 |
2012 |